Front. Endocrinol. Frontiers in Endocrinology Front. Endocrinol. 1664-2392 Frontiers Media S.A. 10.3389/fendo.2024.1366285 Endocrinology Review Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms Dai Junting 1 † Qiu Lulu 1 † Lu Yi 2 * Li Miao 1 * 1 Department of Pharmacy, The Second Hospital of Dalian Medical University, Dalian, China 2 Department of Cardiovascular, The Second Affiliated Hospital of Dalian Medical University, Dalian, China

Edited by: Gaetano Santulli, Albert Einstein College of Medicine, United States

Reviewed by: Ping Chung Leung, The Chinese University of Hong Kong, China

Liu Ouyang, Georgia State University, United States

Ying Xie, University of California, Berkeley, United States

*Correspondence: Miao Li, limiaodyey@163.com; Yi Lu, 750109471@qq.com

†These authors have contributed equally to this work

 30 09 2024 2024 15 1366285 06 01 2024 03 09 2024 Copyright © 2024 Dai, Qiu, Lu and Li 2024 Dai, Qiu, Lu and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Cardiovascular disease (CVD) is the leading cause of human mortality worldwide. Despite Western medicine having made encouraging results in the clinical management of CVD, the morbidity, mortality, and disability rates of the disease remain high. Modern pharmacology has confirmed that traditional Chinese medicine (TCM), characterized by its multi-component, multi-target, and integrity, plays a positive and important role in the prevention and treatment of various CVDs in China, which has notable advantages in stabilizing disease, improving heart function, and enhancing the quality of life. Importantly, TCM is gradually being accepted by the international community due to its low cost, high safety, versatile bioactivity, and low toxicity. Unfortunately, comprehensive studies on the therapeutic effect of TCM on CVD and its mechanisms are very limited, which may restrict the clinical application of TCM in CVD. Therefore, this review is performed to analyze the pathogenesis of CVD, including inflammatory response, oxidative stress, mitochondrial dysfunction, pyroptosis, ferroptosis, dysbiosis of gut microbiota, etc. Moreover, we summarized the latest progress of TCM (formulas, extracts, and compounds) in curing CVD according to published literature from 2018 to 2023, as well as its mechanisms and clinical evidence. In conclusion, this review is expected to provide useful information and reference for the clinical application of TCM in the prevention and treatment of CVD and further drug development of CVD.

 cardiovascular disease traditional Chinese medicine heart function therapeutic mechanisms gut microbiota section-in-acceptance Cardiovascular Endocrinology Introduction

Cardiovascular disease (CVD) is the diseases of the circulatory system, including disorders of the heart and blood vessels. As a chronic progressive condition, CVD is characterized by high morbidity, mortality, hospitalization, and disability rates, causing a huge economic and health burden worldwide (1, 2). According to the World Health Organization, CVD was the leading cause of the highest number of deaths in 2019 (3), and about 23 million CVD-related deaths in 2030 (4). Meanwhile, CVD remains the predominant cause of human mortality in China (5) and Western countries (6). Recent studies have confirmed that the occurrence and progression of CVD are the results of the interaction of genetic and environmental factors, and common risk factors include age, obesity, tobacco use, alcohol consumption, dyslipidemia, hypertension, diabetes (7–12), etc. Meanwhile, other studies have found that air pollution and circadian syndrome as contributing factors to CVD (13, 14). In addition, numerous studies have demonstrated that oxidative stress, inflammatory response, programmed cell death (such as apoptosis and autophagy, pyroptosis, and ferroptosis), and intestinal flora disorders were associated with the abnormalities of structural and functional in the cardiovascular system (15–17). Currently, surgery and drugs are commonly used in the clinical management of various CVDs, but surgical procedures are both risky and expensive. Besides, the effectiveness of cardiovascular drugs decreases with prolonged use and is accompanied by adverse side effects, which has become a major problem that needs to be urgently addressed in the Western medical treatment of CVD. Therefore, the pathogenesis of CVD needs to be further explored and effective prevention and treatment strategies need to be developed.

Traditional Chinese medicine (TCM) is an accumulation of the Chinese Nation’s clinical experience for thousands of years, characterized by comprehensive resources and low cost, and has been widely used for treating various diseases in clinical practice (18, 19). TCM was an important source of modern drug development for more than 2,000 years. More interestingly, TCM has become increasingly popular in many developed countries (20), such as Australia and the United States, because of its unique advantages including low adverse effects, stable efficacy, and a wide range of targets. Modern medical studies have demonstrated that TCM (including formulas, extracts, and compounds) possessed significant effects on the treatment of CVD, and TCM treatments are well tolerated by patients with CVD (21). Currently, the “compound Dan-Shen dropping pill”, which consists of three TCMs for the treatment of coronary heart disease and angina pectoris, was the first TCM formula in the world to complete a phase III randomized, double-blind, and international multicenter clinical trial approved by the U.S. Food and Drug Administration (NCT00797953) and this drug was widely used in Australia after being approved by the Australian Therapeutic Goods Administration. Meanwhile, the standard of Panax notoginseng extracts has been incorporated into the German Drug Code for the benefit of patients with CVD. Functionally, TCM can exert cardioprotective effects through multiple targets on oxidative stress, inflammation, autophagy, lipid metabolism, cardiomyocyte/vascular endothelial cell function, and gut microbiota (22–24), which compensates for the lack of a single drug model for the treatment of CVD in clinical. Several studies have confirmed that TCM combined with Western drugs can more effectively alleviate clinical symptoms and disease progression in patients with CVD (25, 26). Importantly, with the development of omics technologies such as transcriptome, proteome, metabolome, and bioinformatics, the detailed mechanisms of TCM in the prevention and treatment of CVD have been systematically and comprehensively expanded to multiple levels such as RNA, protein, and metabolites, and also extend to the single-cell microscopic level from the perspective of time and space (27). This suggests that TCM provides new perspectives and strategies to combat various CVDs in modern society.

Currently, there are few reviews on TCM for the prevention and treatment of various CVDs. In this review, the current pathogenesis of CVD was comprehensively overviewed. Moreover, the current research on TCM (including TCM formulas, extracts, and compounds) protection against CVD was summarized and discussed based on the published literature from 2018-2023 through global and local databases including PubMed, Web of Science, and China National Knowledge Infrastructure, as well as its mechanisms and clinical efficacy, which may provide a reference for the clinical application of TCM in the treatment of CVD and a theoretical basis for the development of new drugs to combat CVD.

 The pathogenesis of CVDs

The development and progression of CVD were associated with genetic mutations, obesity, environmental factors, and poor lifestyle (28, 29). Increasing evidence has demonstrated that the possible pathogenesis of CVD includes inflammation, oxidative stress, mitochondrial dysfunction, cell death (e.g., apoptosis, ferroptosis, and pyroptosis), and gut microbiota imbalance, which would lead to cardiomyocyte injury, inflammatory response, and vascular lesions (15, 30, 31), etc.

Inflammation

Inflammation plays an important role in the pathogenesis of various CVDs (32), and anti-inflammatory therapies have proven beneficial in several recent clinical trials (33, 34). Increased incidence of cardiovascular events has also been shown in patients with chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, inflammatory myopathies, and inflammatory bowel disease (35). Evidence suggested that the upregulation of circulating C reactive protein resulted in a greater risk of incident acute myocardial infarction (36) or cerebrovascular events (37). Previous studies have shown that atherosclerosis is a low-grade and aseptic inflammatory disease (38). For example, Mai et al. (39) demonstrated that nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome was a key driver of atherosclerosis. Meanwhile, the inflammatory response was considered to be a trigger for the developmental process of atrial fibrillation (40). Over-activation of NLRP3 inflammasome was directly associated with hospitalization rates in patients with cardiac insufficiency and dilated cardiomyopathy, accompanied by cellular scorching of cardiomyocytes (41). In addition, it has also been demonstrated that inhibition of the inflammatory response or NLRP3 gene deletion improved cardiac remodeling and reduced proinflammatory cytokines secretion and fibrotic processes (42, 43), as well as attenuated angiotensin II (Ang II)-induced hypertension (44). Taken together, inflammation was involved in the pathogenesis of several CVDs ( Figure 1 ), which also provides new strategies for the prevention and management of CVD.

Role of inflammation in the pathogenesis of cardiovascular diseases. ANP, Atrial natriuretic peptide; Bak, Bcl-2 antagonist/killer; COX2, Cyclooxygenase 2; ECM, Extracellular matrix; HG, High glucose; LDL, Low-density lipoprotein; LPS, Lipopolysaccharide; MCP1, Monocyte chemotactic protein 1; NLRP3, Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3; ROS, Reactive oxygen species; TGFβ, Transforming growth factor beta; TLRs, Toll-like receptors; TRAF6, Tumor necrosis factor receptor-associated factor 6; VCAM1, Vascular cell adhesion molecule 1; βMHC, Beta-myosin heavy chain.

 Oxidative stress

Oxidative stress is a pathological state of reactive oxygen species (ROS) accumulation caused by excessive production of oxygen free radicals or impaired intracellular antioxidant defense systems (45). Normal physiological state of ROS levels contributes to the maintenance of cardiovascular homeostasis (46), while excessive and/or sustained increases in ROS production play an important role in the pathological statute of CVD ( Figure 2 ), such as atherosclerosis, hypertension, myocardial ischemia-reperfusion injury, arrhythmia, heart failure, and acute myocardial infarction (47). Of note, oxidative stress has emerged as a new target for the prevention and treatment of CVD (48). It has also been found that common CVD risk factors contribute to a sustained increase in ROS production in the vascular wall (49). Functionally, oxidative stress not only promotes lipid peroxidation, protein and enzyme denaturation, DNA damage, and severe functional impairment of vascular endothelial cells and cardiomyocytes, but also participates in the pathogenesis of hypertension, myocardial ischemia-reperfusion injury, atherosclerosis, and other CVDs by regulating inflammation and stimulating vascular smooth muscle cell proliferation (50). In addition, endogenous antioxidant enzymes (e.g., superoxide dismutase, glutathione peroxidase, catalase, glutathione S-transferase, and peroxidase) and exogenous antioxidants may act by scavenging free radicals and exerting anti-CVD activities. For example, overexpression of glutathione peroxidase 4 (GPX4) inhibited atherosclerosis progression in apolipoprotein E-deficient (ApoE-/-) mice (51). Giam et al. (52) showed that the antioxidant NAC attenuated cardiac injury and prevented cardiac fibrosis which improved cardiac function in mice with heart failure.

Role of oxidative stress in the pathogenesis of cardiovascular diseases. NO: one of the members of reactive nitrogen, damages cardiomyocytes through direct cytotoxicity or generates ONOO− with O2− to cause cardiomyocyte damage. CVD, Cardiovascular diseases; ER, Endoplasmic reticulum; MAPK, Mitogen-activated protein kinase; MI/RI, Myocardial ischemia/reperfusion injury; NF-κB, Nuclear transcription factor-κB; NLRP3, Nucleotide-binding oligomerization domain-like receptor protein 3.

 Mitochondrial dysfunction

Mitochondria, a key site of cellular metabolism for ATP production, provides enough energy for the contraction and diastole of human cardiomyocytes, but mitochondrial dysfunction accelerates the occurrence and progression of CVD ( Figure 3 ). For example, mitochondrial dysfunction in macrophages contributes to inducing inflammation and inhibiting repair after myocardial infarction, but mitochondrial-targeted ROS scavenging alleviates these phenomena and reduces death after myocardial infarction in mice (53). Currently, mitochondrial dysfunction, mitochondrial DNA and nuclear DNA gene mutation, and the presence of mutant proteins associated with mitochondria are considered to be non-negligible causes of CVD pathogenesis (54). For instance, four mitochondrial DNA mutation genes (e.g., MT-RNR1, MT-TL1, MT-TL2, and MT-CYB) have been reported to be connected with atherosclerosis progression (55). Functionally, mutations in the mitochondrial genome and nuclear genome may disrupt mitochondrial homeostasis, leading to excessive ROS production and reducing oxidative phosphorylation capacity, which are risk factors for CVD (56). For example, specific targeted antioxidant treatments that reduced ROS production and enhanced ROS scavenging have been shown to alleviate impaired mitochondrial-induced oxidative stress (57). Jacinto et al. (58) showed that the overproduction of mitochondrial ROS promoted atherosclerosis progression by triggering DNA fragmentation and cell apoptosis. Moreover, mitophagy plays an important regulatory role in maintaining cellular homeostasis, whereas mitophagy damage predisposes to cause abnormal function of cardiovascular-derived cells (59). Notably, several intervention strategies ameliorate CVD by improving four important characteristics of mitochondria, such as scavenging mitochondrial ROS (60), mitochondrial DNA editing or mitochondrial replacement therapy (61), increased oxidative phosphorylation (62), and enhanced mitophagy (63). Therefore, maintaining normal mitochondrial function has the potential to be used as an effective therapeutic strategy for CVDs.

Role of mitochondrial dysfunction in the pathogenesis of cardiovascular diseases. ECM, Extracellular matrix; HG, High glucose; IR, ischemia/reperfusion; Keap1, Kelch-like ECH-associated protein 1; LDL, Low-density lipoprotein; mPTP, Mitochondrial permeability transition pore; Nrf2, Nuclear factor erythroid 2-related factor 2.

 Pyroptosis

Pyroptosis, a form of programmed cell death, is closely related to the inflammatory response, mediated by the Gasdermin protein, and dependent on caspase activity (64). Pyroptosis is typically characterized by the swelling and rupture of cell membranes, the release of pro-inflammatory factors, and cell contents from the plasma membrane to the extracellular environment (65), which aggravates inflammatory response. Recent studies have shown that pyroptosis was involved in the development and progression of several CVDs ( Figure 4 ), including atherosclerosis, diabetic cardiomyopathy, myocardial infarction, myocardial ischemia-reperfusion injury, myocarditis (66), etc. Mechanistically, NLRP3 inflammasome activated caspase-1 and triggered an inflammatory cascade, which plays an important role in pyroptosis (67). For example, NLRP3 inhibitor MCC950 has the potential to prevent NLRP3-related diseases, such as cardiac hypertrophy (68), hypertension (69), atherosclerosis (70), and myocardial injury (71). Jin et al. (72) showed that caspase-1 inhibitor VX765 ameliorated mitochondrial damage induced by the NLRP3 inflammasome activation and inhibition of vascular inflammation in both low-density lipoprotein receptor-deficient (Ldlr-/-) and ApoE-/- mice. These results suggested that inhibition of pyroptosis may provide a new avenue for the treatment and management of CVDs.

Role of pyroptosis in the pathogenesis of cardiovascular diseases.

 Ferroptosis

Ferroptosis is a new type of cellular iron-dependent programmed cell death, and the process mainly involves the accumulation of lipid peroxidation products and lethal ROS (73). Increasing evidence has demonstrated that ferroptosis was morphologically, biochemically, and genetically distinct from cell apoptosis, necrosis, and autophagy (74), which was mainly characterized by impaired cell membrane integrity, mitochondrial atrophy, normal nuclei, and a significant decrease in the levels of GPX4, glutamate-cystine antiporter system components (SLC3A2 and SLC7A11), and coenzyme II. Available studies have shown that ferroptosis was closely associated with the development of various CVDs including cardiomyopathy, myocardial ischemia-reperfusion injury, heart failure, myocardial infarction, vascular injury, and atherosclerosis (75). For example, Wang et al. (76) reported that increased levels of lipid peroxidation and reduced SLC7A11 levels were observed in the development of diabetic cardiomyopathy. Bai et al. (77) found that ferrostatin-1 (Fer-1, ferroptosis inhibitor) alleviated atherosclerotic lesions by reducing iron accumulation and lipid peroxidation, and enhancing the expression of GPX4 and SLC7A11 in a high-fat diet (HFD)-fed ApoE-/- mice. Another study showed that the inactivation of the Nrf2/GPX4 pathway could aggravate doxorubicin-induced cardiomyopathy by promoting cardiomyocyte ferroptosis (78). Importantly, three types of iron chelators (e.g., deferiprone, deferoxamine, deferasirox) have been used in clinical practice for the treatment of iron overload cardiomyopathy (79). Although many preclinical studies suggest that pharmacological regulation of ferroptosis and genetic inhibition of iron uptake are promising treatment strategies for CVD ( Figure 5 ), the underlying mechanism and regulatory networks need to be fully investigated during the pathological process of CVD, which will provide new ideas and strategies for the prevention and treatment of CVD.

Role of ferroptosis in the pathogenesis of cardiovascular diseases. AA, Arachidonic acid; ACSL4, Long-chain fatty acyl-CoA synthase 4; AdA, Adrenal acid; DMT1, Divalent metal transporter 1; FfR1, Transferrin receptor 1; GCL, Glutamate-cysteine ligase; GPX4, Glutathione peroxidase 4; GSH, Glutathione; GSS, Glutathione synthase; HO-1, Heme oxygenase 1; LPCAT3, Lysolecithin acyltransferase 3; LOXs, Lipoxygenases; NCOA4, Nuclear receptor coactivator 4; POR, Cytochrome P450 oxidoreductase; PUFAs, Polyunsaturated fatty acids; SLC7A11, Solute carrier family 7 member 11; xCT, System Xc-.

 Gut microbiota and metabolomics

Gut microbiota refers to the large number of commensal microorganisms living in the human intestinal tract, which mainly consists of Firmicutes, Bacteroidetes, Proteobacteria, Fusobacteria, and Actinobacteria at the phylum level, but its balance is easily disturbed by food intake, lifestyle, and environment (80). Functionally, the gut microbiota can form the intestinal epithelial barrier, regulate intestinal immunity, and prevent the invasion of pathogenic bacteria and metabolic abnormalities (81), which are essential for human health. Numerous studies have demonstrated that dysbiosis of intestinal bacteria and its metabolites, such as Trimethylamine oxide (TMAO), lipopolysaccharides (LPS), short-chain fatty acids (SCFAs), and bile acids, were closely associated with the development of CVD (82), and targeting the gut microbiota was expected to be a potential new target for the treatment of CVD ( Figure 6 ). For example, Jie et al. (83) reported that patients with atherosclerotic cardiovascular disease (ACVD) possessed an increased relative abundance of Enterobacteriaceae and Streptococcus spp., which contributed to aggravating ACVD as well as other diseases. In another survey, high levels of Prevotella, Hungatella, and Succinclasticum and low levels of Lachnospiraceae family and Faecalibacterium were observed in patients with heart failure (84). Meanwhile, elevated plasma levels of TMAO were positively associated with stroke (85), hypertension (86), and atherosclerosis (87), as well as increased cardiovascular events (88), suggesting that reducing intake of dietary TMAO precursors was an effective strategy to decrease the risk of CVD. The above studies suggest that gut microbiota serves as a “microbial organ” that affects cardiovascular health and the “gut-heart” axis is a potential avenue in the prevention and treatment of CVD.

Role of gut microbiota in the pathogenesis of cardiovascular diseases. SCFAs, Short chain fatty acids; LPS, Lipopolysaccharides; TGR5, Takeda G-protein-coupled receptor 5; FXR, farnesoid X receptor; TMAO, trimethylamine-N-oxide; TMA, trimethylamine.

 Others

Except for the pathogenesis mentioned above, researchers believe that CVD is associated with endoplasmic reticulum stress (ERS) (89), autophagy deficiency (90), diabetes (91), metabolic syndrome (92), etc. Moreover, searching for biomarkers used to determine the occurrence and progression of CVDs and revealing their mechanisms are of great clinical significance for the early diagnosis and treatment of CVD. Meanwhile, the exploration of assessment tools for the early identification of people at high risk of CVD is an important guarantee to reduce cardiovascular mortality. However, the drugs developed to address this pathogenesis can only alleviate the symptoms of CVD, but cannot inhibit or reverse CVD progression. Therefore, elucidating the pathogenesis of CVD remains a key clinical problem that needs to be addressed. Of note, understanding the pathogenesis of CVD may provide effective biomarkers and pathways for subsequent therapeutic and new drug development.

 TCM in the treatment of CVD

With in-depth research on the pathogenesis of CVD, TCM has shown unique therapeutic advantages in CVD by virtue of its multi-component, multi-target, and integrity (93). More and more studies have demonstrated that TCM (including formulas, extracts, and compounds) exhibited a protective effect on cardiovascular (21), and mechanisms of action of TCM in preventing CVD are shown in Figure 7 and Tables 1 – 3 . Meanwhile, the majority of Chinese patients with CVD have been treated with TCM during the diagnosis and treatment process (94). Herein, we summarized the research progress of TCM in the treatment of various CVDs to provide a reference for the research on the complex mechanism of TCM in combating CVD.

Therapeutic effects of TCM on cardiovascular diseases and its mechanism.

Summary of traditional Chinese medicine formulas in the prevention and treatment of various cardiovascular diseases from 2018-2023.

Prescription Composition (In Chinese) Evaluation model Effects and action mechanism Ref.
Atherosclerosis
Buyang huanwu decoction Huangqi, Chishao, Chuanxiong, Danggui, Dilong, Taoren, and Honghua in a ratio of 120:6:4:5:3:3:3 HFD-induced ApoE-/- mice Levels of TC, TG, LDL-c↓and HDL-c↑Levels of TNF-α, IL-1β, IL-6, iNOS↓NF-κB pathway↓ (196)
Huang-Lian-Jie-Du decoction Huanglian, Huangqin, Huangbo, and Zhizi in a weight ratio of 3:2:2:3 HFD-induced ApoE-/- miceox-LDL-induced RAW264.7 cells Carotid lesion plaques stability↑Levels of IL-1β, IL-6, TNF-α↓Foam cell formation↓and M2 polarization↑ (197)
Guanxinkang decoction Huangqi, Yimucao, Danshen, Xiebai, Banxia, and Gualou in a weight ratio of 10:10:4:4:4:5 HFD-induced LDLR-/- miceox-LDL-induced RAW264.7 cells Body weight and levels of TC, TG, LDL-c↓Atherosclerotic plaques↓and α-SMA level↑Levels of IL-1β, IL-6, TNF-α, LOX-1, MCP-1↓MAPKs/NF-κB pathway↓ (198)
Qing-Xin-Jie-Yu granule Huangqi, Danshen, Chuanxiong, Guanghuoxiang, and Huanglian in a ratio of 3:3:2:2:1 HFD-induced ApoE-/- mice Body weight and levels of TC, TG, and LDL-c↓Levels of HDL-c↑and IL-1β, IL-6↓The abundance of Turicibacter and Roseburia↑The abundance of Alistripes, Rikenella, Blautia↓ (102)
Qing-Xin-Jie-Yu granule Huangqi, Danshen, Chuanxiong, Guanghuoxiang, and Huanglian in a ratio of 3:3:2:2:1 HFD-induced ApoE-/- mice TC, TG, LDL-c levels, and ferroptosis↓Levels of IL-6, IL-1β, TNF-α, Fe2+, ROS↓Expression of GPX4/xCT in aorta tissues↑ (199)
Yiqihuoxue decoction Chuanxiong, Chishao, and Xiyangshen in a ratio of 40:20:1 HFD-induced ApoE-/- mice Blood glucose and levels of TNF-α and IL-6↓Aortic arch plaque area↓ (200)
Wu-Zhu-Yu decoction Wuzhuyu, Shengjiang, Renshen, and Dazao in a ratio of 1:2:1:1 HFD-induced ApoE-/- mice Aortic lesion areas↓Levels of TC, TG, LDL-c↓and HDL-c↑ (201)
Tongqiaohuoxue decoction Shaoyao, Chuanxiong, Taoren, Honghua, Onion, Wuchizao, Ginger, and Yunmuxiang in a ratio of 16:16:48:48:12:8:48:20 HFD-induced ApoE-/- miceox-LDL-induced THP-1 cellsox-LDL-induced HUVECs Lipid deposition, plaque formation, lipid uptake↓Levels of ICAM-1, VCAM-1, and MCP-1↓ (202)
Si-Miao-Yong-An decoction Rendong, Xuanshen, Danggui, and Gancao in a ratio of 3:3:2:1 HFD-induced ApoE-/- mice lipid accumulation↓and Autophagy↑NF-κB pathway↓ (203)
Tao Hong decoction Taoren, Honghua, Chuanxiong, Danggui, and Weilingxian in a ratio of 9:9:9:9:9 HFD-induced ApoE-/- mice Plaque area and Levels of inflammatory cytokines↓PI3K/Akt/p38 pathway↓ (204)
Bunao-Fuyuan decoction Huangqi, Baizhi, Chishao, Chuanxiong, Honghua, and Taoren in a ratio of 120:6:5:3:3:3 ox-LDL-induced VMSCs α-SMA protein and cell proliferation↓Cell invasion and migration↓RHOA/ROCK pathway↓ (205)
Huanglian Jiedu decoction Huanglian, Huangqi, Huangbo, and Zhizi in a ratio of 9:6:6:9 HFD-induced ApoE-/- mice Levels of TC, TG, LDL-c↓and HDL-c↑Expression of CRP, IL-6, TNF-α↓ (206)
Liuwei Dihuang formula Dihuang, Shanzhuyu, Chinese Yam, Zexie, Diaozhilan, and Fuling in a ratio of 32:16:16:12:12:12 HFD-induced ApoE-/- miceHcy-induced HUVECs HUVEC apoptosis↓The ratio of SAM/SAH and plaque formation↓ (207)
Liuwei Dihuang soft capsule Dihuang, Shanzhuyu, Chinese Yam, Zexie, Diaozhilan, and Fuling in a ratio of 32:16:16:12:12:12 HFD-induced ApoE-/- micePDGF-BB-induced VSMCs Lipid deposition and levels of TG, TC, LDL-c↓Expression of ERα, ERβ, SRC3↑CyclinD expression and cell migration↓ (208)
Danggui Buxue decoction Danggui and Huangqi in a ratio of 1:5 hyperplasia/neointima mice model Levels of IL-1β, TNF-α, MCP-1↓PI3K/Akt pathway↓ (209)
Qingre Huoxue decoction Huangqin, Chishao, Chuanxiong, Maodongqing, Honghua, Jiangxiang, and Danshen in a ratio of 3:3:2:6:2:2:6 HFD-induced ApoE-/- miceLPS-induced RAW264.7 cells Body weight and levels of TC, TG, LDL-c↓Plaque area↓and M2 polarization↑NF-κB pathway↓ (210)
Liuwei Dihuang formula Shudihuang, Shanzhuyu, Shanyao, Zexie, Mudanpi, and Fuling in a ratio of 8:4:4:3:3:3 Ang II-induced VSMCs VSMC proliferation and migration↓Expression of α-SMA and OPN↓ (211)
Chaihu-Shugan-San formula Chaihu, Chenpi, Chuanxiong, Baishao, Xiangfu, Zhike, and Gancao in a ratio of 4:4:3:3:3:3:1. HFD-induced ApoE-/- miceLPS-induced HUVECs Atherosclerotic plaque areas↓Levels of TC, TG, LDL-c, TNF-α, IL-1β, IL-6↓Expression of BDNF and TrkB↑ (212)
Guanmaitong granule Huangqi, Danshen, Gualou, Huanglian, Sanqi, Xuanshen, Zhebeimu, Huzhang, Shuizhi, and Muli in a ratio of 6:3:3:1.5:3:4.5:3:2:1:0.5 HFD-induced ApoE-/- mice Levels of TG, TC, LDL-c, TNF-α, IL-6, IL-1β↓Plaque lipid deposition↓Plaque collagen content↓TLR4/MyD88/NF-κB pathway↓ (213)
Myocardial ischemia-reperfusion injury
Tongmai Yangxin pill Dihuang, Jixueteng, Maidong, Zhiheshouwu, Ejiao, Gancao, Wuweizi, Dangshen, Cuguijia, Dazao, and Guizhi in a ratio of 10:10:6:6:6:6:6:6:4:4:2 I/R-induced myocardial injury LVEF and LVFS↑and CK and CK-MB levels↓MDA content and inflammatory cell infiltration↓Cardiomyocyte apoptosis↓andPI3K/Akt pathway↑ (214)
Tongmai Yangxin pill Dihuang, Jixueteng, Maidong, Zhiheshouwu, Ejiao, Gancao, Wuweizi, Dangshen, Cuguijia, Dazao, and Guizhi in a ratio of 10:10:6:6:6:6:6:6:4:4:2 I/R-induced myocardial injury LVDd and LVDs↓Inflammatory cell number↓Activities of CK, LDH, MDA↓and NO activity↑cAMP/PKA and NO/cGMP pathways↑ (215)
QishenYiqi dripping pill Huangqi, Danshen, Sanqi, and Jiangxiang in a ratio of 20:65:1:33 I/R-induced myocardial injury Myocardial infarct size, LVDd, NLRP3 expression↓LVEF and LVFS↑and PI3K/Akt-mTOR pathway↑ (216)
Yiqi Huoxue formula Huangqi, Danshen, Sanqi, Chuanxiong, Danggui, Yiyiren, Baizhu, Fuling, Banxia, Juhong, Dilong, and Shuizhi in a ratio of 30:15:10:10:10:15:15:15:15:10:10:3 I/R-induced myocardial injuryH/R-induced H9c2 cell injury Myocardial infarct size↓Levels of CK and LDH↓MDA content↓and SOD level↑H9c2 cell proliferation↑ (217)
Huoxue Jiedu formula Shaoyao, Chuanxiong, and Huanglian in a ratio of 1:1:1 I/R-induced myocardial injuryH/R-induced H9c2 cell injury Infarcted area, CK-MB and cTnT levels↓Beclin-1 and LC3-II↓and Bcl-2, p62↑PI3K/AKT/mTOR pathway↑ (218)
Dried ginger-aconite decoction Wutou and Ginger in a ratio of 1:1 I/R-induced myocardial injuryH/R-induced H9c2 cell injury SOD level↑and MDA content↓H9c2 cell apoptosis and myocardial infarct size↓PI3K/AKT/GSK-3β pathway↑ (219)
Tongmai formula Danshen, Gegen, and Chuanxiong in a ratio of 1:1:1 I/R-induced myocardial injuryH/R-induced neonatal rat ventricular myocyte injury Myocardial infarct size and cell apoptosis↓cTnT, CK, LDH levels, and MDA content↓GSH and SOD activities↑and ROS content↓ (220)
Xin-Ji-Er-Kang formula Renshen, Yuzhu, Sanqi, Xiebai, Danggui, Maidong, Wuweizi, Danshen, Kushen, Gancao, Huangqi, Yinyanghuo, Jinsilian, and Bingpian in a ratio of 11.71:7.03:3.09:7.80:7.80:7.80:3.93: 7.80:7.80:7.80:11.69:7.80:7.8:0.15 I/R-induced myocardial injuryH/R-induced cardiomyocyte-like cell injury Myocardial infarct size and LVDd↓LVEF and LVFS↑Apoptosis of cardiomyocytes↓JAK2/STAT3 pathway↑ (221)
Si-Miao-Yong-An decoction Jinyinhua, Xuanshen, Danggui, and Gancao in a ratio of 5:5:3:3 I/R-induced myocardial injury Myocardial infarct size↓and LVEF, LVFS↑Levels of CK, LDH, TNF-α, IL-6, IL-1β↓TLR4/NF-κB pathway↓ (222)
Heart failure
Qishen granule Huangqi, Danshen, Jinyinhua, Xuanshen, Fuzi, and Gancao in a ratio of 30:15:10:10:9:6 TAC-induced heart failure modelTGF-β-stimulated cardiac fibroblasts LVDd and LVDs↓and LVEF and LVFS↑Collagen deposition↓TGF-β/SMADs and PI3K/GSK-3β pathways↓ (223)
Si-Miao-Yong-An decoction Rendong, Xuanshen, Danggui, and Gancao in ratio of 3:3:2:1 ISO-induced heart failure modelISO-induced H9c2 cell injury LVEF and LVFS↑and LVDd and LVDs↓Expression of fibronectin, collagen I, α-SMA↓PDE5A-Akt and TLR4-NOX4 pathways↓ (224)
Lingguizhugan decoction Fuling, Guizhi, Baizhu, and Gancao in a ratio of 4:3:3:3 TAC-induced heart failure model LVEF and LVFS↑and LVDd and LVDs↓Heart weight, ANP, BNP, α-MHC, cardiac fibrosis↓Akt-GSK3β/mTOR/P70S6K pathway↓ (225)
XinLi formula Cheqiancao, Huangqi, Hongshen, Ezhu, and Shanzhuyu in a ratio of 30:40:10:9:12 LAD-induced heart failure model Ang II-induced H9c2 cell injury LVEF↑and levels of NT-proBNP, cTnT, CK-MB↓Content of ALD, AGTR1, TGF-β1, HYP↓Expression of NLRP3, caspase-1, IL-1β, IL-18↓ (226)
Zhenwu decoction Wutou, Shaoyao, Baishu, Fuling, and Ginger in a ratio of 3:3:2:3:3 DOX-induced heart failure model LVDd and LVDs↓and LVFS and LVEF↑Levels of CK-MB, BNP, and NT-proBNP↓Fibrosis area, collagen I↓and SOD activity↑Expression of IL-1β, TNF-α, IL-6↓NF-κB pathway↓and PI3K/Akt pathway↑ (227)
Linggui Zhugan decoction Fuling, Guizhi, Baizhu, and Gancao in a ratio of 4:3:3:2 LAD-induced heart failure model LVEF and LVFS↑and LVDs and LVDd↓MDA production and NT-proBNP levels↓SOD activity and SIRT1/AMPK/PGC1α pathway↑ (228)
Shenqi Lixin decoction Renshen, Huangqi, Rougui, Yinyanghuo, Luhui, Shuweicao, Fuling, Baishu, Longyacao, Yimucao, and Gancao in a ratio of 4:4:2:4:3:3:4:3:6:3:2 Adriamycin-induced heart failure model LVEF and LVFS↑and LVDs and LVDd↓Myocardial fibrosis↓NT-proBNP level↓and ATP level↑Expression of Bax and caspase-3↓ (229)
Jijiu Huiyang decoction Fuzi, Ginger, Danshen, Baizhu, Taoren, Honghua, and Zhigancao in a ratio of 5:3:9:9:6:6:5 DOX-induced heart failure model LVEF and LVFS↑LVDs and LVDd↓PPARα pathway↓ (230)
Xinfuli granule Huangqi, Renshen, Danshen, Fuling, and Maidong in a ratio of 9:6:3:3:2 LAD-induced heart failure modelHypoxia/ischemia-induced H9c2 cell injury LVEF and LVFS↑and LVDs and LVDd↓Levels of ADP, AMP, LA, LDH, FFA↓RHOA/ROCK pathway↓ (231)
Qishen granule Huangqi, Danshen, Rendong, Xuanshen, Wutou, and Gancao in a ratio of 30:15:10:10:9:6 LAD-induced heart failure modelLPS-induced RAW264.7 cells LVEF and LVFS↑and LVDs and LVDd↓Levels of CK-MB and LDH↓TLR4/MyD88/NF-κB pathway↓ (232)
BAOXIN granule Huangqi, Danshen, Zelan, Gancao, Maidong, Fuling, Danggui, Zhike, Dihuang, Jiegeng, Dahuang, and Mahuang in a ratio of 20:13:10:10:10:10:7:7:7:4:4:4 TAC-induced heart failure model Heart weight and cardiac fibrosis↓LVEF and LVFS↑and LVDs and LVDd↓Expression of ANP, BNP, β-MHC, IL-1β, IL-6↓Expression of TGF-β and collagen I/III↓ (233)
Guanxining injection Danshen and Chuanxiong in a ratio of 1:1 TAC-induced heart failure model LVEF and pro-BNP level↑Collagen volume fraction↓Expression of SLC7A11, GPX4↑and FTH1↓ (234)
YiQiFuMai powder Renshen, Maidong, and Wuweizi in a ratio of 1:3:1.5 LAD-induced heart failure model LVEF and LVFS↑and LVDs and LVDd↓Cardiac fibrosis and p38 MAPK/ERK1/2 pathway↓ (235)
Guanxinning injection Danshen and Chuanxiong TAC-induced heart failure model SBP, DBP, LVDs, LVDd↓LVEF and LVFS↑and p38/c-Fos/Mmp1 pathway↓ (236)
Qiangxin recipe Huangqi, Chuanxiong, Fuzi, Fuling, Cheqianzi, Dangshen, Guizhi, Nvzhenzi, Tinglizi, Taoren, Taizishen, and Zhuling in a ratio of 10:5:5:5:5:5:3:5:10:5:5:5 DOX-induced heart failure modelDOX-induced H9c2 cell injury Cell viability and glucose metabolism↑Levels of BNP and cTnl↓LVEF↑ (237)
Xinshuitong capsule Huangqi, Danshen, Guizhi, Zexie, and Yumixu in a ratio of 6:4:4:3:3 DOX-induced heart failure model LVEF and LVFS↑and LVDs and LVDd↓Levels of BNP, BUN, AST, ALT↓ (238)
WuShen decoction Renshen, Danshen, Xuanshen, Beishashen, and Kushen in a ratio of 1:3:2:2:1 LAD-induced heart failure model LVEF and LVFS↑and LVDs and LVDd↓Cardiac fibrosis and infarct size↓TGF-β1/Smad2/3 pathway↓ (239)
Hypertension
Qingda granule Tianma, Gouteng, Huangqin, and Lianzixin in a ratio of 12:10:6:5 Spontaneously hypertensive ratsAng II-stimulated cardiac fibroblasts SBP, DBP, MAP↓and LVEF and LVFS↑α-SMA, collagen III, cardia fibrosis↓TGF-β1/Smad2/3 pathway↓ (240)
Danzhi Xiaoyao powder Chaihu, Baishao, Danggui, Fuling, Baizhu, Mudanpi, Zhizi, and Gancao ina ratio of 2:2:2:2:2:1:1:1 Spontaneously hypertensive rats SBP, DBP, MAP↓Anxiety-like behavior↓ (241)
Guizhi decoction Guizhi, Baishao, and Gancao in a ratio of 3:2:2 HFD-induced hypertension model Blood pressure and collagen content↓Expression of IL-6, IL-1β, MMP2, MMP9↓ (242)
Qingda granule Tianma, Gouteng, Huangqin, and Lianzixin in a ratio of 12:10:5:6 Ang II-hypertension modelAng II-stimulated VSMCs SBP, DBP, MAP, Cell viability↓MAPK and PI3K/Akt pathways↓ (243)
Gedan Jiangya decoction Gouteng, Danshen, Gegen, Duzhong, Xiakucao, and Niuxi in a ratio of 2:5:6:3:3:4 Spontaneously hypertensive rats SBP and DBP↓Expression of collagen I/III, α-SMA, IL-1β, IL-6↓NF-κB pathway↓ (244)
Zhengganxifeng decoction Niuxi, Ludou, Longgu, Mulike, Guike, Baishao, Xuanshen, Tiandong, Chuanxiong, Maiya, Yinchenhao, and Gancao in a ratio of 30:30:15:15:15:15:15:15:6:6:6:4.5 Spontaneously hypertensive rats SBP, DBP, MAP↓Firmicutes to Bacteroidetes ratio↓SCFA production↑ (245)
Qing Gan Zi Shen Tang formula Guizhencao, Weimao, Huanglian, Nvzhen, Shanzhuyu, and Xuanshen in a ratio of 10:5:1:4:4:5 HFD-induced hypertension model SBP, DBP, MAP↓Levels of TG, LDL-c↓and HDL-c↑ (246)
Zi Shen Huo Luo formula Xuanshen, Niuxi, Huanglian, Mudan, Yimucao, and Rougui in a ratio of 20:15:12:12:20:3 Spontaneously hypertensive ratsAldosterone-induced H9c2 cells and cardiac fibroblasts SBP, DBP, MAP↓and LVSP, ± dp/dt max↑Cardiac fibrosis↓and cell proliferation↑EGFR/ERK pathway↓ (247)
Myocardial infarction
Buyang Huanwu decoction Huangqi, Danggui, Chisao, Chuanxiong, Taoren, Honghua, and Dilong in a ratio of 120:10:10:10:10:10:4.5 Ligature-induced myocardial infarction model Angiogenesis↑PI3K/Akt/GSK3β pathway↑ (248)
Taohong siwu decoction Shudihuang, Chuanxiong, Chishao, Danggui, Honghua, and Taoren in a ratio of 3:2:2:3:3:4 Ligature-induced myocardial infarction modelTGF-β1-induced cardiac fibroblasts Myocardial fibrosis↓Cell proliferation and collagen expression↓TGFBR1/Smad2/3 pathway↓ (249)
Xuefu Zhuyu decoction Danggui, Dihuang, Taoren, Honghua, Chisao, Zhiqiao, Gancao, Chaihu, Chuanxiong, Jiegeng, and Niuxi in a ratio of 9:9:12:9:6:6:6:3:4.5:4.5:9 Ligature-induced myocardial infarction model Mitochondria damage↓Number of autophagosomes and lysosomes↓Expression of LC3-B and P62↓ (250)
Yiqihuoxue decoction Huangqi, Danggui, Renshen, Chuanxiong, and Sanqi Ligature-induced myocardial infarction model LVEF and LVFS↑and levels of LDH, CK-MB↓JNK/MAPK pathway↑ (251)
Qingre Huoxue decoction Huangqin, Shaoyao, Chuanxiong, Maodongqing, Honghua, Jiangxiang, and Danshen in a ratio of 3:3:2:6:2:2:6 Ligature-induced myocardial infarction model LVEF and LVFS↑MCP-1, IL-17A, TNF-α and IL-1β levels↓LC3B, Beclin-1, ATG5, ATG7↑and p62 level↓PI3K/Akt pathway↓ (252)
Qingyi decoction Dahuang, Baishao, Chaihu, Zhizi, Yanhusuo, Muxiang, and Huangqin, in a ratio of 3:3:3:3:2:2:2 Severe acute pancreatitis-induced myocardial infarction model LVEF and LVFS↑Levels of IL-1β, IL-6, TNF-α↓STIM1/Orai1-SOCE pathway↓ (253)
Shuangxinfang Danshen, Chuanxiong, Baihe, and Dazao in a ratio of 20:12:30:30 Ligature-induced myocardial infarction model LVEF and LVFS↑and LVDs and LVDd↓Myocardial fibrosis and levels of IL-1β, TNF-α↓TLR4/NF-κB pathway↓ (254)
Qishen granule Huangqi, Danshen, Rendong, Xuanshen, Wutou, and Gancao in a ratio of 30:15:10:10:9:6 Ligature-induced myocardial infarction modelOGD/R, ISO, Ang II and LPS-ATP-induced H9c2 cell injury LVEF and LVFS↑and LVDs and LVDd↓Levels of LDH, CK-MB, NLRP3, IL-1β, IL-18↓Cell apoptosis, ROS level, NF-κB pathway↓ (101)
Others
Jia-Wei-Si-Miao-Yong-An decoction Jinyinhua, Lianqiao, Xuanshen, Rougui, Danggui, Danshen, Gancao, and Huzhang in a ratio of 15:15:15:9:15:15:15:9 Acute coronary syndrome model(acute coronary syndrome) Levels of CK-MB, cTnl, IL-2, TNF-α↓The abundance of Bacteroides and Rikenellaceae RC9 gut group↑The abundance of Clostridium sensu stricto 1, Prevotella, unclassified o Bacteroidales, and Ruminococcus gauvreauii group↓ (255)
Zhen-Wu decoction Fuzi, Shaoyao, Fuling, Baizhu, and Shengjiang in a ratio of 3:3:3:2:3 Uremia-induced cardiac endothelial injuryNpx-induced cardiovascular endothelial injury(uremic cardiomyopathy) LVEF↑and fibrosis area, MDA level↓Expression of IL-1β and IL-6↓Cell death and ROS level↓Nrf2/keap1 pathway↑ (256)
Qingda granule Tianma, Gouteng, Huangqin, Hehua in a ratio of 12:10:6:5 Obesity-induced hypertension and cardiac dysfunction(hypertension and cardiac dysfunction) SBP, DBP, MAP↓and LVEF, LVFS↑Levels of TG, TC↓and HDL-c, Akt pathway↓ (257)
Si-Miao-Yong-An decoction Jinyinhua, Xuanshen, Danggui, and Gancao in a ratio of 3:3:2:1 TAC-induced heart failure model(heart failure) LVEF↑and fibrosis area and collagen content↓TGFβ1/TAK1/p38/Smad pathway↓ (258)
Huoxin pill Lingzhi, Linshe, Xiongzhang, Niudanfen, Zhenzhufen, Renshen, Ganchan, Chuanwutou, Bingpian, and Honghua in a ratio of 20:1.2:2.4:1.2:2.4:18:1.8:9:1.2:2 ISO-induced cardiac fibrosis model(myocardial fibrosis) Expression of α-SMA and collagen I/III↓Cell viability and migration↓TGF-β1/Smad pathway↓ (259)
Yunpi-Huoxue-Sanjie formula Baizhu, Zhiqiao, Tianhuafen, Muli, and Tubiechong in a ratio of 5:2:3:10:2 HFD/streptozotocin-induced diabetic cardiomyopathyHigh glucose-induced H9c2 cells(diabetic cardiomyopathy) Levels of FFA, TG, MDA↓and CAT activity↑LVDs and LVDd↑and LVEF and LVFS↓Expression of Atg7, Beclin1, LC3 II/LC3 I↑ (260)
Fufang Xueshuantong formula Sanqi, Danshen, Huangqi, and Xuanshen in a ratio of 25:8:5:8 Streptozotocin-induced diabetic cardiomyopathy(diabetic cardiomyopathy) LVEF and LVFS↑and collagen I/III and TGF-β1↓Wnt/β-Catenin pathway↓ (261)
Danzhi Jiangtang capsule Taizishen, Dihuang, Mudanpi, Xieze, Tusizi, and Shuizhi in a ratio of 6:5:4:4:3:3 HFD/streptozotocin-induced diabetic cardiomyopathyHigh glucose-induced H9c2 cells(diabetic cardiomyopathy) LVEF and LVFS↑Cell apoptosis and levels of IL-1β and IL-6↓TLR4/MyD88/NF-κB pathway↓ (262)

ABCA1, ATP-binding cassette transporter A1; ACSL4, Acyl-CoA synthetase long-chain family member 4; ApoE-/-, Apolipoprotein-E deficient; BA, Bile acid; CK-MB, Creatine kinase MB; COX2, Cyclooxygenase-2; cTnT, Cardiac troponin T; DBP, Diastolic blood pressure; FTH1, Ferritin heavy chain 1; GPX4, Glutathione peroxidase 4; GSH, Glutathione; HDL-c, High-density lipoprotein-cholesterol; HFD, High-fat diet; H/R, Hypoxia/reoxygenation; HUVECs, Human umbilical vein endothelial cells; ICAM-1, Intercellular adhesion molecule-1; ISO, Isoproterenol; I/R, Ischemia/reperfusion; iNOS, Inducible nitric oxide synthase; LAD, left anterior descending ligation; LDH, Lactate dehydrogenase; LDLR-/-, LDL receptor deficient; LDL-c, Low-density lipoprotein cholesterol; LOX-1, Lectin-like oxidized low-density lipoprotein receptor-1; LVDd, Left ventricular diastolic diameter; LVDs, Left ventricular systolic diameter; LVDP, Left ventricular diastolic pressure; LVEF, Left ventricular ejection fraction; LVFS, Left ventricular shortening fraction; LVSP, Left ventricular systolic pressure; LV Vol, Left ventricle volume; MAP, Mean arterial pressure; MCP-1, Monocyte chemoattractant protein-1; MDA, Malondialdehyde; OGD/R, Oxygen-glucose deprivation/reoxygenation; PDGF, Platelet-derived growth factor; PDE5A, Phosphodiesterase 5A; PKG I, cGMP-dependent protein kinase 1; PPARγ, Peroxisome proliferator-activated receptor gamma; SAM, S-Adenosyl methionine; SAH, S-Adenosyl homocysteine; SBP, Systolic blood pressure; SRA1, scavenger receptor A1; TAC, Transverse abdominal aortic constriction; TC, Total cholesterol; TG, Triglyceride; VCAM-1, Vascular cell adhesion molecule-1; VSMCs, Vascular smooth muscle cell.

↑ upregulated, ↓ downregulated.

Summary of traditional Chinese medicine extracts in the prevention and treatment of various cardiovascular diseases from 2018-2023.

Extracts Evaluation model Effects and action mechanism Ref.
Atherosclerosis
Aqueous extracts of Tribulus terrestris HFD-induced ApoE-/- miceox-LDL/FBS-induced VSMCs Liver weight and atherosclerotic plaque size↓VSMC proliferation and migration↓Akt/MEK/ERK pathway↓ (263)
Aqueous extracts of Dendrobium catenatum High-cholesterol diet-induced zebrafish atherosclerosis modelLow shear stress-induced endothelial cell dysfunction model Atherosclerotic plaque size and macrophage infiltration↓Levels of TC and TG↓MDA content↓and SOD activity↑ (264)
Ethanol extracts of Psoralea corylifolia HFD-induced LDLR-/- miceox-LDL-induced HUVEC injury Atherosclerotic lesion size and macrophage infiltration↓Expression of VCAM-1 and ICAM-1↓and cholesterol efflux↑PARγ-ABCA1/ABCG1 pathway↑and NF-κB pathway↓ (265)
Ethyl acetate extracts of Caesalpinia sappan HFD-induced ApoE-/- mice Macrophage infiltration and atherosclerotic lesion size↓ (266)
Methanol extracts of Ophiopogonis Radix ox-LDL-induced mouse peritoneal macrophage cells Levels of TG and TC↓SOD, GSH-Px activities, and ABCA1 expression↑ (267)
Ethanol extracts of Arctium lappa TNF-α-induced HUVEC injury Cell viability and expression of IL-1β, TNF-α, IL-6↓NF-κB pathway↓ (268)
Aqueous extracts of Eucommia ulmoides HFD-induced ApoE-/- mice Atherosclerotic lesion sizes and total cholesterol↓Expression of TNF-α, IL-1β, MIF↓ (269)
Ethanol extracts of Usnea diffracta HFD- and vitamin D3-induced atherosclerotic rat model Atherosclerotic lesion sizes↓Levels of TC, TG, LDL-c↓and HDL-c↑AST and ALT activities and levels of TNF-α, IL-1β, MCP-1↓TLR5/MyD88/NF-κB pathway↓ (270)
Ethanol extracts of Ganoderma lucidum spore HFD-induced atherosclerotic rabbit modelox-LDL-induced THP-1 cells Levels of TC, TG, LDL-c↓and HDL-c↑Atherosclerotic lesion sizes and foam cell formation↓Expression of LXRα, ABCA1 and ABCG1↑ (271)
Aqueous extracts of Salvia miltiorrhiza HFD-induced ApoE-/- miceox-LDL-induced HUVECsox-LDL-induced RAW264.7 cells Atherosclerotic lesion sizes and levels of TG and IL-6↓Expression of p62↓and LC3B II↑Foam cell formation↓ (272)
Ethanol extracts of Salvia miltiorrhiza HFD-induced atherosclerotic rat model Levels of TC, TG, LDL-c↓and HDL-c↑Abundance of Actinobacteriota and Proteobacteria↑Growth of Firmicutes and Desulfobacterita↓ (273)
Butanol extracts of Acanthopanax senticosus HFD-induced ApoE-/- mice Atherosclerotic lesion sizes↓Levels of TC, TG, LDL-c↓and HDL-c↑Levels of TNF-α, IL-1β, IL-6↓and NF-κB pathway↓ (274)
Ethanol extracts of Edgeworthia gardneri HFD-induced ApoE-/- miceox-LDL-induced macrophages and RAW264.7 cells Atherosclerotic lesion sizes↓Macrophage content in atherosclerotic plaque↓Macrophage foam cell formation↓and CYP7A11 expression↑ (275)
Ethanol extract of Schisandrae chinensis HFD-induced atherosclerotic rat model Atherosclerotic lesion sizes↓Levels of TG, LDL-c↓and HDL-c↑and Nrf2/HO-1 pathway↑ (276)
Myocardial ischemia-reperfusion injury
Ethyl acetate extracts of Cinnamomi Ramulus I/R-induced myocardial injury LVEF and LVFS↑and expression of IL-1β, IL-6, TNF-α↓NLRP3/Caspase-1 pathway↓ (107)
Ethanol extracts of Origanum majorana I/R-induced myocardial injuryLPS-treated aorta segments Cardiac contractility (noradrenaline and endothelin-1)↓Expression of IL-1β, IL-6↓and SOD-1↑ (113)
Ethanol extracts of Melissa officinalis I/R-induced myocardial injury dp/dt max and dp/dt min values↑Coronary venous effluent, collagen content, oxidative stress↓ (277)
Methanol extracts of Galium verum I/R-induced myocardial injury dp/dt max values and dp/dt min↑Levels of TBARS, O2-, H2O2↓and SOD, CAT activities↑ (278)
Methanol extracts of Allium ursinum I/R-induced myocardial injury dp/dt max values, dp/dt min, SLVP, SOD, CAT activities↑Levels of TBARS, O2-, H2O2↓ (279)
Ethanol extracts of Cinnamomum zeylanicum I/R-induced myocardial injury Myocardial infarct size and levels of cTnl, LDH, MDA↓SOD, GSH, and CAT activities↑ (280)
n-butanol extract of Potentilla anserina I/R-induced myocardial injury Activities of GSH, SOD, CAT↑and MDA content↓Apoptosis of cardiomyocyte↓ (281)
Methanol extracts of Dunaliella salina I/R-induced myocardial injury Myocardial infarct size, LDH level, number of neutrophils↓dp/dt max, SLVP↑and TLR4/NF-κB pathway↓ (282)
Methanol extracts of Taraxacum officinale I/R-induced myocardial injury LDH and CK levels, myocardial infarct size↓Activities of GSH and CAT↑ (283)
Aqueous extracts of Crataegus persica I/R-induced myocardial injury in diabetic rats Expression of Nrf2, DJ-1↑Activities of GSH, SOD, CAT↑and MDA content↓ (284)
Ethanol extracts of Melissa Officinalis I/R-induced myocardial injury Myocardial infarct size, MDA content, LDH level↓SOD activity↑ (285)
Ethanol extracts of Pueraria lobata and Salvia miltiorrhiza I/R-induced myocardial injury Myocardial infarct size and levels of CK and LDH↓VEGFR2/ERK pathway↑ (286)
Ethanol extracts of Salvia miltiorrhiza and Andrographis paniculata I/R-induced myocardial injury Levels of IL-6, TNF-α, IL-1β, MCP-1, IL-33↓NLRP3/ASC/Caspase-1 pathway↓ (287)
Heart failure
Ethanol extracts of Crataegus pinnatifida DOX-induced heart failure model LVDs and LVDd↓and dp/dt max↑Levels of BNP, CK-MB, IL-6, IL-1β, TNF-α↓GSH-Px and CAT activity↑and MDA content↓ (288)
Ethanol extracts of Ginkgo biloba LAD-induced heart failure model Expression of IL-1β and TNF-α↓LVEF and LVFS↑ (289)
Ethanol extracts of Ophiopogon japonicus DOX-induced heart failure model dp/dt max, LVEF, LVFS↑and LVDs, LVDd↓Levels of CK-MB, LDH, AST, IL-6, IL-1β, TNF-α↓Activities of SOD, GSH-Px, CAT↑and MDA content↓p38 MAPK pathway↓ (290)
Alkaloid extracts of Aconitum carmichaeli AAC-induced heart failure model LVEF and LVFS↑and LVDs and LVDd↓Levels of ANP, NT-proBNP, TNF-α↓Expression of α-SMA and collagen I/III↓ (291)
Myocardial infarction
Aqueous extracts of Salvia miltiorrhiza LAD-induced myocardial infarction model LVEF and LVFS↑and LVDs and LVDd↓Levels of BNP, TNF-α, IL-1β↓TLR4/TRAF6/NF-κB pathway↓ (292)
Ethanol extracts of Schisandra chinensis ISO-induced myocardial infarction model LDH, CK levels↓and SOD, GSH-Px, CAT activities↑Nrf2/HO-1 pathway↑ (293)
Aqueous extracts of Spinacia oleracea ISO-induced myocardial infarction model Levels of LDH, CK-MB, IL-6, TNF-α, TC, TG↓Activities of SOD, CAT, GSH-Px and GR↑ (294)
Aqueous extracts of Gentianella acuta ISO-induced myocardial infarction model Levels of LDH, CK, IL-6, TNF-α↓TLR4/MyD88/NF-κB pathway↓ (295)
Methanol extracts of Agrimonia pilosa ISO-induced myocardial infarction model Levels of CK-MB, LDH, CK↓ROS generation and MDA levels↓and SOD activity↑PI3K/Akt pathway↑ (296)
Ethanol extracts of Syringa pinnatifolia LAD-induced myocardial infarction modelHypoxia-induced H9c2 cell injury Levels of CK-MB, LDH, and inflammatory cell infiltration↓p53-mediated apoptotic pathway↓ (297)
Ethanol extracts of Anchusa italica LAD-induced acute myocardial infarction model LVEF and LVFS↑and LVDs and LVDd↓Myocardial infarct size and levels of TNF-α, IL-1β, IL-6↓PI3K/Akt/mTOR pathway↓ (298)
Hypertension
Aqueous extracts of Whitmania pigra Spontaneously hypertensive ratsAng II-induced H9c2 cells LVEF and LVFS↑and LVDs and LVDd↓Blood pressure↓and expression of collagen I/III, TGF-β↓H9c2 cell viability↑and p38/JNK pathway↓ (299)
Aqueous extracts of Momordica charantia High salt-induced hypertension MAP, SBP, MDA content↓and activities of CAT and SOD↑ (300)
Ethanol extracts of Plantago asiatica Spontaneously hypertensive rats MAP, SBP, collagen deposition↓LVEF and LVFS↑and LVDs and LVDd↓ (301)
Aqueous extracts of Eriobotrya japonica Spontaneously hypertensive ratsAng II-induced H9c2 cells LVEF and LVFS↑GATA4-NFATc3 pathway↓ (302)
Aqueous extracts of Chimonanthus salicifolius Spontaneously hypertensive rats LDL-c, TC, TG levels↓and HDL-c level↑and ERS↓ (303)
Others
Aqueous extracts of Salvia miltiorrhiza HFD-fed db/db miceHigh glucose-induced VSMCs Plaque area and ROS generation↓Expression of KLF10 and HO-1↓and cell viability↓ (304)
Ethanol extracts of Plantago asiatica ISO-cardiac hypertrophyISO-induced H9c2 cells Collagen deposition and expression of BNP, ANP, β-MHC↓Cardiomyocyte apoptosis↓ (106)
Ethanol extracts of Lycium chinense HFD/streptozotocin-induced diabetic cardiomyopathy Blood glucose and levels of TG, AST, LDH, CK-MB↓Expression of IL-6, IL-1β, TNF-α↓MDA content↓and activities of CAT, GSH-Px, SOD↑p53-mediated apoptotic pathway and NF-κB pathway↓ (305)
Aqueous extracts of Arnebiae Radix Acetylcholine and CaCl2-induced atrial fibrillation AF duration↓and induction time of AF↑Atrial fibrosis, α-SMA, and collagen I expression↓LVFS↑and atrial enlargement (LAD, LA area)↓ (306)
Aqueous extracts of Dendrobium candidum ISO-induced cardiac hypertrophy modelISO-induced H9c2 cells LVSP, Heart body/body weight ratio, LV/TL ratio↓Serum levels of ANP and BNP↓Collagen deposition and ERK pathway↓ (307)
Ethanol extracts of Smilax glabra TAC-induced cardiac hypertrophy modelISO-induced H9c2 cells Myocardial fibrosis and collagen content↓Expression of ANP, BNP, β-MHC, NT-proBNP↓Raf/MEK/ERK pathway↓ (308)
Ethanol extracts of Centella asiatica ISO-induced cardiac hypertrophy modelISO-induced atrial cardiomyocytes Heart/body weight ratio↓and levels of AST, BNP, ANP↓Collagen content, cardiac fibrosis, expression of TNF-α, IL-6↓MDA content↓and SOD expression↑PI3K/Akt pathway↑and NF-κB pathway↓ (309)
Aqueous extracts of Angelica sinensis and Hedysarum polybotrys X-irradiation-induced myocardial fibrosisX-irradiation-induced cardiac fibroblasts Myocardial fibrosis↓and TGF-β1 expression↓Cardiac fibroblast apoptosis↓Expression of miR-21, collagen 1α, c-Jun, OPN↓ (310)
Aqueous extracts of Salvia miltiorrhiza and Carthamus tinctorius HFD/streptozotocin-induced diabetic cardiomyopathySodium palmitate-treated H9c2 cells Glucose level↓and insulin level↑Cardiomyocyte cross-sectional↓and LVFS↑Levels of BNP and cell apoptosis↓ (311)

AAC, Abdominal aortic coarctation surgery; ANP, Atrial natriuretic peptide; BNP, Brain natriuretic peptide; dp/dt min, Minimum rate of left ventricular pressure development; dp/dt max, Maximum rate of left ventricular pressure development; GSH, glutathione; LA, left atrium; LAD, Left atrial diameter; LVEDP, Left ventricular end-diastolic pressure; LV/TL, Left ventricular weight/tibia length; LVSP, Left ventricular systolic pressure; SLVP, Systolic left ventricular pressure.

↑ upregulated, ↓ downregulated.

Summary of traditional Chinese medicine compounds in the prevention and treatment of various cardiovascular diseases from 2018-2023.

Compound cardiovascular diseases (model) Biological activity Ref.
Phenolic acids
Salvianolic acid A Atherosclerosis (animal and cellular models) Anti-pyroptosis and anti-inflammation (312)
Myocardial infarction (animal and cellular models) Anti-apoptosis (313)
Diabetic cardiomyopathy (animal model) Improving mitochondrial function and anti-apoptosis (314)
Hypertension (animal and cellular models) Anti-apoptosis (315)
Salvianolic acid B Atherosclerosis (cellular model) Anti-inflammation, anti-pyroptosis, and anti-ERS (316)
Myocardial ischemia-reperfusion injury (animal and cellular models) Anti-ferroptosis, anti-apoptosis, antioxidant, and anti-inflammation (317, 318)
Myocardial infarction (animal model) Anti-ferroptosis (119)
Uremic cardiomyopathy (animal model) Anti-inflammation and anti-fibrosis (319)
Diabetic cardiomyopathy (animal and cellular models) Angiogenesis (320)
Chlorogenic acid Heart failure (animal model) Anti-inflammation, antioxidant, and anti-apoptosis (321)
Myocardial infarction (animal model) Anti-inflammation and anti-oxidative stress (322)
Hypertension (animal model) Modulation of gut microbiota (323)
Diabetic cardiomyopathy (animal and cellular models) Anti-ERS and anti-apoptosis (324)
Gallic acid Atherosclerosis (animal model) Modulation of gut microbiota (325)
Heart failure (animal and cellular models) Activation of autophagy and anti-fibrosis (326, 327)
Atrial fibrillation (animal model) Inhibiting immunoproteasome (328)
Hypertension (animal model) Antioxidant (329)
Cardiac hypertrophy (animal model) Antioxidant (330)
Syringic acid Myocardial ischemia-reperfusion injury (animal model) Anti-apoptosis (331)
Cardiac hypertrophy (animal model) Anti-fibrosis (332)
Diabetic cardiomyopathy (animal model) Antioxidant (333)
Caffeic acid Atherosclerosis (animal model) Anti-inflammation (334)
Hypertension (animal model) Antioxidant (335)
Cardiac remodeling (animal and cellular models) Anti-fibrosis (336)
Punicalagin Atherosclerosis (cellular model) Anti-inflammation (337)
Myocardial ischemia-reperfusion injury (animal model) Antioxidant and anti-apoptosis (338)
Diabetic cardiomyopathy (animal and cellular models) Improving mitochondrial function (339)
Ferulic acid Atherosclerosis (animal model) Modulation of gut microbiota (120)
Myocardial ischemia-reperfusion injury (animal model) Anti-ferroptosis and antioxidant (340)
Heart failure (animal model) Antioxidant and anti-apoptosis (341)
Myocardial infarction (cellular model) Activation of autophagy (342)
Diabetic cardiomyopathy (animal model) Modulation of gut microbiota and anti-apoptosis (343)
Cinnamic acid Atherosclerosis (animal model) Antioxidant (344)
Myocardial ischemia-reperfusion injury (animal model) Anti-inflammation and anti-pyroptosis (118)
Cardiomyopathy (animal and cellular models) Antioxidant, anti-inflammation, and anti-dyslipidemia (345, 346)
Flavonoids
Formononetin Atherosclerosis (cellular model) Anti-inflammation and antioxidant (347)
Myocardial ischemia-reperfusion injury (animal model) Anti-inflammation and antioxidant (348)
Myocardial infarction (animal model) Anti-inflammation (349)
Hypertension (animal model) Anti-inflammation (350)
Baicalein Atherosclerosis (cellular model) Anti-inflammation (128)
Myocardial ischemia-reperfusion injury (cellular model) Antioxidant (351)
Hypertension (cellular model) Anti-fibrosis and anti-inflammation (352)
Cardiac hypertrophy (animal model) Antioxidant and activation of autophagy (353)
Diabetic cardiomyopathy (animal model) Antioxidant and anti-inflammation (354)
Baicalin Atherosclerosis (animal model) Anti-inflammation (355)
Myocardial ischemia-reperfusion injury (animal and cellular models) Anti-ferroptosis and anti-inflammation (356, 357)
Cardiac hypertrophy (animal model) Activation of the SIRT3 pathway (358)
Cardiomyopathy (animal model) Anti-inflammation (359)
Hypertension (animal model) Modulation of gut microbiota (360)
Hesperidin Atherosclerosis (animal model) Anti-inflammation (361)
Myocardial ischemia-reperfusion injury (animal model) Inhibition of autophagy (362)
Cardiac hypertrophy (animal model) Anti-inflammation, anti-apoptosis, and antioxidant (363)
Hyperoside Atherosclerosis (cellular model) Anti-inflammation (364)
Myocardial ischemia-reperfusion injury (animal model) Antioxidant (365)
Myocardial infarction (animal model) Anti-inflammation (366)
Heart failure (animal model) Anti-apoptosis and activation of autophagy (367)
Puerarin Atherosclerosis (cellular model) Anti-inflammation and antioxidant (368)
Myocardial ischemia-reperfusion injury (animal and cellular models) Anti-ferroptosis and anti-inflammation (369)
Heart failure (animal and cellular models) Anti-apoptosis and anti-inflammation (370)
Cardiac hypertrophy (animal model) Activation of PPARα/PGC-1 pathway (371)
Hypertension (animal model) Antioxidant (372)
Myocardial infarction (animal model) Anti-apoptosis (373)
Diabetic cardiomyopathy (animal and cellular models) Anti-inflammation (374)
Quercetin Atherosclerosis (cellular model) Anti-inflammation and activation of autophagy (375)
Myocardial ischemia-reperfusion injury (animal and cellular models) Anti-apoptosis (376)
Diabetic cardiomyopathy (animal model) Anti-inflammation (377)
Myocardial infarction (animal model) Anti-fibrosis (378)
Atrial fibrillation (animal and cellular models) Anti-fibrosis (379)
Kaempferol Atherosclerosis (animal model) Antioxidant (380)
Heart failure (animal model) Antioxidant and anti-inflammation (381)
Diabetic cardiomyopathy (animal model) Antioxidant (382)
Naringenin Atherosclerosis (animal model) Anti-inflammation, activation of autophagy, and anti-ERS (383, 384)
Myocardial ischemia-reperfusion injury (animal and cellular models) Anti-ferroptosis, antioxidant, and anti-inflammation (130, 385)
Hypertension (animal model) Antioxidant (131)
Cardiac hypertrophy (animal and cellular models) Antioxidant (386)
Diabetic cardiomyopathy (animal model) Antioxidant, anti-inflammation, and anti-apoptosis (387)
Tilianin Atherosclerosis (cellular model) Anti-inflammation (388)
Myocardial ischemia-reperfusion injury (animal model) Antioxidant, anti-apoptosis, and anti-inflammation (389, 390)
Diabetic cardiomyopathy (animal and cellular models) Antioxidant and anti-inflammation (391)
Biochanin A Atherosclerosis (animal and cellular models) Anti-inflammation (392)
Myocardial ischemia-reperfusion injury (animal model) Anti-inflammation (393)
Diabetic cardiomyopathy (animal model) Antioxidant (394)
Myocardial infarction (animal model) Anti-inflammation (395)
Hydroxysafflor Yellow A Atherosclerosis (animal model) Anti-inflammation (396)
Myocardial ischemia-reperfusion injury (animal model) Activation of autophagy and anti-inflammation (397)
Diabetic cardiomyopathy (animal model) Antioxidant (398)
Cardiac hypertrophy (animal model) Antioxidant (399)
Xanthohumol Atherosclerosis (cellular model) Modulation lipid metabolism (400)
Myocardial ischemia-reperfusion injury (animal model) Anti-ferroptosis (401)
Cardiac hypertrophy (animal model) Anti-fibrosis (402)
Dihydromyricetin Atherosclerosis (animal model) Anti-inflammation (403)
Myocardial ischemia-reperfusion injury (animal and cellular models) Improving mitochondrial function and antioxidant (404)
Cardiomyopathy (animal model) Anti-inflammation and antioxidant (405)
Cardiac hypertrophy (animal model) Antioxidant (406)
Acacetin Atherosclerosis (animal model) Antioxidant and anti-inflammation (407)
Myocardial ischemia-reperfusion injury (animal model) Antioxidant, anti-inflammation, and anti-apoptosis (408)
Cardiac hypertrophy (animal model) Anti-inflammation, antioxidant, and anti-apoptosis (409)
Diabetic cardiomyopathy (animal and cellular models) Antioxidant (410)
Hypertension (animal model) Improving mitochondrial function (411)
Icariin Atherosclerosis (animal and cellular models) Anti-apoptosis (412)
Myocardial ischemia-reperfusion injury (cellular model) Antioxidant and anti-ferroptosis (413)
Myocardial infarction (animal model) Immunomodulatory (414)
Atrial fibrillation (animal model) Improving mitochondrial function (415)
Hypertension (animal model) Antioxidant (416)
Cardiac hypertrophy (cellular model) Activation of autophagy (417)
Diabetic cardiomyopathy (animal model) Improving mitochondrial function and anti-fibrosis (418)
Scutellarin Atherosclerosis (animal model) Anti-apoptosis (125)
Myocardial ischemia-reperfusion injury (animal and cellular models) Anti-inflammation and anti-apoptosis (126)
Cardiac hypertrophy (cellular model) Anti-inflammation (123)
Diabetic cardiomyopathy (animal model) Anti-apoptosis, anti-inflammation, and antioxidant (124, 419)
Myocardial infarction (animal model) Antioxidant, anti-apoptosis, and anti-inflammation (127)
Morin Atherosclerosis (cellular model) Anti-inflammation and activation of autophagy (420)
Myocardial ischemia-reperfusion injury (animal model) Antioxidant (421)
Epigallocatechin-3-gallate Myocardial ischemia-reperfusion injury (animal model) Antioxidant and anti-inflammation (422)
Heart failure (animal model) Antioxidant (423)
Myocardial infarction (animal model) Anti-apoptosis and anti-inflammation (424)
Hypertension (animal model) Antioxidant (425)
Cardiac hypertrophy (cellular model) Improving mitochondrial function and anti-fibrosis (426, 427)
Diabetic cardiomyopathy (animal model) Anti-fibrosis (428)
Atrial fibrillation (animal model) Anti-fibrosis (429)
Stilbenes
Resveratrol Atherosclerosis (cellular model) Anti-inflammation (430)
Myocardial ischemia-reperfusion injury (cellular model) Anti-ferroptosis, improving mitochondrial function, and antioxidant (134, 431)
Heart failure (patients with heart failure) Anti-inflammation (432)
Myocardial infarction (animal model) Antioxidant, anti-inflammation, and anti-ferroptosis (433, 434)
Hypertension (animal model) Antioxidant, anti-inflammation, and modulation of gut microbiota (435, 436)
Cardiac hypertrophy (animal model) Antioxidant and activation of autophagy (437)
Diabetic cardiomyopathy (animal model) Antioxidant (438)
Atrial fibrillation (animal model) Anti-apoptosis and anti-fibrosis (439)
Polydatin Atherosclerosis (animal model) Anti-inflammation, antioxidant, and activation of autophagy (138, 440)
Myocardial infarction (cellular model) Antioxidant (137)
Cardiomyopathy (animal model) Improving mitochondrial function and antioxidant (441)
Raloxifene Atherosclerosis (animal model) Anti-inflammation (442)
Heart failure (animal model) Anti-inflammation and antioxidant (443)
Anthraquinones
Emodin Myocardial ischemia-reperfusion injury (cellular model) Anti-inflammation and anti-pyroptosis (444)
Heart failure (animal model) Anti-apoptosis (445)
Cardiac hypertrophy (animal model) Anti-fibrosis (446)
Aloe-emodin Atherosclerosis (animal model) Activation of autophagy (150)
Myocardial infarction (animal model) Anti-apoptosis and anti-fibrosis (151)
Hypertension (animal and cellular models) Anti-inflammation (152)
Kanglexin Atherosclerosis (animal and cellular models) Hypolipidemic (447)
Myocardial ischemia-reperfusion injury (animal model) Anti-inflammation and anti-pyroptosis (448)
Saponins
Astragaloside IV Atherosclerosis (cellular model) Anti-inflammation, antioxidant, and anti-apoptosis (157, 449)
Myocardial ischemia-reperfusion injury (animal model) Antioxidant and anti-apoptosis (450)
Heart failure (animal model) Angiogenesis (451)
Myocardial infarction (animal and cellular models) Anti-inflammation, angiogenesis, and anti-pyroptosis (155, 452)
Hypertension (animal model) Anti-inflammatory and antioxidant (453)
Diabetic cardiomyopathy (animal model) Anti-ferroptosis, antioxidant, and activation of autophagy (454, 455)
Ginsenoside Rb1 Atherosclerosis (cellular model) Antioxidant and anti-inflammation (456)
Myocardial ischemia-reperfusion injury (animal and cellular models) Antioxidant and improving mitochondrial function (457)
Heart failure (animal model) Improving mitochondrial function (458)
Diabetic cardiomyopathy (animal model) Antioxidant, anti-apoptosis, anti-fibrosis, and anti-inflammation (459)
Ginsenoside Rb2 Atherosclerosis (animal and cellular models) Anti-inflammation (460)
Myocardial ischemia-reperfusion injury (animal model) Anti-inflammation and antioxidant (461)
Notoginsenoside R1 Atherosclerosis (cellular model) Anti-inflammation, anti-apoptosis, and antioxidant (462)
Myocardial ischemia-reperfusion injury (animal model) Anti-apoptosis (463)
Cardiomyopathy (animal and cellular models) Anti-apoptosis, antioxidant, and anti-fibrosis (464)
Cardiac hypertrophy (animal model) Anti-inflammation (465)
Terpenoids
Tanshinone IIA Atherosclerosis (animal model) Anti-inflammation and anti-pyroptosis (466)
Myocardial ischemia-reperfusion injury (animal model) Antioxidant, anti-inflammation, and anti-apoptosis (467)
Myocardial infarction (animal model) Antioxidant (468)
Diabetic cardiomyopathy (cellular model) Anti-ERS and anti-oxidative stress (469)
Cardiac fibrosis (animal model) Anti-fibrosis and antioxidant (470)
Paeoniflorin Atherosclerosis (cellular model) Anti-apoptosis and activation of autophagy (163)
Myocardial ischemia-reperfusion injury (animal model) Antioxidant and anti-apoptosis (471)
Heart failure (animal model) Anti-fibrosis (472)
Hypertension (animal model) Anti-inflammation and antioxidant (473)
Catalpol Atherosclerosis (cellular model) Anti-inflammation, antioxidant, and anti-ERS (474)
Myocardial ischemia-reperfusion injury (animal and cellular models) Antioxidant and anti-inflammation (475)
Hypertension (cellular model) Anti-inflammation (476)
Diabetic cardiomyopathy (animal model) Anti-apoptosis (477)
Crocin Atherosclerosis (animal model) Anti-inflammation (478)
Myocardial ischemia-reperfusion injury (animal and cellular models) Anti-ERS (479)
Myocardial infarction (animal model) Anti-inflammation (480)
Hypertension (animal model) Antioxidant (481)
Diabetic cardiomyopathy (animal model) Activation of autophagy and anti-apoptosis (482)
Ginkgolide B Atherosclerosis (animal model) Modulation of gut microbiota, anti-inflammation, and antioxidant (483, 484)
Myocardial ischemia-reperfusion injury (cellular model) Anti-inflammation and anti-apoptosis (485, 486)
Myocardial infarction (animal model) Anti-inflammation (487)
Cardiac hypertrophy (cellular model) Activation of autophagy (488)
Diabetic cardiomyopathy (animal model) Antioxidant and anti-fibrosis (489)
Lycopene Atherosclerosis (animal model) Inhibition of cholesterol and antioxidant (490)
Myocardial ischemia-reperfusion injury (cellular model) Improving mitochondrial function, anti-apoptosis, and anti-ERS (491, 492)
Cardiac hypertrophy (animal and cellular models) Antioxidant and improving mitochondrial function (493)
Artemisinin Atherosclerosis (animal model) Anti-inflammation and antioxidant (494, 495)
Myocardial ischemia-reperfusion injury (animal model) Anti-inflammation (165)
Hypertension (animal model) Antioxidant (496)
Diabetic cardiomyopathy (animal model) Anti-inflammation and anti-fibrosis (497)
Oridonin Atherosclerosis (animal model) Anti-inflammation and antioxidant (498)
Myocardial ischemia-reperfusion injury (animal model) Anti-inflammation and anti-pyroptosis (499)
Myocardial infarction (animal model) Anti-inflammation and anti-fibrosis (500)
Cardiac hypertrophy (animal and cellular models) Activation of autophagy (501)
Alkaloids
Berberine Atherosclerosis (animal model) Modulation of gut microbiota (502)
Myocardial ischemia-reperfusion injury (animal and cellular models) Anti-inflammation, antioxidant, and anti-apoptosis (503, 504)
Heart failure (animal model) Improving mitochondrial function (505)
Myocardial infarction (animal model) Anti-inflammation (506)
Hypertension (animal model) Modulation of gut microbiota (507)
Cardiac hypertrophy (animal and cellular models) Activation of autophagy (508)
Diabetic cardiomyopathy (cellular model) Anti-inflammation (509)
Colchicine Atherosclerosis (cellular model) Anti-inflammation and anti-pyroptosis (510)
Heart failure (animal model) Anti-inflammation (511)
Cardiomyopathy (animal and cellular models) Anti-inflammation (512)
Myocardial infarction (animal model) Anti-inflammation (513)
Sinomenine Atherosclerosis (animal model) Anti-inflammation and antioxidant (514)
Myocardial ischemia-reperfusion injury (animal model) Anti-apoptosis, anti-inflammation, antioxidant (515)
Heart failure (animal model) Anti-fibrosis and anti-inflammation (516)
Cardiac hypertrophy (animal and cellular models) Antioxidant and anti-inflammation (517)
Nuciferine Atherosclerosis (animal model) Anti-apoptosis and activation of MMP12/Akt pathway (518)
Myocardial ischemia-reperfusion injury (animal model) Anti-apoptosis and activation of PPAR-γ (519)
Myocardial infarction (animal model) Anti-inflammation (520)
Polysaccharides
Dendrobium huoshanense Atherosclerosis (zebrafish model) Antioxidant and anti-inflammation (521)
Laminaria japonica Atherosclerosis (animal model) Modulation of gut microbiota (522)
Cordyceps militaris Atherosclerosis (animal model) Improving hyperlipidemia (523)
Undaria pinnatifida Atherosclerosis (animal model) Anti-inflammation (524)
Cipangopaludina chinensis Atherosclerosis (animal model) Modulation of gut microbiota (525)
Poria cocos Atherosclerosis (animal model) Anti-inflammation (526)
Lycium barbarum Atherosclerosis (animal model) Modulation of gut microbiota (527)
Myocardial ischemia-reperfusion injury (animal model) Improving mitochondrial function and antioxidant (528)
Cardiac hypertrophy (animal model) Anti-inflammation (529)
Schisandra chinensis Cardiac hypertrophy (animal model) Antioxidant (530)
Chuanminshen violaceum Myocardial ischemia-reperfusion injury (animal model) Anti-ferroptosis (531)
Polygonatum sibiricum Heart failure (animal model) Antioxidant, anti-inflammation, and anti-apoptosis (532)
Astragalus membranaceus Heart failure (animal model) Anti-inflammation (533)

↑ upregulated, ↓ downregulated.

 TCM formulas for CVD

Chinese herbal compounding (fu fang or prescription in Chinese) is the main form of TCM for the prevention and treatment of various diseases, which is the simultaneous application of multiple herbs to regulate the body as a whole for therapeutic purposes in clinical practice. A meta-analysis showed that the efficacy of Bushen Huoxue decoction in treating coronary heart disease was superior to conventional Western medicine (95). Bi and his colleagues (96) confirmed that Qingre Huatan formulae for the phlegm-heat-stasis syndrome pattern of coronary heart disease was safe and can effectively improve vascular endothelial function. In a randomized, multicenter, double-blind, non-inferiority trial, the results showed that treatment with the Songling Xuemaikang capsule had a well-tolerated and improved total hypertension symptom score and total cholesterol in patients with essential hypertension (97). In addition, TCM prescriptions have been shown to improve sleep disorders in patients with CVD (98). Mechanistically, the Qing-Xue-Xiao-Zhi formula can alleviate the development of atherosclerosis by blocking the TLR4/MyD88/NF-κB pathway to promote lipid efflux, reducing atherosclerotic plaques in the aorta and aortic root and serum TMAO levels, and inhibiting macrophage-mediated inflammation (99). Wu et al. (100) observed that the QiShenYiQi dripping pill can inhibit myocardial ischemia-induced ferroptosis in cardiomyocytes by reducing mitochondrial ROS levels and restoring mitochondrial function (e.g., biogenesis and dynamic homeostasis). Chen et al. (101) demonstrated that Qishen granule administration exhibited cardioprotective effects by inactivation of NF-κB/NLRP3/GSDMD pathway in myocardial infarction, as evidenced by improving cardiac function, reducing inflammatory cell infiltration and collagen deposition, as well as inhibiting NLRP3 inflammasome activation and pyroptosis. Qing-Xin-Jie-Yu granule treatment contributed to the alleviation of atherosclerosis development by regulating gut microbiota composition (that is, the relative abundance of Turicibacter and Roseburia was enhanced), increasing bile acids production, and reducing metaflammation induced by HFD (102). Zhou et al. (103) showed by a comprehensive network analysis that Shenfu injection can be used to treat coronavirus disease 2019 (COVID-19) combined with heart failure. Except for the above-mentioned TCM prescriptions, there are still numerous studies reported on the use of some classical TCM formulas for the prevention and treatment of CVD according to ancient works and the modern clinical. Herein, we summarized the pharmacological effects and molecular mechanisms of TCM prescriptions on CVD based on published studies from 2018 to 2023 and listed in Table 1 .

 TCM extracts for CVD

Increasing evidence has proved that single TCM extracts also possessed a protective effect against CVD except for TCM preparations mentioned above ( Table 2 ). For example, a network pharmacology study showed that Schisandra extracts have the potential for therapeutic effects on atherosclerosis by regulating immune inflammation and oxidative stress (104). Recently, the key mechanisms of TCM extracts in CVD may be associated with immunomodulation, antioxidant, anti-cell death, anti-inflammatory, and gut microbiota regulation. For example, Quince extract exhibited hypolipidemic, antioxidant, anti-inflammatory, anti-thrombotic, and vascular endothelium protective effects on HFD-induced atherosclerosis (105). Plantago asiatica L. seeds extracts prevented isoproterenol-induced cardiac hypertrophy by restoration of autophagy and inhibition of cardiomyocyte apoptosis (106). The ethyl acetate extracts of Cinnamomi Ramulus protect rats from myocardial ischemia-reperfusion injury by suppression of NLRP3 inflammasome activation and pyroptosis (107). In doxorubicin-induced chronic heart failure, the combination of aqueous extracts of Aconiti Lateralis Radix Praeparata and Zingiberis Rhizoma has a better therapeutic effect than their single aqueous extracts, which may be associated with improving left ventricular function and promoting mitochondrial energy metabolism through activation of the PPARα/PGC-1α/Sirt3 pathway (108). Treatment with bay leaf extracts exhibited an anti-inflammatory effect in the rat model of myocardial infarction (109), reflected by reducing the levels of C-reactive protein and myeloperoxidase. Another study showed that aqueous extracts of Ligustrum robustum attenuated atherosclerosis development by modulating gut microbiota composition and metabolism, as evidenced by increased relative abundance of genus Bifidobacterium, and reduced serum TMAO and bile acid, as well as decreased cholesterol absorption (110). In addition, single TCM extracts used for the treatment of CVD have been shown to regulate mitochondrial homeostasis and maintain normal autophagy function, as well as have anti-ERS and anti-contractile effects. For instance, Vilella et al. (111) reported that green tea extracts ameliorated cardiomyopathy progression by improving mitochondrial function. In streptozotocin-induced diabetic atherosclerosis, Ginkgo biloba leaf extracts reduced plaque lipid deposition and serum inflammatory cytokines secretion via inhibiting ERS and mTOR-mediated autophagy (112). Granado et al. (113) proved that Marjoram extracts prevented inflammatory response, apoptosis, and oxidative stress of cardiomyocytes induced by coronary ischemia-reperfusion, as well as possessed anti-contractile effects in aorta segments. Taken together, the cardioprotective effects of single TCM extracts on various CVDs were confirmed, but its underlying mechanisms and safety need to be further explored before clinical practice.

 Compounds isolated from TCM for CVD

With the development of pharmaceutical chemistry and pharmacology, many scholars have conducted studies on the bioactive components of TCM in recent years. It has been found that a large number of effective compounds extracted from TCM, such as phenolic acids, flavonoids, stilbenes, anthraquinones, saponins, terpenoids, alkaloids, polysaccharides, etc., all of which possessed therapeutic effects on various CVDs ( Table 3 ).

Phenolic acids

Phenolic acids are a subclass of plant phenolics that can be isolated and extracted from many traditional Chinese herbs such as Angelica sinensis, Salvia miltiorrhiza, Cinnamomi ramulus, Lonicera japonica, Radix Paeoniae Rubra, Ligusticum wallichii, etc. Modern pharmacological studies have confirmed that phenolic acids have a variety of biological activities, including antioxidant, anti-inflammation, anti-coagulant, and hypolipidemic (114). Of note, numerous studies have demonstrated that phenolic acids have been shown to have a therapeutic effect on CVD (115, 116). Vanillic acid, a phenolic compound extracted from Angelica sinensis, could alleviate hypoxia/reoxygenation-induced H9c2 cardiomyocyte injury by inhibiting cell apoptosis and oxidative stress (117). Cinnamic acid is an active phenolic acid extracted from Cinnamomi ramulus that has a cardioprotective effect against myocardial ischemia-reperfusion injury by inhibiting NLRP3 inflammasome-mediated inflammation and cardiomyocyte pyroptosis (118). Shen et al. (119) showed that Salvianolic acid B can effectively inhibit ferroptosis and mitochondrial oxidative stress by activation of the Nrf2 pathway, thereby attenuating myocardial infarction. Another study reported that ferulic acid ameliorated atherosclerotic injury by modulating gut microbiota and lipid metabolism (120), as evidenced by reducing the relative abundance of Erysipelotrichaceae and Firmicutes and increasing the relative abundance of Ruminococcaceae, as well as downregulating serum levels of total cholesterol, triglyceride, and low-density lipoprotein cholesterol and atherogenic index in HFD-fed ApoE-/- mice. In addition, we summarized many phenolic acids such as caffeic acid, protocatechuic acid, chlorogenic acid, gallic acid, benzoic acid, and erucic acid for the treatment and prevention of CVD, which are listed in Table 3 .

 Flavonoids

Flavonoids are secondary metabolites widely found in TCM and have various pharmacological activities that are beneficial to human health (121), such as antioxidant, anti-apoptosis, anti-inflammation, antitumor, etc. Of note, many studies have found that flavonoid compounds can play an effective protective role in the treatment of CVD (122). Functionally, scutellarin, a flavonoid compound extracted from Erigeron breviscapus, possessed protective effects against cardiac hypertrophy (123), diabetic cardiomyopathy (124), atherosclerosis (125), myocardial ischemia-reperfusion injury (126), and myocardial infarction (127) via inhibition of inflammation, oxidative stress, and apoptosis. Baicalein extracted from Scutellaria baicalensis inhibited Ang II/oxidized low-density lipoprotein-induced inflammation via inactivation of the AMPK/NF-κB pathway, thus showing anti-atherosclerotic activity (128). Wogonin, one of the main flavonoid compounds of Scutellaria radix, ameliorated isoproterenol-induced myocardial infarction via suppression of inflammation and oxidative stress (129). Naringenin was the main flavonoid that existed in various citrus fruits, bergamots, and tomatoes. Naringenin treatment inhibited myocardial ischemia-reperfusion-induced inflammation, lipid peroxidation, and ferroptosis by activating the Nrf2/GPX4 pathway (130). Naringenin suppressed blood pressure, cholesterol triglycerides, LDL, serum malondialdehyde (MDA), and nitric oxide, as well as increased serum superoxide dismutase and glutathione via blocking the STAT3 pathway in obesity-associated hypertension (131). Abukhalil et al. (132) reported that galangin, a natural flavonoid found in lesser galangal and honey, exerted a protective effect on diabetic cardiomyopathy by reduction of oxidative stress, inflammation, and hyperglycemia. Last but not least, pinocembrin belongs to this series of flavonoids and exerts an antioxidant effect on heart failure by activating the Nrf2/HO-1 pathway, evidenced by reducing ROS level in heart tissue and serum MDA level and improving cardiac function (133). Taken together, flavonoids possess a range of biological activities that prevent the development and progression of CVD, and their potential mechanisms are summarized in Table 3 .

 Stilbenes

Stilbenes are compounds with a stilbene parent structure connected by a vinyl group between two benzene rings and have a typical conjugated structure. Stilbenes are widely found in TCM, including Polygonum cuspidatum and Polygonum multiflorum, and have beneficial effects on human health. Resveratrol, a main compound extracted from Polygonum cuspidatum, can prevent myocardial ischemia-reperfusion injury by inhibition of oxidative stress and ferroptosis (134). Maayah et al. (135) found that resveratrol treatment inhibited cardiac NLRP3 inflammasome activation and reduced inflammatory responses, and thus alleviated doxorubicin-induced cardiomyopathy. Another study showed that resveratrol protects against atherosclerosis by reducing TMAO levels and enhancing hepatic bile acid biosynthesis through the remodeling of intestinal flora (136). Polydatin, an active component in Polygonum cuspidatum, can ameliorate acute myocardial infarction-induced cardiac damage by inhibition of oxidative stress and cell apoptosis via activation of the Nrf2/HO-1 pathway (137). Zhang and colleagues (138) confirmed that polydatin can inhibit inflammation and pyroptosis by blocking the NLRP3/caspase-1 pathway and triggering mTOR-mediated autophagy, thereby exerting an anti-atherosclerosis effect. 2,3,4’,5-tetrahydroxystilbene 2-O-β-D-glucoside (TSG) is extracted and purified from Polygonum multiflorum, which can prevent the development and progression of atherosclerosis by reducing lipid accumulation and inflammation in ApoE-/- mice fed with HFD (139). These results suggested that stilbenes exhibited therapeutic effects on CVD via different mechanisms ( Table 3 ).

 Anthraquinones

Anthraquinones are compounds with unsaturated cyclic diketone structures and are widely found in some Chinese herbal medicines (140). Accumulating studies have shown that anthraquinones have various biological activities, including antitumor, antioxidant, and anti-inflammation (141), etc. Emodin (1,3,8-trihydroxy-6-methylanthraquinone), a natural anthraquinone derivative, can be extracted and purified from natural plants such as Rhei radix et rhizoma, Polygoni Cuspidat, Polygoni multiflori, which protects against various CVDs (142). Previous studies have demonstrated that emodin exhibited a therapeutic effect on atherosclerosis via inhibition of inflammatory response (143), suppression of PPAR-γ-mediated lipid metabolism (144) and endothelial cell apoptosis (145), reducing oxidative stress (146). Other studies found that emodin can prevent cardiac hypertrophy (147), restrict vasodilation by activation of K+-ATP channels (148), and inhibition of myocardial fibrosis (149). Aloe-emodin is an active ingredient in Rheum palmatum and Aloe vera, which prevents the progression of various CVDs. For example, Tang et al. (150) reported that aloe-emodin exerted an anti-atherosclerosis effect by reducing atherosclerotic plaque in the aorta and lipid accumulation and promoting endothelial autophagy. Yu et al. (151) showed that aloe-emodin inhibited the development of cardiac fibrosis and hypertrophy in rats with chronic myocardial infarction by suppressing cardiac apoptosis and oxidative stress via the inactivation of the TGF-β/Smad pathway. Another study found that aloe-emodin exhibited specific therapeutic value in hypertension-related CVD by inhibiting NLRP3 inflammasome activation (152). Moreover, other anthraquinone compounds have protective effects against CVD, which is summarized in Table 3 .

 Saponins

Saponins are a class of glycosides with triterpenoids or steranes, which are widely found in natural plants and have been reported to have many pharmacological activities, including antitumor, anti-inflammation, anti-oxidative stress, etc. Importantly, previous studies have shown that saponins were shown to be effective in treating CVD ( Table 3 ) (153), such as atherosclerosis, myocardial infarction, myocardial ischemia-reperfusion injury, heart failure, cardiomyopathy, and hypertension. Astragaloside IV (AS-IV) is the main active ingredient purified from Astragalus membranaceus and serves as an effective therapeutic agent for the treatment of CVD (154). For example, AS-IV could markedly reduce myocardial infarction-induced myocardial fibrosis, cardiac hypertrophy, and macrophage pyroptosis by inhibition of the ROS/caspase-1/GSDMD pathway (155). Yin et al. (156) showed that AS-IV protects against myocardial ischemia-reperfusion injury by suppressing cardiomyocyte apoptosis and serum cardiac troponin levels via blocking CaSR/ERK1/2 and the related apoptotic pathways. Another study found that AS-IV treatment suppressed inflammation, plaque area, and serum lipids in HFD-induced atherosclerosis by blocking the MAPK/NF-κB pathway (157). Other studies proved that AS-IV can attenuate the progression of myocardial fibrosis (158), heart failure (159), and cardiac hypertrophy (160) by inhibiting Nrf2-mediated oxidative stress. Ginsenosides (mainly including the ginsenosides Rb1, Rb2, Rb3, Rc, Rd, Re, Rg3, and Rh2 and compound K) serve as the main active constituents of Panax ginseng and exert protection against CVD by suppression of oxidative stress, cholesterol accumulation, inflammation, and insulin resistance (161).

 Terpenoids

Terpenoids are a large group of organic compounds present in TCM and can be effectively used for treating various diseases. Importantly, the preventive and therapeutic effects of terpenoids on CVD have received increasing attention ( Table 3 ), which was associated with their remarkable biological activities, such as anti-inflammation, antioxidant, and anti-apoptosis. Tanshinone IIA, a fat-soluble component of Salvia miltiorrhiza, could protect against heart failure by inhibition of cardiomyocyte apoptosis via activating the AMPK/mTOR-mediated autophagy pathway (162). Paeoniflorin, a bioactive component extracted from Paeonia lactiflora, can ameliorate ox-LDL-induced atherosclerosis by inhibiting apoptosis and adhesion molecule expression via autophagy enhancement in human umbilical vein endothelial cells (163). Andrographolide, a bioactive labdane diterpenoid extracted from Andrographis paniculate, exhibited anti-oxidative stress capacity against adverse cardiac remodeling after myocardial infarction by activating the Nrf2/HO-1 pathway (164). Artemisinin, a sesquiterpene lactone compound with peroxisome bridging group structure purified from Artemisia annua, prevented myocardial ischemia-reperfusion injury by inhibition of cardiac autophagy and NLRP3 inflammasome activation (165). Taken together, terpenoids may serve as an effective therapeutic agent for the treatment of various CVDs by different mechanisms.

 Alkaloids

Alkaloids are a class of nitrogen-containing basic organic compounds and widely found in TCM. Of note, alkaloids exert protective effects against CVDs by suppression of inflammation, oxidative stress, and cardiomyocyte apoptosis ( Table 3 ). Berberine, a natural isoquinoline alkaloid isolated from Rhizoma coptidis, possessed profound pharmacological activities for the treatment of various CVDs (166), including atherosclerosis, cardiac hypertrophy, heart failure, myocardial infarction, and arrhythmia. Similarly, palmatine was a potential candidate drug for the treatment of cardiac hypertrophy by activating the Nrf2/ARE pathway (167). Matrine, a quinolizidine alkaloid derived from Sophora flavescens, could attenuate diabetic cardiomyopathy by reducing inflammatory cytokines levels and oxidative stress (168). Cyclovirobuxine D, a steroidal alkaloid extracted from Buxus microphylla, exerted a cytoprotective effect against HFD diet- and streptozotocin-induced rat diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses (169). Cordycepin is an active ingredient in Cordyceps sinensis that can prevent myocardial ischemia-reperfusion injury by activating the AMPK/mTOR-mediated autophagy (170). Colchicine, a botanical alkaloid derived from Colchicum autumnale, exerted unique anti-inflammatory effects in the therapy of various CVDs (171), including atherosclerosis, heart failure, atrial fibrillation, and myocardial infarction.

 Polysaccharides

Polysaccharides widely exist in natural plants, which are a kind of complex structure of natural polymer compounds (172). Currently, natural polysaccharides are attracting considerable attention worldwide due to their versatile biological activities and few side effects. Of note, numerous studies have shown that bioactive polysaccharides exhibit profound efficiency in controlling the risk factors of CVD (173), such as inflammatory response, oxidative stress, hypertension, and hyperlipidemia. Polysaccharides derived from Gelidium crinale reduced oxidative stress and inflammation in oxidized low-density lipoprotein-induced atherosclerosis (174). Huang et al. (175) found that the administration of polysaccharides from Eriobotrya japonica effectively reduced oxidative damage and inflammation induced by myocardial ischemia-reperfusion injury. Astragalus polysaccharides could ameliorate diabetic cardiomyopathy progression by improving cardiac function and inhibiting cardiomyocyte apoptosis via the inactivation of the ERS pathway (176). Lycium barbarum polysaccharides could reduce the levels of inflammatory cytokines (e.g., IL-6 and TNF-α) and plasma lipid peroxidation in a pressure overload-induced heart failure rat model (177). In addition, polysaccharides extracted from TCM, such as Polygonatum sibiricum, Opuntia dilleniid, Plantago asiatica, Angelica sinensis, and Ganoderma lucidum, also have therapeutic effects on various CVDs ( Table 3 ).

 Others

In addition to the above-mentioned compounds isolated from TCM for the prevention of CVD, other active ingredients in TCM have been reported to have therapeutic effects on various CVDs. Schisandrin B, bioactive dibenzocyclooctadiene derivatives found in Schisandra chinensis, could alleviate diabetic cardiomyopathy by reducing cardiac inflammation and damage via blocking MyD88-dependent inflammation (178). Schisandrin B prevented hypoxia/reoxygenation-induced cardiomyocyte injury by inhibiting inflammation and oxidative stress, which was associated with the activation of the AMPK/Nrf2 pathway (179). Morronisid, an iridoid glycoside extracted from Cornus officinalis, promoted angiogenesis and improved cardiac function in rats with acute myocardial infarction (180). Sulforaphane is a natural glucosinolate found in Raphanus sativus, which inhibited cardiac cell ferroptosis by activating the AMPK/Nrf2 pathway (76). Schisandrol A, a bioactive lignan extracted from Schisandra chinensis, could inhibit cardiomyocyte apoptosis induced by myocardial ischemia-reperfusion via increasing 14-3-3θ expression (181). Collectively, natural compounds from TCM exert anti-CVD effects, which may be developed as an effective therapeutic agent for the treatment of CVD in clinical.

 Clinical study of the TCM for the prevention and treatment of CVD

Accumulating evidence has reported that TCM has a wide range of pharmacological effects in various CVDs and its beneficial efficacy has been proved in vitro cell models or animal experiments. Importantly, several clinical studies are underway to explore the safety and efficacy of TCM decoction and injections for the treatment of various CVDs. For example, several studies provided a reliable evaluation of the efficacy and safety of Xuefu Zhuyu granules (182) and Xuefu Zhuyu granules (183) in the treatment of patients with coronary heart disease. Other randomized controlled trials similarly analyzed the efficacy and safety of Zhuling decoction (184) and Buyang Huanwu decoction (185) in the treatment of heart failure. A multicenter, randomized, double-blind, placebo-controlled clinical trial found that Qing-Xin-Jie-Yu granule reduced inflammation and cardiovascular endpoint in patients with coronary heart disease (186). A phase I clinical trial by Hu et al. (187) showed that Danhong injection promoted endothelial progenitor cell mobilization by increasing the expression of Akt, eNOS, and MMP-9 in patients with coronary heart disease. Lai et al. (97) found that treatment with TCM formula (Songling Xuemaikang capsule) improved blood pressure in patients with mild hypertension and was well tolerated. Another study confirmed that astragalus injection was a safe and effective therapeutic agent in the clinical management of heart failure (188). In addition, several clinical trials have shown that the combination of TCM and standard drugs for CVD treatment was advantageous to simple conventional Western medicine in relieving clinical symptoms (25, 189). Chao et al. (190) reported that TCM formula combined with Western medicine reduced blood lipid levels and inflammatory factors in patients with coronary heart disease. Zhang et al. (191) showed that modified Xiaojianzhong decoction combined with conventional Western medicine alleviated the progression of chronic heart failure by improving heart function and maintaining gastrointestinal hormones. Another study found that treatment with Jianpi Huazhi pill combined with Western medicine (anti-heart failure) led to decreasing the levels of inflammatory cytokines and improving the composition of the gut microbiota (192). Meanwhile, several clinical studies are completed or ongoing to evaluate the safety and efficacy of TCM combined with Western medicine for the treatment of CVD according to Chinese Clinical Trial Registry ( Table 4 ). Many researchers have proved that treatment with TCM based on the standard drug not only prevented CVD progression and improved quality of life but also reduced the incidence of adverse cardiovascular events in patients (193–195). More interestingly, TCM may be an effective alternative method to Western medicine in modern American healthcare, but some barriers prevent its integration into Western health systems, such as the fact that TCM is not accredited by the American Board of Medical Specialties, available TCM therapies may impose an undesired burden for patients, and TCM therapies are individualized. However, no cardiovascular drug or combination of drugs has shown significant efficacy in all patients with CVD, and standard Western medicine can lead to adverse side effects. From an economic point of view, TCM therapies are cheaper than Western medicine and have a better prognosis for patients with CVD. Based on the current situation, TCM may be an attractive alternative for patients with CVD.

The ongoing clinical trials of traditional Chinese medicine combined with Western medicine for cardiovascular diseases therapy from 2018-2023.

No. Disease Interventions Status Sponsor Clinical Trial ID
1 Atherosclerosis Tongxinluo capsule+CWM Completed Qilu Hospital of Shandong University ChiCTR1900025842
2 Atherosclerosis Xiaochaihu decoction+CWM Not recruiting Shanghai Sixth People’s Hospital ChiCTR2000032470
3 Atherosclerosis Yanshi Jiangzhi formula+CWM Not recruiting Shanghai Tenth People’s Hospital ChiCTR2000036785
4 Atherosclerosis Yishen Huazhuo decoction+CWM Not recruiting Longhua Hospital Shanghai University of Traditional Chinese Medicine ChiCTR2300071014
5 Atherosclerosis Huoxue Jiedu formula+CWM Recruiting Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine ChiCTR2300074283
6 Atherosclerosis Huazhuo Tiaozhi granule+CWM Not recruiting Guang’anmen Hospital, China Academy of Chinese Medical Sciences ChiCTR2400079454
7 Myocardial ischemia-reperfusion injury Shenxiang Suhe pill+CWM Recruiting Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University ChiCTR2200055170
8 Heart failure Yiqihuoxuelishui formula+CWM Recruiting Dongfang Hospital Affiliated to Beijing University of Chinese Medicine ChiCTR1900022036
9 Heart failure Yangyin Shuxin formula+CWM Completed The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine ChiCTR2000030921
10 Heart failure LuHong formula+CWM Not recruiting Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine ChiCTR2000037368
11 Heart failure Qiangxin formula+CWM Recruiting Shanghai Hospital of Traditional Chinese Medicine ChiCTR2000037254
12 Heart failure Shenfu Xiangshao decoction+CWM Not recruiting Shanghai Putuo District Central Hospital ChiCTR2000036639
13 Heart failure Shen’ge formula+CWM Not recruiting Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine ChiCTR2000036533
14 Heart failure Shenshao pill+CWM Recruiting The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine ChiCTR2100042242
15 Heart failure Shenge powder+CWM Not recruiting Nanxiang Hospital ChiCTR2100049790
16 Heart failure Yixin formula+CWM Not recruiting Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine ChiCTR2100051882
17 Heart failure Fangji Huangqi decoction+CWM Recruiting The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine ChiCTR2100054580
18 Heart failure Xin-Li-Fang formula+CWM Not recruiting The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial of Chinese Medicine) ChiCTR2200058649
19 Heart failure Kangxin formula+CWM Not recruiting The First Affiliated Hospital of Guangzhou University of Chinese Medicine ChiCTR2300069435
20 Heart failure Yangxinxue granules+CWM Not recruiting Qionglai Hospital of Traditional Chinese Medicin ChiCTR2300074840
21 Heart failure Shexiang Baoxin pill+CWM Not recruiting Sichuan Provincial People’s Hospital ChiCTR2300076014
22 Heart failure Yiqi Huayu decoction+CWM Recruiting Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine ChiCTR2400082425
23 Heart failure Qiwei Fangji Huangqi granule+CWM Not recruiting Hangzhou Traditional Chinese Medicine Hospital ChiCTR2400080029
24 Hypertension Bushen Jiangya granule+CWM Recruiting Guang′anmen Hospital, China Academy of Chinese Medical Sciences ChiCTR1900028572
25 Hypertension Shugan Wendan decoction+CWM Not recruiting Guangzhou University of Chinese Medicine ChiCTR2000034557
26 Hypertension Dingxuan Shuyu formula+CWM Completed Shuguang Hospital Affiliated to Shanghai University of Chinese Medicine ChiCTR2000040386
27 Hypertension Chaigui decoction+CWM Completed Wuxi Hospital of Traditional Chinese Medicine ChiCTR2300076783
28 Hypertension Huoxue Qiyang Qutan prescription+CWM Recruiting Shanghai Yueyang Integrated Traditional Chinese Medicine and Western Medicine Hospital ChiCTR2400081580
29 Myocardial infarction Qishen Yiqi drop pill+CWM Not recruiting The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine ChiCTR2000029136
30 Peking University First Hospital ChiCTR2300069035
31 Myocardial infarction Shexiang Tongxin drop pill+CWM Recruiting Beijing University of Chinese Medicine Dongzhimen Hospital ChiCTR2300075069
32 Septic cardiomyopathy Fuling Sini decoction+CWM Recruiting Beijing University of Chinese Medicine Shenzhen Hospital (Longgang) ChiCTR2100045549
33 Combined blood stasis with dilated cardiomyopathy Kuoxinfang granule+CWM Recruiting Longhua Hospital, Shanghai University of Traditional Chinese Medicine ChiCTR2100049536
34 Coronary artery disease Shexiang Baoxin pill+CWM Recruiting Gansu Provincial Hospital ChiCTR2400080152

CWM, conventional Western medicine.

 Conclusion and prospects

As the leading cause of death after malignant tumors, CVD is difficult to treat clinically and imposes a huge economic and health burden on people worldwide. The morbidity and mortality of CVD are continuously increasing, and the treatment is ineffective because of its complex pathogenesis. In recent years, TCM has been particularly prominent in the treatment of 95 certain diseases, including CVD, offering a new perspective in the modern era for the prevention and treatment of diseases such as COVID-19. In this review, we found that TCM (formulas, extracts, and compounds) can combat CVD through multiple mechanisms, including anti-inflammatory, antioxidant, improving mitochondrial dysfunction, anti-cell death (such as autophagy, apoptosis, ferroptosis, pyroptosis), and regulating gut microbiota. Meanwhile, clinical trials have proven the efficacy and safety of TCM in alleviating the symptoms of CVD. However, there are still some challenges that must be overcome in TCM for CVD treatment. (1) With the rapid advancement of science, there is a need to utilize network pharmacology approaches and multi-omics technologies, such as nutrigenomics, metabolomics, proteomics, gut microbial macrogenomics and immunomics, to reveal the physiological functions and mechanism explanations of TCM in combating CVD; (2) The metabolic, toxicity, and pharmacokinetic profiles of TCM fight against patients with CVD in clinical trials need to be further validated; (3) The construction of TCM resources for common quality standards to ensure active ingredient in TCM; (4) Research on active ingredients of TCM is limited by defects includes unstable chemical structure, low bioavailability and easy oxidation, and liposome embedding or nanoparticle formulation can be considered; (5) Development of CVD models with human disease characteristics for exploring the pharmacological activity of TCM, such as primate animal models that can avoid species barriers leading to ineffectiveness; (6) Designing TCM delivery systems to improve its stability, bioavailability, and efficacy in the gastrointestinal tract.

In conclusion, TCM possesses good anti-CVD effects and is an indispensable active drug for the treatment of CVD. Based on the latest evidence, this review summarized the pathogenesis of CVD and systematically analyzed and discussed the mechanisms of TCM in preventing CVD, as well as its clinical trials. This review aims to provide a scientific and effective comprehensive reference for TCM in CVD therapy and to better utilize and develop the treasures of TCM.

 Author contributions

JD: Conceptualization, Investigation, Writing – original draft. LQ: Investigation, Writing – original draft. YL: Writing – review & editing. ML: Funding acquisition, Writing – review & editing.

 Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Provincial Doctoral Research Initiation Fund (NO: 2022-BS-249) and the Natural Science Foundation of Liaoning Province (No.2022-MS-325).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Petersen KS Kris-Etherton PM . Diet quality assessment and the relationship between diet quality and cardiovascular disease risk. Nutrients. (2021) 13:4305. doi: 10.3390/nu13124305 Liu S Li Y Zeng X Wang H Yin P Wang L . Burden of cardiovascular diseases in China, 1990-2016: findings from the 2016 global burden of disease study. JAMA Cardiol. (2019) 4:342–52. doi: 10.1001/jamacardio.2019.0295 Mamani-Ortiz Y San Sebastián M Armaza AX Luizaga JM Illanes DE Ferrel M . Prevalence and determinants of cardiovascular disease risk factors using the WHO STEPS approach in Cochabamba, Bolivia. BMC Public Health. (2019) 19:786. doi: 10.1186/s12889-019-7064-y Roth GA Forouzanfar MH Moran AE Barber R Nguyen G Feigin VL . Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. (2015) 372:1333–41. doi: 10.1056/NEJMoa1406656 Zhou M Wang H Zhu J Chen W Wang L Liu S . Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. (2016) 387:251–72. doi: 10.1016/S0140-6736(15)00551-6 Siasos G Bletsa E Stampouloglou PK Oikonomou E Tsigkou V Paschou SA . MicroRNAs in cardiovascular disease. Hellenic J Cardiol. (2020) 61:165–73. doi: 10.1016/j.hjc.2020.03.003 Ciumărnean L Milaciu MV Negrean V Orășan OH Vesa SC Sălăgean O . Cardiovascular risk factors and physical activity for the prevention of cardiovascular diseases in the elderly. Int J Environ Res Public Health. (2021) 19:207. doi: 10.3390/ijerph19010207 Rosenthal T Touyz RM Oparil S . Migrating populations and health: risk factors for cardiovascular disease and metabolic syndrome. Curr Hypertens Rep. (2022) 24:325–40. doi: 10.1007/s11906-022-01194-5 Gyldenkerne C Mortensen MB Kahlert J Thrane PG Warnakula Olesen KK Sørensen HT . 10-year cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus. J Am Coll Cardiol. (2023) 82:1583–94. doi: 10.1016/j.jacc.2023.08.015 Millwood IY Im PK Bennett D Hariri P Yang L Du H . Alcohol intake and cause-specific mortality: conventional and genetic evidence in a prospective cohort study of 512 000 adults in China. Lancet Public Health. (2023) 8:e956–67. doi: 10.1016/S2468-2667(23)00217-7 Ouyang L Su X Li W Tang L Zhang M Zhu Y . ALKBH1-demethylated DNA N6-methyladenine modification triggers vascular calcification via osteogenic reprogramming in chronic kidney disease. J Clin Invest. (2021) 131::e146985. doi: 10.1172/JCI146985 An J Ouyang L Yu C Carr SM Ramprasath T Liu Z . Nicotine exacerbates atherosclerosis and plaque instability via NLRP3 inflammasome activation in vascular smooth muscle cells. Theranostics. (2023) 13:2825–42. doi: 10.7150/thno.81388 Hu X Nie Z Ou Y Lin L Qian Z Vaughn MG . Long-term exposure to ambient air pollution, circadian syndrome and cardiovascular disease: A nationwide study in China. Sci Total Environ. (2023) 868:161696. doi: 10.1016/j.scitotenv.2023.161696 Huang H Li Z Ruan Y Feng W Chen J Li X . Circadian rhythm disorder: a potential inducer of vascular calcification? J Physiol Biochem. (2020) 76:513–24. doi: 10.1007/s13105-020-00767-9 Papaconstantinou J . The role of signaling pathways of inflammation and oxidative stress in development of senescence and aging phenotypes in cardiovascular disease. Cells. (2019) 8:1383. doi: 10.3390/cells8111383 Chen F Yin S Feng Z Liu C Lv J Chen Y . Knockdown of circ_NEK6 decreased 131I resistance of differentiated thyroid carcinoma via regulating miR-370-3p/MYH9 axis. Technol Cancer Res Treat. (2021) 20:15330338211004950. doi: 10.1177/15330338211004950 Witkowski M Weeks TL Hazen SL . Gut microbiota and cardiovascular disease. Circ Res. (2020) 127:553–70. doi: 10.1161/CIRCRESAHA.120.316242 Song XY Li YD Shi YP Jin L Chen J . Quality control of traditional Chinese medicines: a review. Chin J Nat Med. (2013) 11:596–607. doi: 10.3724/SP.J.1009.2013.00596 Wang X Wang ZY Zheng JH Li S . TCM network pharmacology: A new trend towards combining computational, experimental and clinical approaches. Chin J Nat Med. (2021) 19:1–11. doi: 10.1016/S1875-5364(21)60001-8 Luo Y Wang CZ Hesse-Fong J Lin JG Yuan CS . Application of Chinese medicine in acute and critical medical conditions. Am J Chin Med. (2019) 47:1223–35. doi: 10.1142/S0192415X19500629 Hao P Jiang F Cheng J Ma L Zhang Y Zhao Y . Traditional Chinese medicine for cardiovascular disease: evidence and potential mechanisms. J Am Coll Cardiol. (2017) 69:2952–66. doi: 10.1016/j.jacc.2017.04.041 Li X Li L Lei W Chua HZ Li Z Huang X . Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms. BioMed Pharmacother. (2021) 142:111979. doi: 10.1016/j.biopha.2021.111979 Jia Q Wang L Zhang X Ding Y Li H Yang Y . Prevention and treatment of chronic heart failure through traditional Chinese medicine: Role of the gut microbiota. Pharmacol Res. (2020) 151:104552. doi: 10.1016/j.phrs.2019.104552 Pan L Zhang XF Wei WS Zhang J Li ZZ . The cardiovascular protective effect and mechanism of calycosin and its derivatives. Chin J Nat Med. (2020) 18:907–15. doi: 10.1016/S1875-5364(20)60034-6 Liu J Dong Y Hu X . Efficacy of Yangxin recipe in combination with conventional Western medicine in treatment of angina pectoris of coronary heart disease. Clin Appl Thromb Hemost. (2022) 28:10760296221076152. doi: 10.1177/10760296221076152 Lu Y Wang F Ni H Sun Y Shi H . Observation of curative effect of trimetazidine combined with metoprolol in elderly patients with coronary heart disease complicated with heart failure and the effect of myocardial remodeling by integrated traditional Chinese and Western medicine. BioMed Res Int. (2022) 2022:6098799. doi: 10.1155/2022/6098799 Guo R Luo X Liu J Liu L Wang X Lu H . Omics strategies decipher therapeutic discoveries of traditional Chinese medicine against different diseases at multiple layers molecular-level. Pharmacol Res. (2020) 152:104627. doi: 10.1016/j.phrs.2020.104627 Andersson C Vasan RS . Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. (2018) 15:230–40. doi: 10.1038/nrcardio.2017.154 Said MA Verweij N van der Harst P . Associations of combined genetic and lifestyle risks with incident cardiovascular disease and diabetes in the uk biobank study. JAMA Cardiol. (2018) 3:693–702. doi: 10.1001/jamacardio.2018.1717 Lin X Ouyang S Zhi C Li P Tan X Ma W . Focus on ferroptosis, pyroptosis, apoptosis and autophagy of vascular endothelial cells to the strategic targets for the treatment of atherosclerosis. Arch Biochem Biophys. (2022) 715:109098. doi: 10.1016/j.abb.2021.109098 Peng J Xiao X Hu M Zhang X . Interaction between gut microbiome and cardiovascular disease. Life Sci. (2018) 214:153–7. doi: 10.1016/j.lfs.2018.10.063 Akhmerov A Parimon T . Extracellular vesicles, inflammation, and cardiovascular disease. Cells. (2022) 11:2229. doi: 10.3390/cells11142229 Fan Y Liu J Miao J Zhang X Yan Y Bai L . Anti-inflammatory activity of the Tongmai Yangxin pill in the treatment of coronary heart disease is associated with estrogen receptor and NF-κB signaling pathway. J Ethnopharmacol. (2021) 276:114106. doi: 10.1016/j.jep.2021.114106 Everett BM Cornel JH Lainscak M Anker SD Abbate A Thuren T . Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. (2019) 139:1289–99. doi: 10.1161/CIRCULATIONAHA.118.038010 Roifman I Beck PL Anderson TJ Eisenberg MJ Genest J . Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol. (2011) 27:174–82. doi: 10.1016/j.cjca.2010.12.040 Holzknecht M Tiller C Reindl M Lechner I Troger F Hosp M . C-reactive protein velocity predicts microvascular pathology after acute ST-elevation myocardial infarction. Int J Cardiol. (2021) 338:30–6. doi: 10.1016/j.ijcard.2021.06.023 Ayas NT Hirsch Allen AJ Fox N Peres B Mehrtash M Humphries KH . C-reactive protein levels and the risk of incident cardiovascular and cerebrovascular events in patients with obstructive sleep apnea. Lung. (2019) 197:459–64. doi: 10.1007/s00408-019-00237-0 Henein MY Vancheri S Longo G Vancheri F . The role of inflammation in cardiovascular disease. Int J Mol Sci. (2022) 23:12906. doi: 10.3390/ijms232112906 Mai W Liao Y . Targeting IL-1β in the treatment of atherosclerosis. Front Immunol. (2020) 11:589654. doi: 10.3389/fimmu.2020.589654 Hu YF Chen YJ Lin YJ Chen SA . Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. (2015) 12:230–43. doi: 10.1038/nrcardio.2015.2 Zeng C Duan F Hu J Luo B Huang B Lou X . NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. Redox Biol. (2020) 34:101523. doi: 10.1016/j.redox.2020.101523 Willeford A Suetomi T Nickle A Hoffman HM Miyamoto S Heller Brown J . CaMKIIδ-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis. JCI Insight. (2018) 3:e97054. doi: 10.1172/jci.insight.97054 Nguyen MN Kiriazis H Gao XM Du XJ . Cardiac fibrosis and arrhythmogenesis. Compr Physiol. (2017) 7:1009–49. 10.1002/cphy.c160046 Li X Zhang Z Luo M Cheng Z Wang R Liu Q . NLRP3 inflammasome contributes to endothelial dysfunction in angiotensin II-induced hypertension in mice. Microvasc Res. (2022) 143:104384. doi: 10.1016/j.mvr.2022.104384 Lorenzon Dos Santos J Quadros AS Weschenfelder C Garofallo SB Marcadenti A . Oxidative stress biomarkers, nut-related antioxidants, and cardiovascular disease. Nutrients. (2020) 12:682. doi: 10.3390/nu12030682 Dröge W . Free radicals in the physiological control of cell function. Physiol Rev. (2002) 82:47–95. doi: 10.1152/physrev.00018.2001 Xiang D Liu Y Zhou S Zhou E Wang Y . Protective effects of estrogen on cardiovascular disease mediated by oxidative stress. Oxid Med Cell Longev. (2021) 2021:5523516. doi: 10.1155/2021/5523516 Chang X Zhang T Zhang W Zhao Z Sun J . Natural drugs as a treatment strategy for cardiovascular disease through the regulation of oxidative stress. Oxid Med Cell Longev. (2020) 2020:5430407. doi: 10.1155/2020/5430407 Förstermann U Xia N Li H . Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. (2017) 120:713–35. doi: 10.1161/CIRCRESAHA.116.309326 Pignatelli P Menichelli D Pastori D Violi F . Oxidative stress and cardiovascular disease: new insights. Kardiol Pol. (2018) 76:713–22. doi: 10.5603/KP.a2018.0071 Guo Z Ran Q Roberts LJ 2nd Zhou L Richardson A Sharan C . Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic Biol Med. (2008) 44:343–52. doi: 10.1016/j.freeradbiomed.2007.09.009 Giam B Chu PY Kuruppu S Smith AI Horlock D Kiriazis H . N-acetylcysteine attenuates the development of cardiac fibrosis and remodeling in a mouse model of heart failure. Physiol Rep. (2016) 4:e12757. doi: 10.14814/phy2.12757 Cai S Zhao M Zhou B Yoshii A Bugg D Villet O . Mitochondrial dysfunction in macrophages promotes inflammation and suppresses repair after myocardial infarction. J Clin Invest. (2023) 133:e159498. doi: 10.1172/JCI159498 Chistiakov DA Shkurat TP Melnichenko AA Grechko AV Orekhov AN . The role of mitochondrial dysfunction in cardiovascular disease: a brief review. Ann Med. (2018) 50:121–7. doi: 10.1080/07853890.2017.1417631 SoBenin IA Sazonova MA Postnov AY Bobryshev YV Orekhov AN . Changes of mitochondria in atherosclerosis: possible determinant in the pathogenesis of the disease. Atherosclerosis. (2013) 227:283–8. doi: 10.1016/j.atherosclerosis.2013.01.006 Manolis AS Manolis AA Manolis TA Apostolaki NE Apostolopoulos EJ Melita H . Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications. Med Res Rev. (2021) 41:275–313. doi: 10.1002/med.21732 Peoples JN Saraf A Ghazal N Pham TT Kwong JQ . Mitochondrial dysfunction and oxidative stress in heart disease. Exp Mol Med. (2019) 51:1–13. doi: 10.1038/s12276-019-0355-7 Jacinto TA Meireles GS Dias AT Aires R Porto ML Gava AL . Increased ROS production and DNA damage in monocytes are biomarkers of aging and atherosclerosis. Biol Res. (2018) 51:33. doi: 10.1186/s40659-018-0182-7 Tong M Saito T Zhai P Oka SI Mizushima W Nakamura M . Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. Circ Res. (2019) 124:1360–71. doi: 10.1161/CIRCRESAHA.118.314607 Lee TL Lee MH Chen YC Lee YC Lai TC Lin HY . Vitamin D attenuates ischemia/reperfusion-induced cardiac injury by reducing mitochondrial fission and mitophagy. Front Pharmacol. (2020) 11:604700. doi: 10.3389/fphar.2020.604700 Zekonyte U Bacman SR Moraes CT . DNA-editing enzymes as potential treatments for heteroplasmic mtDNA diseases. J Intern Med. (2020) 287:685–97. doi: 10.1111/joim.v287.6 Bagul PK Katare PB Bugga P Dinda AK Banerjee SK . SIRT-3 modulation by resveratrol improves mitochondrial oxidative phosphorylation in diabetic heart through deacetylation of TFAM. Cells. (2018) 7:235. doi: 10.3390/cells7120235 Tong M Saito T Zhai P Oka SI Mizushima W Nakamura M . Alternative mitophagy protects the heart against obesity-associated cardiomyopathy. Circ Res. (2021) 129:1105–21. doi: 10.1161/CIRCRESAHA.121.319377 Wang Y Gao W Shi X Ding J Liu W He H . Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. (2017) 547:99–103. doi: 10.1038/nature22393 Shi J Gao W Shao F . Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. (2017) 42:245–54. doi: 10.1016/j.tibs.2016.10.004 Zeng C Wang R Tan H . Role of pyroptosis in cardiovascular diseases and its therapeutic implications. Int J Biol Sci. (2019) 15:1345–57. doi: 10.7150/ijbs.33568 Huang Y Xu W Zhou R . NLRP3 inflammasome activation and cell death. Cell Mol Immunol. (2021) 18:2114–27. doi: 10.1038/s41423-021-00740-6 Wang M Zhao M Yu J Xu Y Zhang J Liu J . MCC950, a selective NLRP3 inhibitor, attenuates adverse cardiac remodeling following heart failure through improving the cardiometabolic dysfunction in obese mice. Front Cardiovasc Med. (2022) 9:727474. doi: 10.3389/fcvm.2022.727474 Krishnan SM Ling YH Huuskes BM Ferens DM Saini N Chan CT . Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension. Cardiovasc Res. (2019) 115:776–87. doi: 10.1093/cvr/cvy252 Sharma A Choi JSY Stefanovic N Al-Sharea A Simpson DS Mukhamedova N . Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis. Diabetes. (2021) 70:772–87. doi: 10.2337/db20-0357 Zhang L Jiang YH Fan C Zhang Q Jiang YH Li Y . MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis. BioMed Pharmacother. (2021) 143:112133. doi: 10.1016/j.biopha.2021.112133 Jin Y Liu Y Xu L Xu J Xiong Y Peng Y . Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis. Cell Death Dis. (2022) 13:512. doi: 10.1038/s41419-022-04966-8 Tang D Chen X Kang R Kroemer G . Ferroptosis: molecular mechanisms and health implications. Cell Res. (2021) 31:107–25. doi: 10.1038/s41422-020-00441-1 Yan HF Zou T Tuo QZ Xu S Li H Belaidi AA . Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. (2021) 6:49. doi: 10.1038/s41392-020-00428-9 Wu X Li Y Zhang S Zhou X . Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. (2021) 11:3052–9. doi: 10.7150/thno.54113 Wang X Chen X Zhou W Men H Bao T Sun Y . Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways. Acta Pharm Sin B. (2022) 12:708–22. doi: 10.1016/j.apsb.2021.10.005 Bai T Li M Liu Y Qiao Z Wang Z . Inhibition of ferroptosis alleviates atherosclerosis through attenuating lipid peroxidation and endothelial dysfunction in mouse aortic endothelial cell. Free Radic Biol Med. (2020) 160:92–102. doi: 10.1016/j.freeradbiomed.2020.07.026 Wang Y Yan S Liu X Deng F Wang P Yang L . PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway. Cell Death Differ. (2022) 29:1982–95. doi: 10.1038/s41418-022-00990-5 Pennell DJ Udelson JE Arai AE Bozkurt B Cohen AR Galanello R . Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation. (2013) 128:281–308. doi: 10.1161/CIR.0b013e31829b2be6 Khan S Moore RJ Stanley D Chousalkar KK . The gut microbiota of laying hens and its manipulation with prebiotics and probiotics to enhance gut health and food safety. Appl Environ Microbiol. (2020) 86:e00600–20. doi: 10.1128/AEM.00600-20 Qian B Zhang K Li Y Sun K . Update on gut microbiota in cardiovascular diseases. Front Cell Infect Microbiol. (2022) 12:1059349. doi: 10.3389/fcimb.2022.1059349 Sanchez-Rodriguez E Egea-Zorrilla A Plaza-Díaz J Aragón-Vela J Muñoz-Quezada S Tercedor-Sánchez L . The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases. Nutrients. (2020) 12:605. doi: 10.3390/nu12030605 Jie Z Xia H Zhong SL Feng Q Li S Liang S . The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. (2017) 8:845. doi: 10.1038/s41467-017-00900-1 Kummen M Mayerhofer CCK Vestad B Broch K Awoyemi A Storm-Larsen C . Gut microbiota signature in heart failure defined from profiling of 2 independent cohorts. J Am Coll Cardiol. (2018) 71:1184–6. doi: 10.1016/j.jacc.2017.12.057 Sun T Zhang Y Yin J Peng X Zhou L Huang S . Association of gut microbiota-dependent metabolite trimethylamine N-oxide with first ischemic stroke. J Atheroscler Thromb. (2021) 28:320–8. doi: 10.5551/jat.55962 Jiang S Shui Y Cui Y Tang C Wang X Qiu X . Gut microbiota dependent trimethylamine N-oxide aggravates angiotensin II-induced hypertension. Redox Biol. (2021) 46:102115. doi: 10.1016/j.redox.2021.102115 Xiao L Huang L Zhou X Zhao D Wang Y Min H . Experimental periodontitis deteriorated atherosclerosis associated with trimethylamine N-oxide metabolism in mice. Front Cell Infect Microbiol. (2021) 11:820535. doi: 10.3389/fcimb.2021.820535 Haghikia A Li XS Liman TG Bledau N Schmidt D Zimmermann F . Gut microbiota-dependent trimethylamine N-oxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes. Arterioscler Thromb Vasc Biol. (2018) 38:2225–35. doi: 10.1161/ATVBAHA.118.311023 Ren J Bi Y Sowers JR Hetz C Zhang Y . Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. Nat Rev Cardiol. (2021) 18:499–521. doi: 10.1038/s41569-021-00511-w Zhao F Satyanarayana G Zhang Z Zhao J Ma XL Wang Y . Endothelial autophagy in coronary microvascular dysfunction and cardiovascular disease. Cells. (2022) 11:2081. doi: 10.3390/cells11132081 Glovaci D Fan W Wong ND . Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. (2019) 21:21. doi: 10.1007/s11886-019-1107-y Silveira Rossi JL Barbalho SM Reverete de Araujo R Bechara MD Sloan KP Sloan LA . Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev. (2022) 38:e3502. doi: 10.1002/dmrr.3502 Cheng X Hu J Liu X Tibenda JJ Wang X Zhao Q . Therapeutic targets by traditional Chinese medicine for ischemia-reperfusion injury induced apoptosis on cardiovascular and cerebrovascular diseases. Front Pharmacol. (2022) 13:934256. doi: 10.3389/fphar.2022.934256 Gao L Cao M Li JQ Qin XM Fang J . Traditional Chinese medicine network pharmacology in cardiovascular precision medicine. Curr Pharm Des. (2021) 27:2925–33. doi: 10.2174/1381612826666201112142408 Liu LC Mao QY Liu C Hu J Duan L Wang J . The effectiveness and safety of Bushen Huoxue decoction on treating coronary heart disease: a meta-analysis. Evid Based Complement Alternat Med. (2021) 2021:5541228. doi: 10.1155/2021/5541228 Bi YF Wang XL Zhang X Hou YZ Zhao ZQ Ren XY . Protocol to study the effects of traditional Chinese medicine on patients with coronary heart disease showing phlegm-heat-stasis symptom pattern. J Tradit Chin Med. (2021) 41:826–32. doi: 10.19852/j.cnki.jtcm.2021.05.016 Lai X Dong Z Wu S Zhou X Zhang G Xiong S . Efficacy and safety of Chinese herbal medicine compared with losartan for mild essential hypertension: a randomized, multicenter, double-blind, noninferiority trial. Circ Cardiovasc Qual Outcomes. (2022) 15:e007923. doi: 10.1161/CIRCOUTCOMES.121.007923 Song JX Zhao YS Zhen YQ Yang XY Chen Q An JR . Banxia-Houpu decoction diminishes iron toxicity damage in heart induced by chronic intermittent hypoxia. Pharm Biol. (2022) 60:609–20. doi: 10.1080/13880209.2022.2043392 Li Y Zhang L Ren P Yang Y Li S Qin X . Qing-Xue-Xiao-Zhi formula attenuates atherosclerosis by inhibiting macrophage lipid accumulation and inflammatory response via TLR4/MyD88/NF-κB pathway regulation. Phytomedicine. (2021) 93:153812. doi: 10.1016/j.phymed.2021.153812 Wu L Fan Z Gu L Liu J Cui Z Yu B . QiShenYiQi dripping pill alleviates myocardial ischemia-induced ferroptosis via improving mitochondrial dynamical homeostasis and biogenesis. J Ethnopharmacol. (2023) 308:116282. doi: 10.1016/j.jep.2023.116282 Chen X Li Y Li J Liu T Jiang Q Hong Y . Qishen granule (QSG) exerts cardioprotective effects by inhibiting NLRP3 inflammasome and pyroptosis in myocardial infarction rats. J Ethnopharmacol. (2022) 285:114841. doi: 10.1016/j.jep.2021.114841 Wang A Guan B Shao C Zhao L Li Q Hao H . Qing-Xin-Jie-Yu Granule alleviates atherosclerosis by reshaping gut microbiota and metabolic homeostasis of ApoE-/- mice. Phytomedicine. (2022) 103:154220. doi: 10.1016/j.phymed.2022.154220 Zhou W Chen Z Fang Z Xu D . Network analysis for elucidating the mechanisms of Shenfu injection in preventing and treating COVID-19 combined with heart failure. Comput Biol Med. (2022) 148:105845. doi: 10.1016/j.compbiomed.2022.105845 Duan H Khan GJ Shang LJ Peng H Hu WC Zhang JY . Computational pharmacology and bioinformatics to explore the potential mechanism of Schisandra against atherosclerosis. Food Chem Toxicol. (2021) 150:112058. doi: 10.1016/j.fct.2021.112058 Abulizi A Simayi J Nuermaimaiti M Han M Hailati S Talihati Z . Quince extract resists atherosclerosis in rats by down-regulating the EGFR/PI3K/Akt/GSK-3β pathway. BioMed Pharmacother. (2023) 160:114330. doi: 10.1016/j.biopha.2023.114330 Fan W Zhang B Wu C Wu H Wu J Wu S . Plantago asiatica L. seeds extract protects against cardiomyocyte injury in isoproterenol- induced cardiac hypertrophy by inhibiting excessive autophagy and apoptosis in mice. Phytomedicine. (2021) 91:153681. doi: 10.1016/j.phymed.2021.153681 Peng L Lei Z Rao Z Yang R Zheng L Fan Y . Cardioprotective activity of ethyl acetate extract of Cinnamomi Ramulus against myocardial ischemia/reperfusion injury in rats via inhibiting NLRP3 inflammasome activation and pyroptosis. Phytomedicine. (2021) 93:153798. doi: 10.1016/j.phymed.2021.153798 Wen J Zou W Wang R Liu H Yang Y Li H . Cardioprotective effects of Aconiti Lateralis Radix Praeparata combined with Zingiberis Rhizoma on doxorubicin-induced chronic heart failure in rats and potential mechanisms. J Ethnopharmacol. (2019) 238:111880. doi: 10.1016/j.jep.2019.111880 Hasan R Lindarto D Siregar GA Mukhtar Z . The effect of bay leaf extract Syzygium polyanthum (Wight) Walp. on C-reactive protein (CRP) and myeloperoxidase (MPO) level in the heart of rat model of myocardial infarction. Med Glas (Zenica). (2020) 17:41–5. doi: 10.17392/1068-20 Liu S He F Zheng T Wan S Chen J Yang F . Ligustrum robustum alleviates atherosclerosis by decreasing serum TMAO, modulating gut microbiota, and decreasing bile acid and cholesterol absorption in mice. Mol Nutr Food Res. (2021) 65:e2100014. doi: 10.1002/mnfr.202100014 Vilella R Sgarbi G Naponelli V Savi M Bocchi L Liuzzi F . Effects of standardized green tea extract and its main component, EGCG, on mitochondrial function and contractile performance of healthy rat cardiomyocytes. Nutrients. (2020) 12:2949. doi: 10.3390/nu12102949 Tian J Popal MS Liu Y Gao R Lyu S Chen K . Ginkgo biloba leaf extract attenuates atherosclerosis in streptozotocin-induced diabetic ApoE-/- mice by inhibiting endoplasmic reticulum stress via restoration of autophagy through the mTOR signaling pathway. Oxid Med Cell Longev. (2019) 2019:8134678. doi: 10.1155/2019/8134678 Granado M González-Hedström D Amor S Fajardo-Vidal A Villalva M de la Fuente-Fernández M . Marjoram extract prevents ischemia reperfusion-induced myocardial damage and exerts anti-contractile effects in aorta segments of male wistar rats. J Ethnopharmacol. (2022) 282:114660. doi: 10.1016/j.jep.2021.114660 Tinikul R Chenprakhon P Maenpuen S Chaiyen P . Biotransformation of plant-derived phenolic acids. Biotechnol J. (2018) 13:e1700632. doi: 10.1002/biot.201700632 Reboredo-Rodríguez P Varela-López A Forbes-Hernández TY Gasparrini M Afrin S Cianciosi D . Phenolic compounds isolated from olive oil as nutraceutical tools for the prevention and management of cancer and cardiovascular diseases. Int J Mol Sci. (2018) 19:2305. doi: 10.3390/ijms19082305 Panda V Laddha A Nandave M Srinath S . Dietary phenolic acids of Macrotyloma uniflorum (Horse Gram) protect the rat heart against isoproterenol-induced myocardial infarction. Phytother Res. (2016) 30:1146–55. doi: 10.1002/ptr.v30.7 Yao X Jiao S Qin M Hu W Yi B Liu D . Vanillic acid alleviates acute myocardial hypoxia/reoxygenation injury by inhibiting oxidative stress. Oxid Med Cell Longev. (2020) 2020:8348035. doi: 10.1155/2020/8348035 Luan F Rao Z Peng L Lei Z Zeng J Peng X . Cinnamic acid preserves against myocardial ischemia/reperfusion injury via suppression of NLRP3/Caspase-1/GSDMD signaling pathway. Phytomedicine. (2022) 100:154047. doi: 10.1016/j.phymed.2022.154047 Shen Y Shen X Wang S Zhang Y Wang Y Ding Y . Protective effects of Salvianolic acid B on rat ferroptosis in myocardial infarction through upregulating the Nrf2 signaling pathway. Int Immunopharmacol. (2022) 112:109257. doi: 10.1016/j.intimp.2022.109257 Gu Y Zhang Y Li M Huang Z Jiang J Chen Y . Ferulic acid ameliorates atherosclerotic injury by modulating gut microbiota and lipid metabolism. Front Pharmacol. (2021) 12:621339. doi: 10.3389/fphar.2021.621339 Luo Y Jian Y Liu Y Jiang S Muhammad D Wang W . Flavanols from nature: a phytochemistry and biological activity review. Molecules. (2022) 27:719. doi: 10.3390/molecules27030719 Parmenter BH Croft KD Hodgson JM Dalgaard F Bondonno CP Lewis JR . An overview and update on the epidemiology of flavonoid intake and cardiovascular disease risk. Food Funct. (2020) 11:6777–806. doi: 10.1039/D0FO01118E Shi X Hu Y Jiang Y Wu J Zhang C Zhang J . Scutellarein protects against cardiac hypertrophy via suppressing TRAF2/NF-κB signaling pathway. Mol Biol Rep. (2022) 49:2085–95. doi: 10.1007/s11033-021-07026-0 Xu L Chen R Zhang X Zhu Y Ma X Sun G . Scutellarin protects against diabetic cardiomyopathy via inhibiting oxidative stress and inflammatory response in mice. Ann Palliat Med. (2021) 10:2481–93. doi: 10.21037/apm-19-516 Fu Y Sun S Sun H Peng J Ma X Bao L . Scutellarin exerts protective effects against atherosclerosis in rats by regulating the Hippo-FOXO3A and PI3K/AKT signaling pathways. J Cell Physiol. (2019) 234:18131–45. doi: 10.1002/jcp.v234.10 Xu LJ Chen RC Ma XY Zhu Y Sun GB Sun XB . Scutellarin protects against myocardial ischemia-reperfusion injury by suppressing NLRP3 inflammasome activation. Phytomedicine. (2020) 68:153169. doi: 10.1016/j.phymed.2020.153169 Huang H Geng Q Yao H Shen Z Wu Z Miao X . Protective effect of scutellarin on myocardial infarction induced by isoprenaline in rats. Iran J Basic Med Sci. (2018) 21:267–76. doi: 10.22038/ijbms.2018.26110.6415 Zhang X Qin Y Ruan W Wan X Lv C He L . Targeting inflammation-associated AMPK//Mfn-2/MAPKs signaling pathways by baicalein exerts anti-atherosclerotic action. Phytother Res. (2021) 35:4442–55. doi: 10.1002/ptr.v35.8 Bei W Jing L Chen N . Cardio protective role of wogonin loaded nanoparticle against isoproterenol induced myocardial infarction by moderating oxidative stress and inflammation. Colloids Surf B Biointerfaces. (2020) 185:110635. doi: 10.1016/j.colsurfb.2019.110635 Xu S Wu B Zhong B Lin L Ding Y Jin X . Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis. Bioengineered. (2021) 12:10924–34. doi: 10.1080/21655979.2021.1995994 Liu H Zhao H Che J Yao W . Naringenin protects against hypertension by regulating lipid disorder and oxidative stress in a rat model. Kidney Blood Press Res. (2022) 47:423–32. doi: 10.1159/000524172 Abukhalil MH Althunibat OY Aladaileh SH Al-Amarat W Obeidat HM Al-Khawalde AAA . Galangin attenuates diabetic cardiomyopathy through modulating oxidative stress, inflammation and apoptosis in rats. BioMed Pharmacother. (2021) 138:111410. doi: 10.1016/j.biopha.2021.111410 Chen X Wan W Guo Y Ye T Fo Y Sun Y . Pinocembrin ameliorates post-infarct heart failure through activation of Nrf2/HO-1 signaling pathway. Mol Med. (2021) 27:100. doi: 10.1186/s10020-021-00363-7 Li T Tan Y Ouyang S He J Liu L . Resveratrol protects against myocardial ischemia-reperfusion injury via attenuating ferroptosis. Gene. (2022) 808:145968. doi: 10.1016/j.gene.2021.145968 Maayah ZH Alam AS Takahara S Soni S Ferdaoussi M Matsumura N . Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice. FEBS Lett. (2021) 595:1681–95. doi: 10.1002/1873-3468.14091 Chen ML Yi L Zhang Y Zhou X Ran L Yang J . Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. mBio. (2016) 7:e02210–15. doi: 10.1128/mBio.02210-15 Chen G Liu G Cao D Jin M Guo D Yuan X . Polydatin protects against acute myocardial infarction-induced cardiac damage by activation of Nrf2/HO-1 signaling. J Nat Med. (2019) 73:85–92. doi: 10.1007/s11418-018-1241-7 Zhang X Wang Z Li X Chen J Yu Z Li X . Polydatin protects against atherosclerosis by activating autophagy and inhibiting pyroptosis mediated by the NLRP3 inflammasome. J Ethnopharmacol. (2023) 309:116304. doi: 10.1016/j.jep.2023.116304 Li F Zhang T He Y Gu W Yang X Zhao R . Inflammation inhibition and gut microbiota regulation by TSG to combat atherosclerosis in ApoE-/- mice. J Ethnopharmacol. (2020) 247:112232. doi: 10.1016/j.jep.2019.112232 Wang D Wang XH Yu X Cao F Cai X Chen P . Pharmacokinetics of anthraquinones from medicinal plants. Front Pharmacol. (2021) 12:638993. doi: 10.3389/fphar.2021.638993 Cui Y Chen LJ Huang T Ying JQ Li J . The pharmacology, toxicology and therapeutic potential of anthraquinone derivative emodin. Chin J Nat Med. (2020) 18:425–35. doi: 10.1016/S1875-5364(20)30050-9 Wang X Yang S Li Y Jin X Lu J Wu M . Role of emodin in atherosclerosis and other cardiovascular diseases: Pharmacological effects, mechanisms, and potential therapeutic target as a phytochemical. BioMed Pharmacother. (2023) 161:114539. doi: 10.1016/j.biopha.2023.114539 Gao Q Wang F Guo S Li J Zhu B Cheng J . Sonodynamic effect of an anti-inflammatory agent–emodin on macrophages. Ultrasound Med Biol. (2011) 37:1478–85. doi: 10.1016/j.ultrasmedbio.2011.05.846 Fu X Xu AG Yao MY Guo L Zhao LS . Emodin enhances cholesterol efflux by activating peroxisome proliferator-activated receptor-γ in oxidized low density lipoprotein-loaded THP1 macrophages. Clin Exp Pharmacol Physiol. (2014) 41:679–84. doi: 10.1111/cep.2014.41.issue-9 Zhang X Qin Q Dai H Cai S Zhou C Guan J . Emodin protects H9c2 cells from hypoxia-induced injury by up-regulating miR-138 expression. Braz J Med Biol Res. (2019) 52:e7994. doi: 10.1590/1414-431x20187994 Pang X Liu J Li Y Zhao J Zhang X . Emodin inhibits homocysteine-induced C-reactive protein generation in vascular smooth muscle cells by regulating PPARγ expression and ROS-ERK1/2/p38 signal pathway. PloS One. (2015) 10:e0131295. doi: 10.1371/journal.pone.0131295 Evans LW Bender A Burnett L Godoy L Shen Y Staten D . Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy. J Nutr Biochem. (2020) 79:108339. doi: 10.1016/j.jnutbio.2019.108339 Zhou GH Zhang F Wang XN Kwon OJ Kang DG Lee HS . Emodin accentuates atrial natriuretic peptide secretion in cardiac atria. Eur J Pharmacol. (2014) 735:44–51. doi: 10.1016/j.ejphar.2014.04.014 Carver W Fix E Fix C Fan D Chakrabarti M Azhar M . Effects of emodin, a plant-derived anthraquinone, on TGF-β1-induced cardiac fibroblast activation and function. J Cell Physiol. (2021) 236:7440–9. doi: 10.1002/jcp.v236.11 Tang X Zhang Y Liu X Li X Zhao H Cui H . Aloe-emodin derivative produces anti-atherosclerosis effect by reinforcing AMBRA1-mediated endothelial autophagy. Eur J Pharmacol. (2022) 916:174641. doi: 10.1016/j.ejphar.2021.174641 Yu J Zhao X Yan X Li W Liu Y Wang J . Aloe-emodin ameliorated MI-induced cardiac remodeling in mice via inhibiting TGF-β/SMAD signaling via up-regulating SMAD7. Phytomedicine. (2023) 114:154793. doi: 10.1016/j.phymed.2023.154793 Zhang Y Song Z Huang S Zhu L Liu T Shu H . Aloe emodin relieves Ang II-induced endothelial junction dysfunction via promoting ubiquitination mediated NLRP3 inflammasome inactivation. J Leukoc Biol. (2020) 108:1735–46. doi: 10.1002/JLB.3MA0520-582R Liu J Wang Y Qiu L Yu Y Wang C . Saponins of Panax notoginseng: chemistry, cellular targets and therapeutic opportunities in cardiovascular diseases. Expert Opin Investig Drugs. (2014) 23:523–39. doi: 10.1517/13543784.2014.892582 Tan YQ Chen HW Li J . Astragaloside IV: an effective drug for the treatment of cardiovascular diseases. Drug Des Devel Ther. (2020) 14:3731–46. doi: 10.2147/DDDT.S272355 Zhang X Qu H Yang T Liu Q Zhou H . Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway. Cell Cycle. (2022) 21:2309–22. doi: 10.1080/15384101.2022.2093598 Yin B Hou XW Lu ML . Astragaloside IV attenuates myocardial ischemia/reperfusion injury in rats via inhibition of calcium-sensing receptor-mediated apoptotic signaling pathways. Acta Pharmacol Sin. (2019) 40:599–607. doi: 10.1038/s41401-018-0082-y Zhang Y Du M Wang J Liu P . Astragaloside IV relieves atherosclerosis and hepatic steatosis via MAPK/NF-κB signaling pathway in LDLR-/- mice. Front Pharmacol. (2022) 13:828161. doi: 10.3389/fphar.2022.828161 Luo LF Guan P Qin LY Wang JX Wang N Ji ES . Astragaloside IV inhibits adriamycin-induced cardiac ferroptosis by enhancing Nrf2 signaling. Mol Cell Biochem. (2021) 476:2603–11. doi: 10.1007/s11010-021-04112-6 Sui YB Zhang KK Ren YK Liu L Liu Y . The role of Nrf2 in astragaloside IV-mediated antioxidative protection on heart failure. Pharm Biol. (2020) 58:1192–8. doi: 10.1080/13880209.2020.1849319 Nie P Meng F Zhang J Wei X Shen C . Astragaloside IV exerts a myocardial protective effect against cardiac hypertrophy in rats, partially via activating the Nrf2/HO-1 signaling pathway. Oxid Med Cell Longev. (2019) 2019:4625912. doi: 10.1155/2019/4625912 Fan W Huang Y Zheng H Li S Li Z Yuan L . Ginsenosides for the treatment of metabolic syndrome and cardiovascular diseases: Pharmacology and mechanisms. BioMed Pharmacother. (2020) 132:110915. doi: 10.1016/j.biopha.2020.110915 Zhang X Wang Q Wang X Chen X Shao M Zhang Q . Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway. BioMed Pharmacother. (2019) 112:108599. doi: 10.1016/j.biopha.2019.108599 Wang Y Che J Zhao H Tang J Shi G . Paeoniflorin attenuates oxidized low-density lipoprotein-induced apoptosis and adhesion molecule expression by autophagy enhancement in human umbilical vein endothelial cells. J Cell Biochem. (2019) 120:9291–9. doi: 10.1002/jcb.v120.6 Xie S Deng W Chen J Wu QQ Li H Wang J . Andrographolide protects against adverse cardiac remodeling after myocardial infarction through enhancing Nrf2 signaling pathway. Int J Biol Sci. (2020) 16:12–26. doi: 10.7150/ijbs.37269 Wang F Gao Q Yang J Wang C Cao J Sun J . Artemisinin suppresses myocardial ischemia-reperfusion injury via NLRP3 inflammasome mechanism. Mol Cell Biochem. (2020) 474:171–80. doi: 10.1007/s11010-020-03842-3 Feng X Sureda A Jafari S Memariani Z Tewari D Annunziata G . Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics. (2019) 9:1923–51. doi: 10.7150/thno.30787 Cheng D Liu P Wang Z . Palmatine attenuates the doxorubicin-induced inflammatory response, oxidative damage and cardiomyocyte apoptosis. Int Immunopharmacol. (2022) 106:108583. doi: 10.1016/j.intimp.2022.108583 Hou H Zhang Q Dong H Ge Z . Matrine improves diabetic cardiomyopathy through TGF-β-induced protein kinase RNA-like endoplasmic reticulum kinase signaling pathway. J Cell Biochem. (2019) 120:13573–82. doi: 10.1002/jcb.v120.8 Jiang Z Fu L Xu Y Hu X Yang H Zhang Y . Cyclovirobuxine D protects against diabetic cardiomyopathy by activating Nrf2-mediated antioxidant responses. Sci Rep. (2020) 10:6427. doi: 10.1038/s41598-020-63498-3 Xu H Cheng J He F . Cordycepin alleviates myocardial ischemia/reperfusion injury by enhancing autophagy via AMPK-mTOR pathway. J Physiol Biochem. (2022) 78:401–13. doi: 10.1007/s13105-021-00816-x Deftereos SG Beerkens FJ Shah B Giannopoulos G Vrachatis DA Giotaki SG . Colchicine in cardiovascular disease: in-depth review. Circulation. (2022) 145:61–78. doi: 10.1161/CIRCULATIONAHA.121.056171 Yin M Zhang Y Li H . Advances in research on immunoregulation of macrophages by plant polysaccharides. Front Immunol. (2019) 10:145. doi: 10.3389/fimmu.2019.00145 Dong X Zhou M Li Y Li Y Ji H Hu Q . Cardiovascular protective effects of plant polysaccharides: a review. Front Pharmacol. (2021) 12:783641. doi: 10.3389/fphar.2021.783641 Zheng H Pei Y Zhou C Hong P Qian ZJ . Amelioration of atherosclerosis in ox-LDL induced HUVEC by sulfated polysaccharides from Gelidium crinale with antihypertensive activity. Int J Biol Macromol. (2023) 228:671–80. doi: 10.1016/j.ijbiomac.2022.12.245 Huang X Hou R Pan W Wu D Zhao W Li Q . A functional polysaccharide from Eriobotrya japonica relieves myocardial ischemia injury via anti-oxidative and anti-inflammatory effects. Food Funct. (2022) 13:113–20. doi: 10.1039/D1FO03208A Sun S Yang S An N Wang G Xu Q Liu J . Astragalus polysaccharides inhibits cardiomyocyte apoptosis during diabetic cardiomyopathy via the endoplasmic reticulum stress pathway. J Ethnopharmacol. (2019) 238:111857. doi: 10.1016/j.jep.2019.111857 Pop C Berce C Ghibu S Scurtu I Sorițău O Login C . Effects of Lycium barbarum L. polysaccharides on inflammation and oxidative stress markers in a pressure overload-induced heart failure rat model. Molecules. (2020) 25:466. doi: 10.3390/molecules25030466 Luo W Lin K Hua J Han J Zhang Q Chen L . Schisandrin B attenuates diabetic cardiomyopathy by targeting MyD88 and inhibiting MyD88-dependent inflammation. Adv Sci (Weinh). (2022) 9:e2202590. doi: 10.1002/advs.202202590 Zhao B Li GP Peng JJ Ren LH Lei LC Ye HM . Schizandrin B attenuates hypoxia/reoxygenation injury in H9c2 cells by activating the AMPK/Nrf2 signaling pathway. Exp Ther Med. (2021) 21:220. doi: 10.3892/etm.2021.9651 Liu T Sun F Cui J Zheng S Li Z Guo D . Morroniside enhances angiogenesis and improves cardiac function following acute myocardial infarction in rats. Eur J Pharmacol. (2020) 872:172954. doi: 10.1016/j.ejphar.2020.172954 Gong S Liu J Wan S Yang W Zhang Y Yu B . Schisandrol A attenuates myocardial ischemia/reperfusion-induced myocardial apoptosis through upregulation of 14-3-3θ. Oxid Med Cell Longev. (2021) 2021:5541753. doi: 10.1155/2021/5541753 Liu D Zeng Y Liang P Jiang Y An S Ren P . Efficacy and safety of Xuefu Zhuyu Granules combined with western medicine in the treatment of angina pectoris of coronary heart disease: A study protocol of a randomized, double-blind, placebo-controlled clinical trial. Med (Baltimore). (2022) 101:e31235. doi: 10.1097/MD.0000000000031235 Li Y Tao T Song D He T Liu X . Effects of Xuefu Zhuyu granules on patients with stable coronary heart disease: a double-blind, randomized, and placebo-controlled study. Oxid Med Cell Longev. (2021) 2021:8877296. doi: 10.1155/2021/8877296 Yunhu C Lihua F Tao Z Xueqian L . Effectiveness of Zhuling decoction on diuretic resistance in patients with heart failure: a randomized, controlled trial. J Tradit Chin Med. (2022) 42:439–45. doi: 10.19852/j.cnki.jtcm.20220311.003 Zhu M Wei J Li Y Wang Y Ren J Li B . Efficacy and mechanism of buyang huanwu decoction in patients with ischemic heart failure: a randomized, double-blind, placebo-controlled trial combined with proteomic analysis. Front Pharmacol. (2022) 13:831208. doi: 10.3389/fphar.2022.831208 Li J Gao Z Zhang L Li S Yang Q Shang Q . Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial. Complement Ther Med. (2019) 47:102209. doi: 10.1016/j.ctim.2019.102209 Hu Z Wang H Fan G Zhang H Wang X Mao J . Danhong injection mobilizes endothelial progenitor cells to repair vascular endothelium injury via upregulating the expression of Akt, eNOS and MMP-9. Phytomedicine. (2019) 61:152850. doi: 10.1016/j.phymed.2019.152850 Fu S Zhang J Menniti-Ippolito F Gao X Galeotti F Massari M . Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review. PloS One. (2011) 6:e19604. doi: 10.1371/journal.pone.0019604 Xu Y Hu H Li Y Cen R Yao C Ma W . Effects of huoxin formula on the arterial functions of patients with coronary heart disease. Pharm Biol. (2019) 57:13–20. doi: 10.1080/13880209.2018.1561726 Chao W Qiong WU Ping LI Zhigang W Xusheng L Yuanyuan LI . Effect of Traditional Chinese Medicine combined with Western Medicine on blood lipid levels and inflammatory factors in patients with angina pectoris in coronary heart disease identified as intermingled phlegm and blood stasis syndrome: a network Meta-analysis. J Tradit Chin Med. (2023) 43:640–9. doi: 10.19852/j.cnki.jtcm.20230506.001 Zhang H Yin KQ Liu XL Zhang M Ren HF Zhou HW . Clinical efficacy of modified Xiaojianzhong decoction in patients with chronic heart failure and constipation. J Shaanxi Univ Chin Med. (2019) 42:117–119+138. doi: 10.13424/j.cnki.jsctcm.2019.06.031 Peng JX . Clinical study on the regulation effect of Jianpi Huazhi pill on intestinal flora in patients with acute exacerbation of chronic heart failure. Asia-Pacific Traditional Med. (2020) 16:140–2. doi: 10.11954/ytctyy.202006044 Shen Z Chen T Deng B Fan M Hua J Zhang M . Effects on Suxiao Jiuxin Pills in the treatment of patients with acute coronary syndrome undergoing early percutaneous coronary intervention: A multicenter randomized double-blind placebo-controlled trial. J Altern Complement Med. (2020) 26:1055–63. doi: 10.1089/acm.2020.0014 Liang B Zou FH Fu L Liao HL . Chinese herbal medicine Dingji Fumai decoction for ventricular premature contraction: a real-world trial. BioMed Res Int. (2020) 2020:5358467. doi: 10.1155/2020/5358467 Chen Y Xiao X Xu X Zhang Z Deng Y . Traditional Chinese Medicine in the prevention and treatment of stable angina pectoris in patients with coronary heart disease based on the theory of "phlegm and blood stasis" under guidance of evidence-based medicine: a prospective cohort study. J Tradit Chin Med. (2021) 41:150–6. doi: 10.19852/j.cnki.jtcm.2021.01.017 Liu B Song Z Yu J Li P Tang Y Ge J . The atherosclerosis-ameliorating effects and molecular mechanisms of BuYangHuanWu decoction. BioMed Pharmacother. (2020) 123:109664. doi: 10.1016/j.biopha.2019.109664 Cai Y Wen J Ma S Mai Z Zhan Q Wang Y . Huang-Lian-Jie-Du decoction attenuates atherosclerosis and increases plaque stability in high-fat diet-induced ApoE-/- mice by inhibiting m1 macrophage polarization and promoting M2 macrophage polarization. Front Physiol. (2021) 12:666449. doi: 10.3389/fphys.2021.666449 Zhang Y Ding J Wang Y Feng X Du M Liu P . Guanxinkang decoction attenuates the inflammation in atherosclerosis by regulating efferocytosis and MAPKs signaling pathway in LDLR-/- mice and RAW264.7 cells. Front Pharmacol. (2021) 12:731769. doi: 10.3389/fphar.2021.731769 Zhang J Wang X Guan B Wang X An X Wang T . Qing-Xin-Jie-Yu Granule inhibits ferroptosis and stabilizes atherosclerotic plaques by regulating the GPX4/xCT signaling pathway. J Ethnopharmacol. (2023) 301:115852. doi: 10.1016/j.jep.2022.115852 Zhou QB Chen Y Zhang Y Li DD Wang HQ Jia ZJ . Hypermethylation effects of Yiqihuoxue decoction in diabetic atherosclerosis using genome-wide DNA methylation analyses. J Inflammation Res. (2022) 15:163–76. doi: 10.2147/JIR.S335374 Li C Chi C Li W Li Z Wang X Wang M . An integrated approach for identifying the efficacy and potential mechanisms of TCM against atherosclerosis-Wu-Zhu-Yu decoction as a case study. J Ethnopharmacol. (2022) 296:115436. doi: 10.1016/j.jep.2022.115436 Ha E Kim M Chun J Seo CS Ahn Y Jung J . Tongqiaohuoxue hinders development and progression of atherosclerosis: a possible role in Alzheimer's disease. Biol (Basel). (2020) 9:363. doi: 10.3390/biology9110363 Zhu ZB Song K Huang WJ Li H Yang H Bai YQ . Si-Miao-Yong-An (SMYA) decoction may protect the renal function through regulating the autophagy-mediated degradation of ubiquitinated protein in an atherosclerosis model. Front Pharmacol. (2020) 11:837. doi: 10.3389/fphar.2020.00837 Li S Liu P Feng X Du M Zhang Y Wang Y . Mechanism of Tao Hong Decoction in the treatment of atherosclerosis based on network pharmacology and experimental validation. Front Cardiovasc Med. (2023) 10:1111475. doi: 10.3389/fcvm.2023.1111475 Guo HY Lu ZY Zhao B Jiang WW Xiong YH Wang K . Effects of Bunao-Fuyuan decoction serum on proliferation and migration of vascular smooth muscle cells in atherosclerotic. Chin J Nat Med. (2021) 19:36–45. doi: 10.1016/S1875-5364(21)60004-3 Liang J Huang Y Mai Z Zhan Q Lin H Xie Y . Integrating network pharmacology and experimental validation to decipher the mechanism of action of Huanglian Jiedu decoction in treating atherosclerosis. Drug Des Devel Ther. (2021) 15:1779–95. doi: 10.2147/DDDT.S304911 Chen Q Zhang Y Meng Q Wang S Yu X Cai D . Liuwei Dihuang prevents postmenopausal atherosclerosis and endothelial cell apoptosis via inhibiting DNMT1-medicated ERα methylation. J Ethnopharmacol. (2020) 252:112531. doi: 10.1016/j.jep.2019.112531 Meng Q Yu X Chen Q Wu X Kong X Wang S . Liuwei Dihuang soft capsules inhibits the phenotypic conversion of VSMC to prevent the menopausal atherosclerosis by up-regulating the expression of myocardin. J Ethnopharmacol. (2020) 246:112207. doi: 10.1016/j.jep.2019.112207 Xu H Zhang T He L Yuan M Yuan X Wang S . Exploring the mechanism of Danggui Buxue Decoction in regulating atherosclerotic disease network based on integrated pharmacological methods. Biosci Rep. (2021) 41:BSR20211429. doi: 10.1042/BSR20211429 Jin Z Luo Y Zhao H Cui J He W Li J . Qingre Huoxue Decoction regulates macrophage polarisation to attenuate atherosclerosis through the inhibition of NF-κB signalling-mediated inflammation. J Ethnopharmacol. (2023) 301:115787. doi: 10.1016/j.jep.2022.115787 Zhang Y Qian X Sun X Lin C Jing Y Yao Y . Liuwei Dihuang, a traditional Chinese medicinal formula, inhibits proliferation and migration of vascular smooth muscle cells via modulation of estrogen receptors. Int J Mol Med. (2018) 42:31–40. doi: 10.3892/ijmm.2018.3622 Li L Yu AL Wang ZL Chen K Zheng W Zhou JJ . Chaihu-Shugan-San and absorbed meranzin hydrate induce anti-atherosclerosis and behavioral improvements in high-fat diet ApoE-/- mice via anti-inflammatory and BDNF-TrkB pathway. BioMed Pharmacother. (2019) 115:108893. doi: 10.1016/j.biopha.2019.108893 Yang M Jiao H Li Y Zhang L Zhang J Zhong X . Guanmaitong granule attenuates atherosclerosis by inhibiting inflammatory immune response in ApoE-/- mice fed high-fat diet. Drug Des Devel Ther. (2022) 16:3145–68. doi: 10.2147/DDDT.S372143 Chen R Chen T Wang T Dai X Meng K Zhang S . Tongmai Yangxin pill reduces myocardial no-reflow by regulating apoptosis and activating PI3K/Akt/eNOS pathway. J Ethnopharmacol. (2020) 261:113069. doi: 10.1016/j.jep.2020.113069 Chen R Chen T Wang T Dai X Zhang S Jiang D . Tongmai Yangxin pill reduces myocardial No-reflow via endothelium-dependent NO-cGMP signaling by activation of the cAMP/PKA pathway. J Ethnopharmacol. (2021) 267:113462. doi: 10.1016/j.jep.2020.113462 Li M Wang Y Qi Z Yuan Z Lv S Zheng Y . QishenYiqi dripping pill protects against myocardial ischemia/reperfusion injury via suppressing excessive autophagy and NLRP3 inflammasome based on network pharmacology and experimental pharmacology. Front Pharmacol. (2022) 13:981206. doi: 10.3389/fphar.2022.981206 Chen M Zhong G Liu M He H Zhou J Chen J . Integrating network analysis and experimental validation to reveal the mitophagy-associated mechanism of Yiqi Huoxue (YQHX) prescription in the treatment of myocardial ischemia/reperfusion injury. Pharmacol Res. (2023) 189:106682. doi: 10.1016/j.phrs.2023.106682 Long L Yu Z Chen S Wu J Liu Y Peng J . Pretreatment of Huoxue Jiedu formula ameliorates myocardial ischaemia/reperfusion injury by decreasing autophagy via activation of the PI3K/AKT/mTOR pathway. Front Pharmacol. (2021) 12:608790. doi: 10.3389/fphar.2021.608790 Xie F Wu YY Duan GJ Wang B Gao F Wei PF . Anti-myocardial ischemia reperfusion injury mechanism of dried ginger-aconite decoction based on network pharmacology. Front Pharmacol. (2021) 12:609702. doi: 10.3389/fphar.2021.609702 Zhao Y Guo R Li L Li S Fan G Zhao X . Tongmai formula improves cardiac function via regulating mitochondrial quality control in the myocardium with ischemia/reperfusion injury. BioMed Pharmacother. (2020) 132:110897. doi: 10.1016/j.biopha.2020.110897 Zhou K Chen H Wang XY Xu YM Liao YF Qin YY . Targeted pharmacokinetics and bioinformatics screening strategy reveals JAK2 as the main target for Xin-Ji-Er-Kang in treatment of MIR injury. BioMed Pharmacother. (2022) 155:113792. doi: 10.1016/j.biopha.2022.113792 Cui Y Zhang F Xu W Li Z Zou J Gao P . Effects of Si-Miao-Yong-An decoction on myocardial I/R rats by regulating gut microbiota to inhibit LPS-induced TLR4/NF-κB signaling pathway. BMC Complement Med Ther. (2023) 23:180. doi: 10.1186/s12906-023-04013-9 Zeng Z Wang Q Yang X Ren Y Jiao S Zhu Q . Qishen granule attenuates cardiac fibrosis by regulating TGF-β /Smad3 and GSK-3β pathway. Phytomedicine. (2019) 62:152949. doi: 10.1016/j.phymed.2019.152949 Liao M Xie Q Zhao Y Yang C Lin C Wang G . Main active components of Si-Miao-Yong-An decoction (SMYAD) attenuate autophagy and apoptosis via the PDE5A-AKT and TLR4-NOX4 pathways in isoproterenol (ISO)-induced heart failure models. Pharmacol Res. (2022) 176:106077. doi: 10.1016/j.phrs.2022.106077 Chen Y Li L Hu C Zhao X Zhang P Chang Y . Lingguizhugan decoction dynamically regulates MAPKs and AKT signaling pathways to retrogress the pathological progression of cardiac hypertrophy to heart failure. Phytomedicine. (2022) 98:153951. doi: 10.1016/j.phymed.2022.153951 Wei XH Liu WJ Jiang W Lan TH Pan H Ma MY . XinLi formula, a traditional Chinese decoction, alleviates chronic heart failure via regulating the interaction of AGTR1 and AQP1. Phytomedicine. (2023) 113:154722. doi: 10.1016/j.phymed.2023.154722 Hu Y Qu H Zhou H . Integrating network pharmacology and an experimental model to investigate the effect of Zhenwu Decoction on doxorubicin-induced heart failure. Comb Chem High Throughput Screen. (2023) 26:2502–16. doi: 10.2174/1386207326666230413091715 Yu S Qian H Tian D Yang M Li D Xu H . Linggui Zhugan Decoction activates the SIRT1-AMPK-PGC1α signaling pathway to improve mitochondrial and oxidative damage in rats with chronic heart failure caused by myocardial infarction. Front Pharmacol. (2023) 14:1074837. doi: 10.3389/fphar.2023.1074837 Zhuang J Zhu J Dou Y Chen X Chen H Liu X . Shenqi Lixin Decoction improves cardiac function in rats with adriamycin-induced heart failure through modulation of PGC-1α and mitochondrial apoptosis pathway. Ann Transl Med. (2021) 9:1592. doi: 10.21037/atm-21-5350 Zhang W Yu M Zhang C Yu Q Xu S Yan Q . Active ingredient paeonol of jijiu huiyang decoction alleviates isoproterenol-induced chronic heart failure via the GSK3A/PPARα pathway. Oxid Med Cell Longev. (2023) 2023:3271057. doi: 10.1155/2023/3271057 Su YN Lu PP Yan SY Guo XT Ma J Guo CX . Xinfuli granule alleviates metabolic remodeling through inhibition of endoplasmic reticulum stress and mitochondrial injury in heart failure. J Ethnopharmacol. (2023) 303:115782. doi: 10.1016/j.jep.2022.115782 Li Y Li X Chen X Sun X Liu X Wang G . Qishen granule (QSG) inhibits monocytes released from the spleen and protect myocardial function via the TLR4-MyD88-NF-κB p65 pathway in heart failure mice. Front Pharmacol. (2022) 13:850187. doi: 10.3389/fphar.2022.850187 Qiu X Ma J Shi Y Zhang D Li D Dong Z . BAOXIN granules protected mouse model with elevated afterload from cardiac hypertrophy by suppressing both inflammatory reaction and collagen deposition. Front Physiol. (2019) 10:820. doi: 10.3389/fphys.2019.00820 Wang C Zhou J Wang S Liu Y Long K Sun T . Guanxining injection alleviates fibrosis in heart failure mice and regulates SLC7A11/GPX4 axis. J Ethnopharmacol. (2023) 310:116367. doi: 10.1016/j.jep.2023.116367 Nie Y Zhang Y Li Z Wan M Li D . Injection of YiQiFuMai powder protects against heart failure via inhibiting p38 and ERK1/2 MAPKs activation. Pharm Biol. (2022) 60:570–8. doi: 10.1080/13880209.2022.2038207 Fan S Xiao G Ni J Zhao Y Du H Liang Y . Guanxinning injection ameliorates cardiac remodeling in HF mouse and 3D heart spheroid models via p38/FOS/MMP1-mediated inhibition of myocardial hypertrophy and fibrosis. BioMed Pharmacother. (2023) 162:114642. doi: 10.1016/j.biopha.2023.114642 Yuan C Wu Z Jin C Cao W Dong Y Chen J . Qiangxin recipe improves doxorubicin-induced chronic heart failure by enhancing KLF5-mediated glucose metabolism. Phytomedicine. (2023) 112:154697. doi: 10.1016/j.phymed.2023.154697 Tan C Zeng J Wu G Zheng L Huang M Huang X . Xinshuitong Capsule extract attenuates doxorubicin-induced myocardial edema via regulation of cardiac aquaporins in the chronic heart failure rats. BioMed Pharmacother. (2021) 144:112261. doi: 10.1016/j.biopha.2021.112261 Qiu H Huang ZY Cao H Zhang Z Ma J Li XQ . Deciphering mechanism of the herbal formula WuShen in the treatment of postinfarction heart failure. Phytomedicine. (2022) 95:153878. doi: 10.1016/j.phymed.2021.153878 Chen X Long L Cheng Y Chu J Shen Z Liu L . Qingda granule attenuates cardiac fibrosis via suppression of the TGF-β1/Smad2/3 signaling pathway in vitro and in vivo. BioMed Pharmacother. (2021) 137:111318. doi: 10.1016/j.biopha.2021.111318 Chen S Hu J Lu DC Liu HY Wei SS . Metabolomic characteristics of spontaneously hypertensive rats under chronic stress and the treatment effect of Danzhi Xiaoyao Powder, a traditional Chinese medicine formula. J Integr Med. (2022) 20:73–82. doi: 10.1016/j.joim.2021.11.007 Chen J Zhang Y Wang Y Jiang P Zhou G Li Z . Potential mechanisms of Guizhi decoction against hypertension based on network pharmacology and Dahl salt-sensitive rat model. Chin Med. (2021) 16:34. doi: 10.1186/s13020-021-00446-x Yu N Shen A Chu J Huang Y Zhang L Lin S . Qingda granule inhibits angiotensin II induced VSMCs proliferation through MAPK and PI3K/AKT pathways. J Ethnopharmacol. (2020) 258:112767. doi: 10.1016/j.jep.2020.112767 Mohammed SAD Liu H Baldi S Chen P Lu F Liu S . GJD modulates cardiac/vascular inflammation and decreases blood pressure in hypertensive rats. Mediators Inflammation. (2022) 2022:7345116. doi: 10.1155/2022/7345116 Yu X Zhang X Jin H Wu Z Yan C Liu Z . Zhengganxifeng decoction affects gut microbiota and reduces blood pressure via renin-angiotensin system. Biol Pharm Bull. (2019) 42:1482–90. doi: 10.1248/bpb.b19-00057 Zhu Y Huang JJ Zhang XX Yan Y Yin XW Ping G . Qing Gan Zi Shen Tang alleviates adipose tissue dysfunction with up-regulation of SIRT1 in spontaneously hypertensive rat. BioMed Pharmacother. (2018) 105:246–55. doi: 10.1016/j.biopha.2018.05.022 Song X Zhao Y Wang S Wang Y Chen Q Zhao H . Zi Shen Huo Luo formula enhances the therapeutic effects of angiotensin-converting enzyme inhibitors on hypertensive left ventricular hypertrophy by interfering with aldosterone breakthrough and affecting caveolin-1/mineralocorticoid receptor colocalization and downstream extracellular signal-regulated kinase signaling. Front Pharmacol. (2020) 11:383. doi: 10.3389/fphar.2020.00383 Han X Zhang G Chen G Wu Y Xu T Xu H . Buyang Huanwu Decoction promotes angiogenesis in myocardial infarction through suppression of PTEN and activation of the PI3K/Akt signalling pathway. J Ethnopharmacol. (2022) 287:114929. doi: 10.1016/j.jep.2021.114929 Tan Z Jiang X Zhou W Deng B Cai M Deng S . Taohong siwu decoction attenuates myocardial fibrosis by inhibiting fibrosis proliferation and collagen deposition via TGFBR1 signaling pathway. J Ethnopharmacol. (2021) 270:113838. doi: 10.1016/j.jep.2021.113838 Yang Y Su C Zhang XZ Li J Huang SC Kuang HF . Mechanisms of Xuefu Zhuyu Decoction in the treatment of coronary heart disease based on integrated metabolomics and network pharmacology approach. J Chromatogr B Analyt Technol BioMed Life Sci. (2023) 1223:123712. doi: 10.1016/j.jchromb.2023.123712 Li FH Guo SW Zhan TW Mo HR Chen X Wang H . Integrating network pharmacology and experimental evidence to decipher the cardioprotective mechanism of Yiqihuoxue decoction in rats after myocardial infarction. J Ethnopharmacol. (2021) 279:114062. doi: 10.1016/j.jep.2021.114062 Jin Z Zhang W Luo Y Li X Qing L Zuo Q . Protective effect of Qingre Huoxue decoction against myocardial infarction via PI3K/Akt autophagy pathway based on UPLC-MS, network pharmacology, and in vivo evidence. Pharm Biol. (2021) 59:1607–18. doi: 10.1080/13880209.2021.2001542 Li L Li YQ Sun ZW Xu CM Wu J Liu GL . Qingyi decoction protects against myocardial injuries induced by severe acute pancreatitis. World J Gastroenterol. (2020) 26:1317–28. doi: 10.3748/wjg.v26.i12.1317 Sun Y Wang Z Hou J Shi J Tang Z Wang C . Shuangxinfang prevents S100A9-induced macrophage/microglial inflammation to improve cardiac function and depression-like behavior in rats after acute myocardial infarction. Front Pharmacol. (2022) 13:832590. doi: 10.3389/fphar.2022.832590 Zhao N Wang Y Ma Y Liang X Zhang X Gao Y . Jia-Wei-Si-Miao-Yong-An decoction modulates intestinal flora and metabolites in acute coronary syndrome model. Front Cardiovasc Med. (2022) 9:1038273. doi: 10.3389/fcvm.2022.1038273 Liu X Li Y Ni SH Sun SN Deng JP Ou-Yang XL . Zhen-Wu decoction and lactiflorin, an ingredient predicted by in silico modelling, alleviate uremia induced cardiac endothelial injury via Nrf2 activation. J Ethnopharmacol. (2022) 298:115579. doi: 10.1016/j.jep.2022.115579 Gao Q Ma E Chen J Zhao Q He J Peng J . Qingda granule prevents obesity-induced hypertension and cardiac dysfunction by inhibiting adverse Akt signaling activation. Heliyon. (2022) 8:e12099. doi: 10.1016/j.heliyon.2022.e12099 Su C Wang Q Luo H Jiao W Tang J Li L . Si-Miao-Yong-An decoction attenuates cardiac fibrosis via suppressing TGF-β1 pathway and interfering with MMP-TIMPs expression. BioMed Pharmacother. (2020) 127:110132. doi: 10.1016/j.biopha.2020.110132 Peng M Yang M Lu Y Lin S Gao H Xie L . Huoxin Pill inhibits isoproterenol-induced transdifferentiation and collagen synthesis in cardiac fibroblasts through the TGF-β/Smads pathway. J Ethnopharmacol. (2021) 275:114061. doi: 10.1016/j.jep.2021.114061 Zhang X You LY Zhang ZY Jiang DX Qiu Y Ruan YP . Integrating pharmacological evaluation and computational identification for deciphering the action mechanism of Yunpi-Huoxue-Sanjie formula alleviates diabetic cardiomyopathy. Front Pharmacol. (2022) 13:957829. doi: 10.3389/fphar.2022.957829 Peng M Liu H Ji Q Ma P Niu Y Ning S . Fufang Xueshuantong improves diabetic cardiomyopathy by regulating the Wnt/β-Catenin pathway. Int J Endocrinol. (2022) 2022:3919161. doi: 10.1155/2022/3919161 Shi H Zhou P Ni YQ Wang SS Song R Shen AL . In vivo and in vitro studies of Danzhi Jiangtang capsules against diabetic cardiomyopathy via TLR4/MyD88/NF-κB signaling pathway. Saudi Pharm J. (2021) 29:1432–40. doi: 10.1016/j.jsps.2021.11.004 Zhang J Zhao WR Shi WT Tan JJ Zhang KY Tang JY . Tribulus terrestris L. extract ameliorates atherosclerosis by inhibition of vascular smooth muscle cell proliferation in ApoE-/- mice and A7r5 cells via suppression of Akt/MEK/ERK signaling. J Ethnopharmacol. (2022) 297:115547. doi: 10.1016/j.jep.2022.115547 Han J Dong J Zhang R Zhang X Chen M Fan X . Dendrobium catenatum Lindl. water extracts attenuate atherosclerosis. Mediators Inflammation. (2021) 2021:9951946. doi: 10.1155/2021/9951946 Liu J Zhang W Li Y Li X Li Y Guo F . Flavonoids extract from the seeds of Psoralea corylifolia L. (PFE) alleviates atherosclerosis in high-fat diet-induced LDLR-/- mice. Phytomedicine. (2022) 98:153983. doi: 10.1016/j.phymed.2022.153983 Liu Z Wang H Li C Yang J Suo Q Zhou Y . Ethyl acetate extract of Caesalpinia sappan L. for the treatment of atherosclerosis in ApoE-/- mice and its mechanism. Mol Omics. (2022) 18:977–90. doi: 10.1039/D2MO00254J Tian Y Chang S Xu J Gong P Yu B Qi J . Investigation of the effective components inhibited macrophage foam cell formation in Ophiopogonis Radix . J Ethnopharmacol. (2022) 283:114678. doi: 10.1016/j.jep.2021.114678 Lee J Ha SJ Park J Kim YH Lee NH Kim YE . Arctium lappa root extract containing L-arginine prevents TNF-α-induced early atherosclerosis in vitro and in vivo . Nutr Res. (2020) 77:85–96. doi: 10.1016/j.nutres.2020.03.003 Hashikawa-Hobara N Hashikawa N Sugiman N Hosoo S Hirata T Yamaguchi Y . Oral administration of Eucommia ulmoides oliv. leaves extract protects against atherosclerosis by improving macrophage function in ApoE knockout mice. J Food Sci. (2020) 85:4018–24. doi: 10.1111/1750-3841.15461 Zhao X Zhu J Wang L Li Y Zhao T Chen X . U. diffracta extract mitigates high fat diet and VD3-induced atherosclerosis and biochemical changes in the serum liver and aorta of rats. BioMed Pharmacother. (2019) 120:109446. doi: 10.1016/j.biopha.2019.109446 Lai P Cao X Xu Q Liu Y Li R Zhang J . Ganoderma lucidum spore ethanol extract attenuates atherosclerosis by regulating lipid metabolism via upregulation of liver X receptor alpha. Pharm Biol. (2020) 58:760–70. doi: 10.1080/13880209.2020.1798471 Ko M Oh GT Park J Kwon HJ . Extract of high hydrostatic pressure-treated danshen (Salvia miltiorrhiza) ameliorates atherosclerosis via autophagy induction. BMB Rep. (2020) 53:652–7. doi: 10.5483/BMBRep.2020.53.12.184 Ai ZL Zhang X Ge W Zhong YB Wang HY Zuo ZY . Salvia miltiorrhiza extract may exert an anti-obesity effect in rats with high-fat diet-induced obesity by modulating gut microbiome and lipid metabolism. World J Gastroenterol. (2022) 28:6131–56. doi: 10.3748/wjg.v28.i43.6131 Jia A Shi Y Zhang Y Diao Y Chang B Jiang M . Butanol extract of Acanthopanax senticosus (Rupr. et Maxim.) harms alleviates atherosclerosis in apolipoprotein E-deficient mice fed a high-fat diet. Chem Biodivers. (2023) 20:e202200949. doi: 10.1002/cbdv.202200949 Tang L Kuang C Shan D Shi M Li J Qiu L . The ethanol extract of Edgeworthia gardneri (Wall.) Meisn attenuates macrophage foam cell formation and atherogenesis in ApoE-/- mice. Front Cardiovasc Med. (2022) 9:1023438. doi: 10.3389/fcvm.2022.1023438 Chen X Cao J Sun Y Dai Y Zhu J Zhang X . Ethanol extract of Schisandrae chinensis fructus ameliorates the extent of experimentally induced atherosclerosis in rats by increasing antioxidant capacity and improving endothelial dysfunction. Pharm Biol. (2018) 56:612–9. doi: 10.1080/13880209.2018.1523933 Draginic N Milosavljevic I Andjic M Jeremic J Nikolic M Sretenovic J . Short-term administration of lemon balm extract ameliorates myocardial ischemia/reperfusion injury: focus on oxidative stress. Pharm (Basel). (2022) 15:840. doi: 10.3390/ph15070840 Bradic J Jeremic N Petkovic A Jeremic J Zivkovic V Srejovic I . Cardioprotective effects of Galium verum L. extract against myocardial ischemia-reperfusion injury. Arch Physiol Biochem. (2020) 126:408–15. doi: 10.1080/13813455.2018.1551904 Rankovic M Krivokapic M Bradic J Petkovic A Zivkovic V Sretenovic J . New insight into the cardioprotective effects of Allium ursinum L. extract against myocardial ischemia-reperfusion injury. Front Physiol. (2021) 12:690696. doi: 10.3389/fphys.2021.690696 Sedighi M Nazari A Faghihi M Rafieian-Kopaei M Karimi A Moghimian M . Protective effects of Cinnamon bark extract against ischemia-reperfusion injury and arrhythmias in rat. Phytother Res. (2018) 32:1983–91. doi: 10.1002/ptr.v32.10 Zhang L Jian LL Li JY Jin X Li LZ Zhang YL . Possible involvement of alpha B-crystallin in the cardioprotective effect of n-butanol extract of Potentilla anserina L. @ on myocardial ischemia/reperfusion injury in rat. Phytomedicine. (2019) 55:320–9. doi: 10.1016/j.phymed.2018.10.024 Tsai CF Lin HW Liao JM Chen KM Tsai JW Chang CS . Dunaliella salina alga protects against myocardial ischemia/reperfusion injury by attenuating TLR4 signaling. Int J Mol Sci. (2023) 24:3871. doi: 10.3390/ijms24043871 Sharma M Pal P Pottoo F Kumar S . Mechanistic role of methanolic extract of Taraxacum officinale roots as cardioprotective against ischemia-reperfusion injury-induced myocardial infarction in rats. Appl Biochem Biotechnol. (2023) 195:3384–405. doi: 10.1007/s12010-022-04282-z Asgari M Salehi I Ranjbar K Khosravi M Zarrinkalam E . Interval training and Crataegus persica ameliorate diabetic nephropathy via miR-126/Nrf-2 mediated inhibition of stress oxidative in rats with diabetes after myocardial ischemia-reperfusion injury. BioMed Pharmacother. (2022) 153:113411. doi: 10.1016/j.biopha.2022.113411 Sedighi M Faghihi M Rafieian-Kopaei M Rasoulian B Nazari A . Cardioprotective effect of ethanolic leaf extract of Melissa officinalis L against regional ischemia-induced arrhythmia and heart injury after five days of reperfusion in rats. Iran J Pharm Res. (2019) 18:1530–42. doi: 10.22037/ijpr.2019.1100761 Zhai S Zhang XF Lu F Chen WG He X Zhang CF . Chinese medicine GeGen-DanShen extract protects from myocardial ischemic injury through promoting angiogenesis via up-regulation of VEGF/VEGFR2 signaling pathway. J Ethnopharmacol. (2021) 267:113475. doi: 10.1016/j.jep.2020.113475 Qu S Li K Yang T Yang Y Zheng Z Liu H . Shenlian extract protects against ultrafine particulate matter-aggravated myocardial ischemic injury by inhibiting inflammation response via the activation of NLRP3 inflammasomes. Environ Toxicol. (2021) 36:1349–61. doi: 10.1002/tox.23131 Cheng F Jiang W Xiong X Chen J Xiong Y Li Y . Ethanol extract of Chinese Hawthorn (Crataegus pinnatifida) fruit reduces inflammation and oxidative stress in rats with doxorubicin-induced chronic heart failure. Med Sci Monit. (2020) 26:e926654. doi: 10.12659/MSM.926654 Zhang L Liu J Ge Y Liu M . Ginkgo biloba extract reduces hippocampus inflammatory responses, improves cardiac functions and depressive behaviors in a heart failure mouse model. Neuropsychiatr Dis Treat. (2019) 15:3041–50. doi: 10.2147/NDT.S229296 Wu Z Zhao X Miyamoto A Zhao S Liu C Zheng W . Effects of steroidal saponins extract from Ophiopogon japonicus root ameliorates doxorubicin-induced chronic heart failure by inhibiting oxidative stress and inflammatory response. Pharm Biol. (2019) 57:176–83. doi: 10.1080/13880209.2019.1577467 Xu X Xie X Zhang H Wang P Li G Chen J . Water-soluble alkaloids extracted from Aconiti radix lateralis praeparata protect against chronic heart failure in rats via a calcium signaling pathway. BioMed Pharmacother. (2021) 135:111184. doi: 10.1016/j.biopha.2020.111184 Wang X Guo D Li W Zhang Q Jiang Y Wang Q . Danshen (Salvia miltiorrhiza) restricts MD2/TLR4-MyD88 complex formation and signalling in acute myocardial infarction-induced heart failure. J Cell Mol Med. (2020) 24:10677–92. doi: 10.1111/jcmm.v24.18 Shen Z Geng Q Huang H Yao H Du T Chen L . Antioxidative and cardioprotective effects of Schisandra chinensis Bee pollen extract on isoprenaline-induced myocardial infarction in rats. Molecules. (2019) 24:1090. doi: 10.3390/molecules24061090 Panda V Bhandare N Mistry K S S Dande P . Cardioprotective potential of Spinacia oleracea (Spinach) against isoproterenol-induced myocardial infarction in rats. Arch Physiol Biochem. (2022) 128:101–10. doi: 10.1080/13813455.2019.1665074 Sun JH Yang HX Yao TT Li Y Ruan L Xu GR . Gentianella acuta prevents acute myocardial infarction induced by isoproterenol in rats via inhibition of galectin-3/TLR4/MyD88/NF-кB inflammatory signalling. Inflammopharmacology. (2021) 29:205–19. doi: 10.1007/s10787-020-00708-4 Zhang M Chen J Wang Y Kang G Zhang Y Han X . Network pharmacology-based combined with experimental validation study to explore the underlying mechanism of Agrimonia pilosa Ledeb. extract in treating acute myocardial infarction. Drug Des Devel Ther. (2022) 16:3117–32. doi: 10.2147/DDDT.S370473 Feng X Zhang R Li J Cao Y Zhao F Du X . Syringa pinnatifolia Hemsl. fraction protects against myocardial ischemic injury by targeting the p53-mediated apoptosis pathway. Phytomedicine. (2019) 52:136–46. doi: 10.1016/j.phymed.2018.09.188 Wang S Zhao Y Song J Wang R Gao L Zhang L . Total flavonoids from Anchusa italica Retz. improve cardiac function and attenuate cardiac remodeling post myocardial infarction in mice. J Ethnopharmacol. (2020) 257:112887. doi: 10.1016/j.jep.2020.112887 Wang CH Pandey S Sivalingam K Shibu MA Kuo WW Yu L . Leech extract: A candidate cardioprotective against hypertension-induced cardiac hypertrophy and fibrosis. J Ethnopharmacol. (2021) 264:113346. doi: 10.1016/j.jep.2020.113346 Zeng L Chen M Ahmad H Zheng X Ouyang Y Yang P . Momordica charantia extract confers protection against hypertension in dahl salt-sensitive rats. Plant Foods Hum Nutr. (2022) 77:373–82. doi: 10.1007/s11130-022-00971-6 Tong RC Qi M Yang QM Li PF Wang DD Lan JP . Extract of Plantago asiatica L. seeds ameliorates hypertension in spontaneously hypertensive rats by inhibition of angiotensin converting enzyme. Front Pharmacol. (2019) 10:403. doi: 10.3389/fphar.2019.00403 Chiang JT Badrealam KF Shibu MA Kuo CH Huang CY Chen BC . Eriobotrya japonica ameliorates cardiac hypertrophy in H9c2 cardiomyoblast and in spontaneously hypertensive rats. Environ Toxicol. (2018) 33:1113–22. doi: 10.1002/tox.v33.11 Zhang X Xu P Lin B Deng X Zhu J Chen X . Chimonanthus salicifolius attenuated vascular remodeling by alleviating endoplasmic reticulum stress in spontaneously hypertensive rats. Food Funct. (2022) 13:6293–305. doi: 10.1039/D1FO04381A Zhou J Zhang L Zheng B Zhang L Qin Y Zhang X . Salvia miltiorrhiza bunge exerts anti-oxidative effects through inhibiting KLF10 expression in vascular smooth muscle cells exposed to high glucose. J Ethnopharmacol. (2020) 262:113208. doi: 10.1016/j.jep.2020.113208 Wen C Liu C Li Y Xia T Zhang X Xue S . Ameliorative potentials of the ethanolic extract from Lycium chinense leaf extract against diabetic cardiomyopathy. Insight into oxido-inflammatory and apoptosis modulation. BioMed Pharmacother. (2022) 154:113583. doi: 10.1016/j.biopha.2022.113583 Zhou Q Chen B Chen X Wang Y Ji J Kizaibek M . Arnebiae radix prevents atrial fibrillation in rats by ameliorating atrial remodeling and cardiac function. J Ethnopharmacol. (2020) 248:112317. doi: 10.1016/j.jep.2019.112317 Cao YY Li K Li Y Tian XT Ba HX Wang A . Dendrobium candidum aqueous extract attenuates isoproterenol-induced cardiac hypertrophy through the ERK signalling pathway. Pharm Biol. (2020) 58:176–83. doi: 10.1080/13880209.2020.1723648 Fu D Zhou J Xu S Tu J Cai Y Liu J . Smilax glabra Roxb. flavonoids protect against pathological cardiac hypertrophy by inhibiting the Raf/MEK/ERK pathway: In vivo and in vitro studies. J Ethnopharmacol. (2022) 292:115213. doi: 10.1016/j.jep.2022.115213 Ding B Niu W Wang S Zhang F Wang H Chen X . Centella asiatica (L.) Urb. attenuates cardiac hypertrophy and improves heart function through multi-level mechanisms revealed by systems pharmacology. J Ethnopharmacol. (2022) 291:115106. doi: 10.1016/j.jep.2022.115106 Ma C Fu Z Guo H Wei H Zhao X Li Y . The effects of Radix Angelica Sinensis and Radix Hedysari ultrafiltration extract on X-irradiation-induced myocardial fibrosis in rats. BioMed Pharmacother. (2019) 112:108596. doi: 10.1016/j.biopha.2019.01.057 Li J Xu M Xing B Liu Y Zhang Q Guo J . Combination of Salviae miltiorrhizae Radix et Rhizoma and Carthami Flos improves cardiac function of diabetic cardiomyopathy mice by regulating the unfolded protein response signaling pathway. Phytother Res. (2022) 36:3571–83. doi: 10.1002/ptr.v36.9 Xie D Song L Xiang D Gao X Zhao W . Salvianolic acid A alleviates atherosclerosis by inhibiting inflammation through Trc8-mediated 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation. Phytomedicine. (2023) 112:154694. doi: 10.1016/j.phymed.2023.154694 Zhou R Gao J Xiang C Liu Z Zhang Y Zhang J . Salvianolic acid A attenuated myocardial infarction-induced apoptosis and inflammation by activating Trx. Naunyn Schmiedebergs Arch Pharmacol. (2020) 393:991–1002. doi: 10.1007/s00210-019-01766-4 Gong DF Sun SC Wang RR Dawuti A Kong DW Liu RQ . Salvianolic acid A improve mitochondrial respiration and cardiac function via inhibiting apoptosis pathway through CRYAB in diabetic cardiomyopathy. BioMed Pharmacother. (2023) 160:114382. doi: 10.1016/j.biopha.2023.114382 Wu Q Yuan X Li B Han R Zhang H Xiu R . Salvianolic acid alleviated blood-brain barrier permeability in spontaneously hypertensive rats by inhibiting apoptosis in pericytes via P53 and the Ras/Raf/MEK/ERK pathway. Drug Des Devel Ther. (2020) 14:1523–34. doi: 10.2147/DDDT.S245959 Tang Y Wa Q Peng L Zheng Y Chen J Chen X . Salvianolic acid B suppresses ER stress-induced NLRP3 inflammasome and pyroptosis via the AMPK/FoxO4 and syndecan-4/rac1 signaling pathways in human endothelial progenitor cells. Oxid Med Cell Longev. (2022) 2022:8332825. doi: 10.1155/2022/8332825 Xu X Mao C Zhang C Zhang M Gong J Wang X . Salvianolic acid B inhibits ferroptosis and apoptosis during myocardial ischemia/reperfusion injury via decreasing the ubiquitin-proteasome degradation of GPX4 and the ROS-JNK/MAPK pathways. Molecules. (2023) 28:4117. doi: 10.3390/molecules28104117 Zhao M Li F Jian Y Wang X Yang H Wang J . Salvianolic acid B regulates macrophage polarization in ischemic/reperfused hearts by inhibiting mTORC1-induced glycolysis. Eur J Pharmacol. (2020) 871:172916. doi: 10.1016/j.ejphar.2020.172916 Ma D Mandour AS Elfadadny A Hendawy H Yoshida T El-Husseiny HM . Changes in cardiac function during the development of uremic cardiomyopathy and the effect of Salvianolic acid B administration in a rat model. Front Vet Sci. (2022) 9:905759. doi: 10.3389/fvets.2022.905759 Li CL Liu B Wang ZY Xie F Qiao W Cheng J . Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol. (2020) 139:98–112. doi: 10.1016/j.yjmcc.2020.01.009 Tian L Su CP Wang Q Wu FJ Bai R Zhang HM . Chlorogenic acid: A potent molecule that protects cardiomyocytes from TNF-α-induced injury via inhibiting NF-κB and JNK signals. J Cell Mol Med. (2019) 23:4666–78. doi: 10.1111/jcmm.2019.23.issue-7 Wang D Tian L Lv H Pang Z Li D Yao Z . Chlorogenic acid prevents acute myocardial infarction in rats by reducing inflammatory damage and oxidative stress. BioMed Pharmacother. (2020) 132:110773. doi: 10.1016/j.biopha.2020.110773 Zhu Q Zhu Y Liu Y Tao Y Lin Y Lai S . Moderation of gut microbiota and bile acid metabolism by chlorogenic acid improves high-fructose-induced salt-sensitive hypertension in mice. Food Funct. (2022) 13:6987–99. doi: 10.1039/D2FO00038E Preetha Rani MR Salin Raj P Nair A Ranjith S Rajankutty K Raghu KG . In vitro and in vivo studies reveal the beneficial effects of chlorogenic acid against ER stress mediated ER-phagy and associated apoptosis in the heart of diabetic rat. Chem Biol Interact. (2022) 351:109755. doi: 10.1016/j.cbi.2021.109755 Clark M Centner AM Ukhanov V Nagpal R Salazar G . Gallic acid ameliorates atherosclerosis and vascular senescence and remodels the microbiome in a sex-dependent manner in ApoE-/- mice. J Nutr Biochem. (2022) 110:109132. doi: 10.1016/j.jnutbio.2022.109132 Yan X Zhang YL Zhang L Zou LX Chen C Liu Y . Gallic acid suppresses cardiac hypertrophic remodeling and heart failure. Mol Nutr Food Res. (2019) 63:e1800807. doi: 10.1002/mnfr.201800807 Jin L Sun S Ryu Y Piao ZH Liu B Choi SY . Gallic acid improves cardiac dysfunction and fibrosis in pressure overload-induced heart failure. Sci Rep. (2018) 8:9302. doi: 10.1038/s41598-018-27599-4 Han D Zhang QY Zhang YL Han X Guo SB Teng F . Gallic acid ameliorates angiotensin II-induced atrial fibrillation by inhibiting immunoproteasome-mediated PTEN degradation in mice. Front Cell Dev Biol. (2020) 8:594683. doi: 10.3389/fcell.2020.594683 Yan X Zhang QY Zhang YL Han X Guo SB Li HH . Gallic acid attenuates angiotensin ii-induced hypertension and vascular dysfunction by inhibiting the degradation of endothelial nitric oxide synthase. Front Pharmacol. (2020) 11:1121. doi: 10.3389/fphar.2020.01121 Sundaresan S John S Paneerselvam G Andiapppan R Christopher G Selvam GS . Gallic acid attenuates cadmium mediated cardiac hypertrophic remodelling through upregulation of Nrf2 and PECAM-1signalling in rats. Environ Toxicol Pharmacol. (2021) 87:103701. doi: 10.1016/j.etap.2021.103701 Dong X Zeng Y Liu Y You L Yin X Fu J . Aloe-emodin: A review of its pharmacology, toxicity, and pharmacokinetics. Phytother Res. (2020) 34:270–81. doi: 10.1002/ptr.v34.2 Han X Bai L Kee HJ Jeong MH . Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg. J Cell Mol Med. (2022) 26:4076–86. doi: 10.1111/jcmm.v26.14 Sabahi Z Khoshnoud MJ Hosseini S Khoshraftar F Rashedinia M . Syringic acid attenuates cardiomyopathy in streptozotocin-induced diabetic rats. Adv Pharmacol Pharm Sci. (2021) 2021:5018092. doi: 10.1155/2021/5018092 Sun R Wu T Xing S Wei S Bielicki JK Pan X . Caffeic acid protects against atherosclerotic lesions and cognitive decline in ApoE-/- mice. J Pharmacol Sci. (2023) 151:110–8. doi: 10.1016/j.jphs.2022.12.006 Oboh G Ojueromi OO Ademosun AO Omayone TP Oyagbemi AA Ajibade TO . Effects of caffeine and caffeic acid on selected biochemical parameters in L-NAME-induced hypertensive rats. J Food Biochem. (2021) 45:e13384. doi: 10.1111/jfbc.13384 Lee SY Kuo YH Du CX Huang CW Ku HC . A novel caffeic acid derivative prevents angiotensin II-induced cardiac remodeling. BioMed Pharmacother. (2023) 162:114709. doi: 10.1016/j.biopha.2023.114709 Huwait E Almowallad S Al-Massabi R Saddeek S Gauthaman K Prola A . Punicalagin targets atherosclerosis: gene expression profiling of THP-1 macrophages treated with punicalagin and molecular docking. Curr Issues Mol Biol. (2022) 44:2153–66. doi: 10.3390/cimb44050145 Yu LM Dong X Xue XD Zhang J Li Z Wu HJ . Protection of the myocardium against ischemia/reperfusion injury by punicalagin through an SIRT1-NRF-2-HO-1-dependent mechanism. Chem Biol Interact. (2019) 306:152–62. doi: 10.1016/j.cbi.2019.05.003 Fu F Liu C Shi R Li M Zhang M Du Y . Punicalagin protects against diabetic cardiomyopathy by promoting Opa1-mediated mitochondrial fusion via regulating PTP1B-Stat3 pathway. Antioxid Redox Signal. (2021) 35:618–41. doi: 10.1089/ars.2020.8248 Liu X Qi K Gong Y Long X Zhu S Lu F . Ferulic acid alleviates myocardial ischemia reperfusion injury via upregulating AMPKα2 expression-mediated ferroptosis depression. J Cardiovasc Pharmacol. (2021) 79:489–500. doi: 10.1097/FJC.0000000000001199 Zhang XJ Cui ZH Zhao YX He TT Wang L Liang XW . Ferulic acid ameliorates isoproterenol-induced heart failure by decreasing oxidative stress and inhibiting cardiocyte apoptosis via activating Nrf2 signaling pathway in rats. Biol Pharm Bull. (2021) 44:396–403. doi: 10.1248/bpb.b20-00783 Li C Chen L Song M Fang Z Zhang L Coffie JW . Ferulic acid protects cardiomyocytes from TNF-α/cycloheximide-induced apoptosis by regulating autophagy. Arch Pharm Res. (2020) 43:863–74. doi: 10.1007/s12272-020-01252-z Salin Raj P Nair A Preetha Rani MR Rajankutty K Ranjith S Raghu KG . Ferulic acid attenuates high glucose-induced MAM alterations via PACS2/IP3R2/FUNDC1/VDAC1 pathway activating proapoptotic proteins and ameliorates cardiomyopathy in diabetic rats. Int J Cardiol. (2023) 372:101–9. doi: 10.1016/j.ijcard.2022.12.003 Chen C . Anti-atherosclerotic activity of para methoxy cinnamic acid in high fat diet induced hyperlipidemia model rats. Appl Biochem Biotechnol. (2022) 194:1911–24. doi: 10.1007/s12010-021-03735-1 Nair A Preetha Rani MR Salin Raj P Ranjit S Rajankutty K Raghu KG . Cinnamic acid is beneficial to diabetic cardiomyopathy via its cardioprotective, anti-inflammatory, anti-dyslipidemia, and antidiabetic properties. J Biochem Mol Toxicol. (2022) 36:e23215. doi: 10.1002/jbt.v36.12 Koczurkiewicz-Adamczyk P Klaś K Gunia-Krzyżak A Piska K Andrysiak K Stępniewski J . Cinnamic acid derivatives as cardioprotective agents against oxidative and structural damage induced by doxorubicin. Int J Mol Sci. (2021) 22:6217. doi: 10.3390/ijms22126217 Fan M Li Z Hu M Zhao H Wang T Jia Y . Formononetin attenuates Aβ(25-35)-induced adhesion molecules in HBMECs via Nrf2 activation. Brain Res Bull. (2022) 183:162–71. doi: 10.1016/j.brainresbull.2022.03.009 Wang DS Yan LY Yang DZ Lyu Y Fang LH Wang SB . Formononetin ameliorates myocardial ischemia/reperfusion injury in rats by suppressing the ROS-TXNIP-NLRP3 pathway. Biochem Biophys Res Commun. (2020) 525:759–66. doi: 10.1016/j.bbrc.2020.02.147 Yang Y Huang T Zhang H Li X Shi S Tian X . Formononetin improves cardiac function and depressive behaviours in myocardial infarction with depression by targeting GSK-3β to regulate macrophage/microglial polarization. Phytomedicine. (2023) 109:154602. doi: 10.1016/j.phymed.2022.154602 Wu Y Cai C Yang L Xiang Y Zhao H Zeng C . Inhibitory effects of formononetin on the monocrotaline−induced pulmonary arterial hypertension in rats. Mol Med Rep. (2020) 21:1192–200. doi: 10.3892/mmr.2020.10911 Li J Chang WT Qin G Wojcik KR Li CQ Hsu CW . Baicalein preconditioning cardioprotection involves pro-oxidant signaling and activation of pyruvate dehydrogenase. Am J Chin Med. (2022) 50:1255–67. doi: 10.1142/S0192415X22500513 Shi R Zhu D Wei Z Fu N Wang C Liu L . Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition. Life Sci. (2018) 207:442–50. doi: 10.1016/j.lfs.2018.06.033 Liu BY Li L Liu GL Ding W Chang WG Xu T . Baicalein attenuates cardiac hypertrophy in mice via suppressing oxidative stress and activating autophagy in cardiomyocytes. Acta Pharmacol Sin. (2021) 42:701–14. doi: 10.1038/s41401-020-0496-1 Ma L Li XP Ji HS Liu YF Li EZ . Baicalein protects rats with diabetic cardiomyopathy against oxidative stress and inflammation injury via phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Med Sci Monit. (2018) 24:5368–75. doi: 10.12659/MSM.911455 Zhao J Wang Z Yuan Z Lv S Su Q . Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice. Diabetes Vasc Dis Res. (2020) 17:1479164120977441. doi: 10.1177/1479164120977441 Fan Z Cai L Wang S Wang J Chen B . Baicalin prevents myocardial ischemia/reperfusion injury through inhibiting ACSL4 mediated ferroptosis. Front Pharmacol. (2021) 12:628988. doi: 10.3389/fphar.2021.628988 Xu M Li X Song L . Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway. Pharm Biol. (2020) 58:655–63. doi: 10.1080/13880209.2020.1779318 Cai Y Jiang S Huang C Shen A Zhang X Yang W . Baicalin inhibits pressure overload-induced cardiac hypertrophy by regulating the SIRT3-dependent signaling pathway. Phytomedicine. (2023) 114:154747. doi: 10.1016/j.phymed.2023.154747 Feng P Yang Y Liu N Wang S . Baicalin regulates TLR4/IκBα/NFκB signaling pathway to alleviate inflammation in Doxorubicin related cardiotoxicity. Biochem Biophys Res Commun. (2022) 637:1–8. doi: 10.1016/j.bbrc.2022.10.061 Wu D Ding L Tang X Wang W Chen Y Zhang T . Baicalin protects against hypertension-associated intestinal barrier impairment in part through enhanced microbial production of short-chain fatty acids. Front Pharmacol. (2019) 10:1271. doi: 10.3389/fphar.2019.01271 Koga M Kanaoka Y Inada K Omine S Kataoka Y Yamauchi A . Hesperidin blocks varenicline-aggravated atherosclerotic plaque formation in apolipoprotein E knockout mice by downregulating net uptake of oxidized low-density lipoprotein in macrophages. J Pharmacol Sci. (2020) 143:106–11. doi: 10.1016/j.jphs.2020.01.012 Li X Hu X Wang J Xu W Yi C Ma R . Inhibition of autophagy via activation of PI3K/Akt/mTOR pathway contributes to the protection of hesperidin against myocardial ischemia/reperfusion injury. Int J Mol Med. (2018) 42:1917–24. doi: 10.3892/ijmm.2018.3794 Bhargava P Verma VK Malik S Khan SI Bhatia J Arya DS . Hesperidin regresses cardiac hypertrophy by virtue of PPAR-γ agonistic, anti-inflammatory, antiapoptotic, and antioxidant properties. J Biochem Mol Toxicol. (2019) 33:e22283. doi: 10.1002/jbt.2019.33.issue-5 Jang SA Park DW Sohn EH Lee SR Kang SC . Hyperoside suppresses tumor necrosis factor α-mediated vascular inflammatory responses by downregulating mitogen-activated protein kinases and nuclear factor-κB signaling. Chem Biol Interact. (2018) 294:48–55. doi: 10.1016/j.cbi.2018.08.013 Shi Y Qiu X Dai M Zhang X Jin G . Hyperoside attenuates hepatic ischemia-reperfusion injury by suppressing oxidative stress and inhibiting apoptosis in rats. Transplant Proc. (2019) 51:2051–9. doi: 10.1016/j.transproceed.2019.04.066 Yang Y Li J Rao T Fang Z Zhang J . The role and mechanism of hyperoside against myocardial infarction in mice by regulating autophagy via NLRP1 inflammation pathway. J Ethnopharmacol. (2021) 276:114187. doi: 10.1016/j.jep.2021.114187 Guo X Zhang Y Lu C Qu F Jiang X . Protective effect of hyperoside on heart failure rats via attenuating myocardial apoptosis and inducing autophagy. Biosci Biotechnol Biochem. (2020) 84:714–24. doi: 10.1080/09168451.2019.1685369 Chang X Zhang T Liu D Meng Q Yan P Luo D . Puerarin attenuates LPS-induced inflammatory responses and oxidative stress injury in human umbilical vein endothelial cells through mitochondrial quality control. Oxid Med Cell Longev. (2021) 2021:6659240. doi: 10.1155/2021/6659240 Ding Y Li W Peng S Zhou G Chen S Wei Y . Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting ferroptosis. Biol Pharm Bull. (2023) 46:524–32. doi: 10.1248/bpb.b22-00174 He L Wang T Chen BW Lu FM Xu J . Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARα expression in rats with chronic heart failure. Exp Ther Med. (2019) 18:3347–56. doi: 10.3892/etm.2019.7984 Hou N Huang Y Cai SA Yuan WC Li LR Liu XW . Puerarin ameliorated pressure overload-induced cardiac hypertrophy in ovariectomized rats through activation of the PPARα/PGC-1 pathway. Acta Pharmacol Sin. (2021) 42:55–67. doi: 10.1038/s41401-020-0401-y Shi W Yuan R Chen X Xin Q Wang Y Shang X . Puerarin reduces blood pressure in spontaneously hypertensive rats by targeting eNOS. Am J Chin Med. (2019) 47:19–38. doi: 10.1142/S0192415X19500022 Chen F Chen ZQ Wang H Zhu JJ . Puerarin pretreatment inhibits myocardial apoptosis and improves cardiac function in rats after acute myocardial infarction through the PI3K/Akt signaling pathway. Adv Clin Exp Med. (2021) 30:255–61. doi: 10.17219/acem/131754 Yin MS Zhang YC Xu SH Liu JJ Sun XH Liang C . Puerarin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of inflammation. J Asian Nat Prod Res. (2019) 21:476–93. doi: 10.1080/10286020.2017.1405941 Cao H Jia Q Yan L Chen C Xing S Shen D . Quercetin suppresses the progression of atherosclerosis by regulating MST1-mediated autophagy in ox-LDL-induced RAW264.7 macrophage foam cells. Int J Mol Sci. (2019) 20:6093. doi: 10.3390/ijms20236093 Tang J Lu L Liu Y Ma J Yang L Li L . Quercetin improve ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro and in vivo study via SIRT1/PGC-1α signaling. J Cell Biochem. (2019) 120:9747–57. doi: 10.1002/jcb.v120.6 Jiang C Li D Chen L Liu Y Zhao Y Mei G . Quercetin ameliorated cardiac injury via reducing inflammatory actions and the glycerophospholipid metabolism dysregulation in a diabetic cardiomyopathy mouse model. Food Funct. (2022) 13:7847–56. doi: 10.1039/D2FO00912A Albadrani GM BinMowyna MN Bin-Jumah MN El-Akabawy G Aldera H Al-Farga AM . Quercetin prevents myocardial infarction adverse remodeling in rats by attenuating TGF-β1/Smad3 signaling: Different mechanisms of action. Saudi J Biol Sci. (2021) 28:2772–82. doi: 10.1016/j.sjbs.2021.02.007 Feng ST Wang XL Wang YT Yuan YH Li ZP Chen NH . Efficacy of traditional Chinese medicine combined with selective serotonin reuptake inhibitors on the treatment for Parkinson's disease with depression: a systematic review and meta-analysis. Am J Chin Med. (2021) 49:627–43. doi: 10.1142/S0192415X21500282 Feng Z Wang C Yue Jin Meng Q Wu J . Kaempferol-induced GPER upregulation attenuates atherosclerosis via the PI3K/AKT/Nrf2 pathway. Pharm Biol. (2021) 59:1106–16. doi: 10.1080/13880209.2021.1961823 Zhang L Guo Z Wang Y Geng J Han S . The protective effect of kaempferol on heart via the regulation of Nrf2, NF-κβ, and PI3K/Akt/GSK-3β signaling pathways in isoproterenol-induced heart failure in diabetic rats. Drug Dev Res. (2019) 80:294–309. doi: 10.1002/ddr.21495 Alshehri AS El-Kott AF Eleawa SM El-Gerbed MSA Khalifa HS El-Kenawy AE . Kaempferol protects against streptozotocin-induced diabetic cardiomyopathy in rats by a hypoglycemic effect and upregulating SIRT1. J Physiol Pharmacol. (2021) 72:339–55. doi: 10.26402/jpp.2021.3.04 Zhao R Xiao H Jin T Xu F Li Y Li H . Naringenin promotes cell autophagy to improve high-fat-diet-induced atherosclerosis in ApoE-/- mice. Braz J Med Biol Res. (2021) 54:e9764. doi: 10.1590/1414-431x20209764 Xu X Lei T Li W Ou H . Enhanced cellular cholesterol efflux by naringenin is mediated through inhibiting endoplasmic reticulum stress - ATF6 activity in macrophages. Biochim Biophys Acta Mol Cell Biol Lipids. (2019) 1864:1472–82. doi: 10.1016/j.bbalip.2019.06.005 Ma K Liu W Liu Q Hu P Bai L Yu M . Naringenin facilitates M2 macrophage polarization after myocardial ischemia-reperfusion by promoting nuclear translocation of transcription factor EB and inhibiting the NLRP3 inflammasome pathway. Environ Toxicol. (2023) 38:1405–19. doi: 10.1002/tox.23774 Li Y He B Zhang C He Y Xia T Zeng C . Naringenin attenuates isoprenaline-induced cardiac hypertrophy by suppressing oxidative stress through the AMPK/NOX2/MAPK signaling pathway. Nutrients. (2023) 15:1340. doi: 10.3390/nu15061340 He Y Wang S Sun H Li Y Feng J . Naringenin ameliorates myocardial injury in STZ-induced diabetic mice by reducing oxidative stress, inflammation and apoptosis via regulating the Nrf2 and NF-κB signaling pathways. Front Cardiovasc Med. (2022) 9:946766. doi: 10.3389/fcvm.2022.946766 Shen W Anwaier G Cao Y Lian G Chen C Liu S . Atheroprotective mechanisms of tilianin by inhibiting inflammation through down-regulating NF-κB pathway and foam cells formation. Front Physiol. (2019) 10:825. doi: 10.3389/fphys.2019.00825 Tian L Cao W Yue R Yuan Y Guo X Qin D . Pretreatment with Tilianin improves mitochondrial energy metabolism and oxidative stress in rats with myocardial ischemia/reperfusion injury via AMPK/SIRT1/PGC-1 alpha signaling pathway. J Pharmacol Sci. (2019) 139:352–60. doi: 10.1016/j.jphs.2019.02.008 Jiang H Xing J Fang J Wang L Wang Y Zeng L . Tilianin protects against ischemia/reperfusion-induced myocardial injury through the inhibition of the Ca(2+)/calmodulin-dependent protein kinase ii-dependent apoptotic and inflammatory signaling pathways. BioMed Res Int. (2020) 2020:5939715. doi: 10.1155/2020/5939715 Yao J Li Y Jin Y Chen Y Tian L He W . Synergistic cardioptotection by tilianin and syringin in diabetic cardiomyopathy involves interaction of TLR4/NF-κB/NLRP3 and PGC1a/SIRT3 pathways. Int Immunopharmacol. (2021) 96:107728. doi: 10.1016/j.intimp.2021.107728 Yu XH Chen JJ Deng WY Xu XD Liu QX Shi MW . Biochanin A mitigates atherosclerosis by inhibiting lipid accumulation and inflammatory response. Oxid Med Cell Longev. (2020) 2020:8965047. doi: 10.1155/2020/8965047 Bai Y Li Z Liu W Gao D Liu M Zhang P . Biochanin A attenuates myocardial ischemia/reperfusion injury through the TLR4/NF-κB/NLRP3 signaling pathway. Acta Cir Bras. (2019) 34:e201901104. doi: 10.1590/s0102-865020190110000004 Oza MJ Kulkarni YA . Biochanin A attenuates cardiomyopathy in type 2 diabetic rats by increasing SIRT1 expression and reducing oxidative stress. Chem Biodivers. (2022) 19:e202100591. doi: 10.1002/cbdv.202100591 Sangeethadevi G VS V Jansy Isabella RAR Saravanan G Ponmurugan P Chandrasekaran P . Attenuation of lipid metabolic abnormalities, proinflammatory cytokines, and matrix metalloproteinase expression by biochanin-A in isoproterenol-induced myocardial infarction in rats. Drug Chem Toxicol. (2022) 45:1951–62. doi: 10.1080/01480545.2021.1894707 Feng X Du M Li S Zhang Y Ding J Wang J . Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF-κB pathway in macrophages to reduce atherosclerosis in ApoE-/- mice. Phytomedicine. (2023) 112:154684. doi: 10.1016/j.phymed.2023.154684 Ye J Lu S Wang M Ge W Liu H Qi Y . Hydroxysafflor yellow A protects against myocardial ischemia/reperfusion injury via suppressing NLRP3 inflammasome and activating autophagy. Front Pharmacol. (2020) 11:1170. doi: 10.3389/fphar.2020.01170 Yao R Cao Y Jiang R Zhang X Li F Wang S . Pharmacokinetic characteristics of hydroxysafflor yellow A in normal and diabetic cardiomyopathy mice. BioMed Chromatogr. (2021) 35:e5173. doi: 10.1002/bmc.v35.10 Ni B Zhou D Jing Y Liu S . Hydroxysafflor yellow A protects against angiotensin II−induced hypertrophy. Mol Med Rep. (2018) 18:3649–56. doi: 10.3892/mmr.2018.9399 Thang SK Chen PY Gao WY Wu MJ Pan MH Yen JH . Xanthohumol suppresses NPC1L1 gene expression through downregulation of HNF-4α and inhibits cholesterol uptake in Caco-2 cells. J Agric Food Chem. (2019) 67:11119–28. doi: 10.1021/acs.jafc.9b05221 Lin JH Yang KT Lee WS Ting PC Luo YP Lin DJ . Xanthohumol protects the rat myocardium against ischemia/reperfusion injury-induced ferroptosis. Oxid Med Cell Longev. (2022) 2022:9523491. doi: 10.1155/2022/9523491 Sun TL Li WQ Tong XL Liu XY Zhou WH . Xanthohumol attenuates isoprenaline-induced cardiac hypertrophy and fibrosis through regulating PTEN/AKT/mTOR pathway. Eur J Pharmacol. (2021) 891:173690. doi: 10.1016/j.ejphar.2020.173690 Yang Z Li T Wang C Meng M Tan S Chen L . Dihydromyricetin inhibits M1 macrophage polarization in atherosclerosis by modulating miR-9-mediated SIRT1/NF-κB signaling pathway. Mediators Inflammation. (2023) 2023:2547588. doi: 10.1155/2023/2547588 Wei L Sun X Qi X Zhang Y Li Y Xu Y . Dihydromyricetin ameliorates cardiac ischemia/reperfusion injury through Sirt3 activation. BioMed Res Int. (2019) 2019:6803943. doi: 10.1155/2019/6803943 Chen Y Zheng Y Chen R Shen J Zhang S Gu Y . Dihydromyricetin attenuates diabetic cardiomyopathy by inhibiting oxidative stress, inflammation and necroptosis via sirtuin 3 activation. Antioxidants (Basel). (2023) 12:200. doi: 10.3390/antiox12010200 Chen Y Luo HQ Sun LL Xu MT Yu J Liu LL . Dihydromyricetin attenuates myocardial hypertrophy induced by transverse aortic constriction via oxidative stress inhibition and SIRT3 pathway enhancement. Int J Mol Sci. (2018) 19:2592. doi: 10.3390/ijms19092592 Wu Y Song F Li Y Li J Cui Y Hong Y . Acacetin exerts antioxidant potential against atherosclerosis through Nrf2 pathway in ApoE-/- mice. J Cell Mol Med. (2021) 25:521–34. doi: 10.1111/jcmm.16106 Wu C Chen RL Wang Y Wu WY Li G . Acacetin alleviates myocardial ischaemia/reperfusion injury by inhibiting oxidative stress and apoptosis via the Nrf-2/HO-1 pathway. Pharm Biol. (2022) 60:553–61. doi: 10.1080/13880209.2022.2041675 Cui YK Hong YX Wu WY Han WM Wu Y Wu C . Acacetin ameliorates cardiac hypertrophy by activating Sirt1/AMPK/PGC-1α pathway. Eur J Pharmacol. (2022) 920:174858. doi: 10.1016/j.ejphar.2022.174858 Song F Mao YJ Hu Y Zhao SS Wang R Wu WY . Acacetin attenuates diabetes-induced cardiomyopathy by inhibiting oxidative stress and energy metabolism via PPAR-α/AMPK pathway. Eur J Pharmacol. (2022) 922:174916. doi: 10.1016/j.ejphar.2022.174916 Li Y Dang Q Li Z Han C Yang Y Li M . Restoration of mitochondrial function is essential in the endothelium-dependent vasodilation induced by acacetin in hypertensive rats. Int J Mol Sci. (2022) 23:11350. doi: 10.3390/ijms231911350 Huang P Wang F Zhang Y Zhang Y Qin M Ji J . Icariin alleviates atherosclerosis by regulating the miR-205-5p/ERBB4/AKT signaling pathway. Int Immunopharmacol. (2023) 114:109611. doi: 10.1016/j.intimp.2022.109611 Liu XJ Lv YF Cui WZ Li Y Liu Y Xue YT . Icariin inhibits hypoxia/reoxygenation-induced ferroptosis of cardiomyocytes via regulation of the Nrf2/HO-1 signaling pathway. FEBS Open Bio. (2021) 11:2966–76. doi: 10.1002/2211-5463.13276 Sai X Li Z Deng G Wang L Xiaowu W Nasser MI . Immunomodulatory effects of icariin in a myocardial infarction mouse model. Bioengineered. (2022) 13:12504–15. doi: 10.1080/21655979.2022.2076453 Yu LM Dong X Xu YL Zhou ZJ Huang YT Zhao JK . Icariin attenuates excessive alcohol consumption-induced susceptibility to atrial fibrillation through SIRT3 signaling. Biochim Biophys Acta Mol Basis Dis. (2022) 1868:166483. doi: 10.1016/j.bbadis.2022.166483 Liu QW Yang ZH Jiang J Jiang R . Icariin modulates eNOS activity via effect on post-translational protein-protein interactions to improve erectile function of spontaneously hypertensive rats. Andrology. (2021) 9:342–51. doi: 10.1111/andr.12875 Hu L Wang Z Li H Wei J Tang F Wang Q . Icariin inhibits isoproterenol-induced cardiomyocyte hypertropic injury through activating autophagy via the AMPK/mTOR signaling pathway. Biochem Biophys Res Commun. (2022) 593:65–72. doi: 10.1016/j.bbrc.2022.01.029 Ni T Lin N Huang X Lu W Sun Z Zhang J . Icariin ameliorates diabetic cardiomyopathy through Apelin/Sirt3 signalling to improve mitochondrial dysfunction. Front Pharmacol. (2020) 11:256. doi: 10.3389/fphar.2020.00256 Su Y Fan X Li S Li Z Tian M Li S . Scutellarin improves type 2 diabetic cardiomyopathy by regulating cardiomyocyte autophagy and apoptosis. Dis Markers. (2022) 2022:3058354. doi: 10.1155/2022/3058354 Zhang X Han X Zhang P Zhou T Chen Y Jin J . Morin attenuates oxidized low-density lipoprotein-mediated injury by inducing autophagy via activating AMPK signalling in HUVECs. Clin Exp Pharmacol Physiol. (2019) 46:1053–60. doi: 10.1111/1440-1681.13160 Verma VK Malik S Mutneja E Sahu AK Bhatia J Arya DS . Attenuation of ROS-mediated myocardial ischemia-reperfusion injury by morin via regulation of RISK/SAPK pathways. Pharmacol Rep. (2020) 72:877–89. doi: 10.1007/s43440-019-00011-2 Salameh A Dhein S Mewes M Sigusch S Kiefer P Vollroth M . Anti-oxidative or anti-inflammatory additives reduce ischemia/reperfusions injury in an animal model of cardiopulmonary bypass. Saudi J Biol Sci. (2020) 27:18–29. doi: 10.1016/j.sjbs.2019.04.003 Mou Q Jia Z Luo M Liu L Huang X Quan J . Epigallocatechin-3-gallate exerts cardioprotective effects related to energy metabolism in pressure overload-induced cardiac dysfunction. Arch Biochem Biophys. (2022) 723:109217. doi: 10.1016/j.abb.2022.109217 Wang J Li P Qin T Sun D Zhao X Zhang B . Protective effect of epigallocatechin-3-gallate against neuroinflammation and anxiety-like behavior in a rat model of myocardial infarction. Brain Behav. (2020) 10:e01633. doi: 10.1002/brb3.v10.6 Mohd Sabri NA Lee SK Murugan DD Ling WC . Epigallocatechin gallate (EGCG) alleviates vascular dysfunction in angiotensin II-infused hypertensive mice by modulating oxidative stress and eNOS. Sci Rep. (2022) 12:17633. doi: 10.1038/s41598-022-21107-5 Li G Pan B Liu L Xu X Zhao W Mou Q . Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy. Mol Cell Biochem. (2023) 479:963–73. doi: 10.1007/s11010-023-04768-2 Cui Y Wang Y Liu G . Epigallocatechin gallate (EGCG) attenuates myocardial hypertrophy and fibrosis induced by transverse aortic constriction via inhibiting the Akt/mTOR pathway. Pharm Biol. (2021) 59:1305–13. doi: 10.1080/13880209.2021.1972124 Gui L Wang F Hu X Liu X Yang H Cai Z . Epigallocatechin gallate protects diabetes mellitus rats complicated with cardiomyopathy through TGF-β1/JNK signaling pathway. Curr Pharm Des. (2022) 28:2758–70. doi: 10.2174/1381612828666220902115437 Li T Tong Q Wang Z Yang Z Sun Y Cai J . Epigallocatechin-3-gallate inhibits atrial fibrosis and reduces the occurrence and maintenance of atrial fibrillation and its possible mechanisms. Cardiovasc Drugs Ther. (2023). doi: 10.1007/s10557-023-07447-y Guo L Zhang X Lv N Wang L Gan J Jiang X . Therapeutic role and potential mechanism of resveratrol in atherosclerosis: TLR4/NF-κB/HIF-1α. Mediators Inflammation. (2023) 2023:1097706. doi: 10.1155/2023/1097706 Zheng M Bai Y Sun X Fu R Liu L Liu M . Resveratrol reestablishes mitochondrial quality control in myocardial ischemia/reperfusion injury through Sirt1/Sirt3-Mfn2-Parkin-PGC-1α pathway. Molecules. (2022) 27:5545. doi: 10.3390/molecules27175545 Gal R Deres L Horvath O Eros K Sandor B Urban P . Resveratrol improves heart function by moderating inflammatory processes in patients with systolic heart failure. Antioxidants (Basel). (2020) 9:1108. doi: 10.3390/antiox9111108 Jiang J Gu X Wang H Ding S . Resveratrol improves cardiac function and left ventricular fibrosis after myocardial infarction in rats by inhibiting NLRP3 inflammasome activity and the TGF-β1/SMAD2 signaling pathway. PeerJ. (2021) 9:e11501. doi: 10.7717/peerj.11501 Liu J Zhang M Qin C Wang Z Chen J Wang R . Resveratrol attenuate myocardial injury by inhibiting ferroptosis via inducing KAT5/GPX4 in myocardial infarction. Front Pharmacol. (2022) 13:906073. doi: 10.3389/fphar.2022.906073 Grujić-Milanović J Jaćević V Miloradović Z Jovović D Milosavljević I Milanović SD . Resveratrol protects cardiac tissue in experimental Malignant hypertension due to antioxidant, anti-inflammatory, and anti-apoptotic properties. Int J Mol Sci. (2021) 22:5006. doi: 10.3390/ijms22095006 Tain YL Lee WC Wu KLH Leu S Chan JYH . Resveratrol prevents the development of hypertension programmed by maternal plus post-weaning high-fructose consumption through modulation of oxidative stress, nutrient-sensing signals, and gut microbiota. Mol Nutr Food Res. (2018) 62:e1800066. doi: 10.1002/mnfr.201800066 Guan P Sun ZM Wang N Zhou J Luo LF Zhao YS . Resveratrol prevents chronic intermittent hypoxia-induced cardiac hypertrophy by targeting the PI3K/AKT/mTOR pathway. Life Sci. (2019) 233:116748. doi: 10.1016/j.lfs.2019.116748 Chen TS Chuang SY Shen CY Ho TJ Chang RL Yeh YL . Antioxidant Sirt1/Akt axis expression in resveratrol pretreated adipose-derived stem cells increases regenerative capability in a rat model with cardiomyopathy induced by diabetes mellitus. J Cell Physiol. (2021) 236:4290–302. doi: 10.1002/jcp.v236.6 Zhang Y Zhang S Liu Z Zhao X Yuan Y Sheng L . Resveratrol prevents atrial fibrillation by inhibiting atrial structural and metabolic remodeling in collagen-induced arthritis rats. Naunyn Schmiedebergs Arch Pharmacol. (2018) 391:1179–90. doi: 10.1007/s00210-018-1554-9 Xiong Q Yan Z Liang J Yuan J Chen X Zhou L . Polydatin alleviates high-fat diet induced atherosclerosis in apolipoprotein E-deficient mice by autophagic restoration. Phytomedicine. (2021) 81:153301. doi: 10.1016/j.phymed.2020.153301 Yu LM Dong X Li N Jiang H Zhao JK Xu YL . Polydatin attenuates chronic alcohol consumption-induced cardiomyopathy through a SIRT6-dependent mechanism. Food Funct. (2022) 13:7302–19. doi: 10.1039/D2FO00966H Luo P Shi W Wang Y Ma H Liu T Yan D . Raloxifene inhibits IL-6/STAT3 signaling pathway and protects against high-fat-induced atherosclerosis in ApoE-/- mice. Life Sci. (2020) 261:118304. doi: 10.1016/j.lfs.2020.118304 Huo S Shi W Ma H Yan D Luo P Guo J . Alleviation of inflammation and oxidative stress in pressure overload-induced cardiac remodeling and heart failure via IL-6/STAT3 inhibition by raloxifene. Oxid Med Cell Longev. (2021) 2021:6699054. doi: 10.1155/2021/6699054 Ye B Chen X Dai S Han J Liang X Lin S . Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes. Drug Des Devel Ther. (2019) 13:975–90. doi: 10.2147/DDDT.S195412 Liu J Ning L . Protective role of emodin in rats with post-myocardial infarction heart failure and influence on extracellular signal-regulated kinase pathway. Bioengineered. (2021) 12:10246–53. doi: 10.1080/21655979.2021.1983977 Xiao D Zhang Y Wang R Fu Y Zhou T Diao H . Emodin alleviates cardiac fibrosis by suppressing activation of cardiac fibroblasts via upregulating metastasis associated protein 3. Acta Pharm Sin B. (2019) 9:724–33. doi: 10.1016/j.apsb.2019.04.003 Li X Hu X Pan T Dong L Ding L Wang Z . Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. BioMed Pharmacother. (2021) 133:110802. doi: 10.1016/j.biopha.2020.110802 Bian Y Li X Pang P Hu XL Yu ST Liu YN . Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis. Acta Pharmacol Sin. (2020) 41:319–26. doi: 10.1038/s41401-019-0307-8 Shao X Liu Z Liu S Lin N Deng Y . Astragaloside IV alleviates atherosclerosis through targeting circ_0000231/miR-135a-5p/CLIC4 axis in AS cell model in vitro . Mol Cell Biochem. (2021) 476:1783–95. doi: 10.1007/s11010-020-04035-8 Jiang M Ni J Cao Y Xing X Wu Q Fan G . Astragaloside IV attenuates myocardial ischemia-reperfusion injury from oxidative stress by regulating succinate, lysophospholipid metabolism, and ROS scavenging system. Oxid Med Cell Longev. (2019) 2019:9137654. doi: 10.1155/2019/9137654 Sui YB Wang Y Liu L Liu F Zhang YQ . Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway. Pharm Biol. (2019) 57:48–54. doi: 10.1080/13880209.2019.1569697 Cheng S Zhang X Feng Q Chen J Shen L Yu P . Astragaloside IV exerts angiogenesis and cardioprotection after myocardial infarction via regulating PTEN/PI3K/Akt signaling pathway. Life Sci. (2019) 227:82–93. doi: 10.1016/j.lfs.2019.04.040 Jing H Xie R Bai Y Duan Y Sun C Wang Y . The mechanism actions of astragaloside IV prevents the progression of hypertensive heart disease based on network pharmacology and experimental pharmacology. Front Pharmacol. (2021) 12:755653. doi: 10.3389/fphar.2021.755653 Li X Li Z Dong X Wu Y Li B Kuang B . Astragaloside IV attenuates myocardial dysfunction in diabetic cardiomyopathy rats through downregulation of CD36-mediated ferroptosis. Phytother Res. (2023) 37:3042–56. doi: 10.1002/ptr.v37.7 Zhu Y Qian X Li J Lin X Luo J Huang J . Astragaloside-IV protects H9c2 cardiomyocytes from high glucose-induced injury via miR-34a-mediated autophagy pathway. Artif Cells Nanomed Biotechnol. (2019) 47:4172–81. doi: 10.1080/21691401.2019.1687492 Wang ZC Niu KM Wu YJ Du KR Qi LW Zhou YB . A dual Keap1 and p47(phox) inhibitor Ginsenoside Rb1 ameliorates high glucose/ox-LDL-induced endothelial cell injury and atherosclerosis. Cell Death Dis. (2022) 13:824. doi: 10.1038/s41419-022-05274-x Jiang L Yin X Chen YH Chen Y Jiang W Zheng H . Proteomic analysis reveals ginsenoside Rb1 attenuates myocardial ischemia/reperfusion injury through inhibiting ROS production from mitochondrial complex I. Theranostics. (2021) 11:1703–20. doi: 10.7150/thno.43895 Li C Zhang X Li J Liang L Zeng J Wen M . Ginsenoside Rb1 promotes the activation of PPARα pathway via inhibiting FADD to ameliorate heart failure. Eur J Pharmacol. (2023) 947:175676. doi: 10.1016/j.ejphar.2023.175676 Zhang C Han M Zhang X Tong H Sun X Sun G . Ginsenoside Rb1 protects against diabetic cardiomyopathy by regulating the adipocytokine pathway. J Inflammation Res. (2022) 15:71–83. doi: 10.2147/JIR.S348866 Wang S Yang S Chen Y Chen Y Li R Han S . Ginsenoside Rb2 alleviated atherosclerosis by inhibiting M1 macrophages polarization induced by microRNA-216a. Front Pharmacol. (2021) 12:764130. doi: 10.3389/fphar.2021.764130 Xue Y Fu W Liu Y Yu P Sun M Li X . Ginsenoside Rb2 alleviates myocardial ischemia/reperfusion injury in rats through SIRT1 activation. J Food Sci. (2020) 85:4039–49. doi: 10.1111/1750-3841.15505 Zhao J Cui L Sun J Xie Z Zhang L Ding Z . Notoginsenoside R1 alleviates oxidized low-density lipoprotein-induced apoptosis, inflammatory response, and oxidative stress in HUVECS through modulation of XIST/miR-221-3p/TRAF6 axis. Cell Signal. (2020) 76:109781. doi: 10.1016/j.cellsig.2020.109781 Zeng JJ Shi HQ Ren FF Zhao XS Chen QY Wang DJ . Notoginsenoside R1 protects against myocardial ischemia/reperfusion injury in mice via suppressing TAK1-JNK/p38 signaling. Acta Pharmacol Sin. (2023) 44:1366–79. doi: 10.1038/s41401-023-01057-y Zhang B Zhang J Zhang C Zhang X Ye J Kuang S . Notoginsenoside R1 protects against diabetic cardiomyopathy through activating estrogen receptor α and its downstream signaling. Front Pharmacol. (2018) 9:1227. doi: 10.3389/fphar.2018.01227 Xiao J Zhu T Yin YZ Sun B . Notoginsenoside R1, a unique constituent of Panax notoginseng, blinds proinflammatory monocytes to protect against cardiac hypertrophy in ApoE-/- mice. Eur J Pharmacol. (2018) 833:441–50. doi: 10.1016/j.ejphar.2018.07.004 Wen J Chang Y Huo S Li W Huang H Gao Y . Tanshinone IIA attenuates atherosclerosis via inhibiting NLRP3 inflammasome activation. Aging (Albany NY). (2020) 13:910–32. doi: 10.18632/aging.202202 Zhu PC Shen J Qian RY Xu J Liu C Hu WM . Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms. Front Pharmacol. (2023) 14:1165212. doi: 10.3389/fphar.2023.1165212 Sun M Wang W Min L Chen C Li Q Weng W . Secreted frizzled-related protein 5 (SFRP5) protects ATDC5 cells against LPS-induced inflammation and apoptosis via inhibiting Wnt5a/JNK pathway. J Orthop Surg Res. (2021) 16:129. doi: 10.1186/s13018-021-02260-5 Wu S Lu D Gajendran B Hu Q Zhang J Wang S . Tanshinone IIA ameliorates experimental diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress in cardiomyocytes via SIRT1. Phytother Res. (2023) 37:3543–58. doi: 10.1002/ptr.v37.8 Huang L Zhu J Zheng M Zou R Zhou Y Zhu M . Tanshinone IIA protects against subclinical lipopolysaccharide induced cardiac fibrosis in mice through inhibition of NADPH oxidase. Int Immunopharmacol. (2018) 60:59–63. doi: 10.1016/j.intimp.2018.04.036 Wu F Ye B Wu X Lin X Li Y Wu Y . Paeoniflorin on rat myocardial ischemia reperfusion injury of protection and mechanism research. Pharmacology. (2020) 105:281–8. doi: 10.1159/000503583 Liu M Feng J Du Q Ai J Lv Z . Paeoniflorin attenuates myocardial fibrosis in isoprenaline-induced chronic heart failure rats via inhibiting P38 MAPK pathway. Curr Med Sci. (2020) 40:307–12. doi: 10.1007/s11596-020-2178-0 Liu X Chen K Zhuang Y Huang Y Sui Y Zhang Y . Paeoniflorin improves pressure overload-induced cardiac remodeling by modulating the MAPK signaling pathway in spontaneously hypertensive rats. BioMed Pharmacother. (2019) 111:695–704. doi: 10.1016/j.biopha.2018.12.090 Hu H Wang C Jin Y Meng Q Liu Q Liu Z . Catalpol inhibits homocysteine-induced oxidation and inflammation via inhibiting Nox4/NF-κB and GRP78/PERK pathways in human aorta endothelial cells. Inflammation. (2019) 42:64–80. doi: 10.1007/s10753-018-0873-9 Ge H Lin W Lou Z Chen R Shi H Zhao Q . Catalpol alleviates myocardial ischemia reperfusion injury by activating the Nrf2/HO-1 signaling pathway. Microvasc Res. (2022) 140:104302. doi: 10.1016/j.mvr.2021.104302 Xia Y Lu YW Hao RJ Yu GR . Catalpol relieved angiotensin II-induced blood-brain barrier destruction via inhibiting the TLR4 pathway in brain endothelial cells. Pharm Biol. (2022) 60:2210–8. doi: 10.1080/13880209.2022.2142801 Zou G Zhong W Wu F Wang X Liu L . Catalpol attenuates cardiomyocyte apoptosis in diabetic cardiomyopathy via Neat1/miR-140-5p/HDAC4 axis. Biochimie. (2019) 165:90–9. doi: 10.1016/j.biochi.2019.05.005 Song R Han S Gao H Jiang H Li X . Crocin alleviates cognitive impairment associated with atherosclerosis via improving neuroinflammation in LDLR-/- mice fed a high-fat/cholesterol diet. Phytother Res. (2022) 36:1284–96. doi: 10.1002/ptr.v36.3 Wang X Yuan B Cheng B Liu Y Zhang B Wang X . Crocin alleviates myocardial ischemia/reperfusion-induced endoplasmic reticulum stress via regulation of miR-34a/Sirt1/Nrf2 pathway. Shock. (2019) 51:123–30. doi: 10.1097/SHK.0000000000001116 Yuan C Chen Z Zhou Q . Crocin inhibits KBTBD7 to prevent excessive inflammation and cardiac dysfunction following myocardial infarction. Mol Med Rep. (2023) 27:20. doi: 10.3892/mmr.2022.12907 Chen X Huang J Lv Y Chen Y Rao J . Crocin exhibits an antihypertensive effect in a rat model of gestational hypertension and activates the Nrf-2/HO-1 signaling pathway. Hypertens Res. (2021) 44:642–50. doi: 10.1038/s41440-020-00609-7 Feidantsis K Mellidis K Galatou E Sinakos Z Lazou A . Treatment with crocin improves cardiac dysfunction by normalizing autophagy and inhibiting apoptosis in STZ-induced diabetic cardiomyopathy. Nutr Metab Cardiovasc Dis. (2018) 28:952–61. doi: 10.1016/j.numecd.2018.06.005 Lv Z Shan X Tu Q Wang J Chen J Yang Y . Ginkgolide B treatment regulated intestinal flora to improve high-fat diet induced atherosclerosis in ApoE-/- mice. BioMed Pharmacother. (2021) 134:111100. doi: 10.1016/j.biopha.2020.111100 Feng Z Yang X Zhang L Ansari IA Khan MS Han S . Ginkgolide B ameliorates oxidized low-density lipoprotein-induced endothelial dysfunction via modulating lectin-like ox-LDL-receptor-1 and NADPH oxidase 4 expression and inflammatory cascades. Phytother Res. (2018) 32:2417–27. doi: 10.1002/ptr.v32.12 Zhang R Xu L Zhang D Hu B Luo Q Han D . Cardioprotection of Ginkgolide B on myocardial ischemia/reperfusion-induced inflammatory injury via regulation of A20-NF-κB pathway. Front Immunol. (2018) 9:2844. doi: 10.3389/fimmu.2018.02844 Liu J Wu P Xu Z Zhang J Liu J Yang Z . Ginkgolide B inhibits hydrogen peroxide−induced apoptosis and attenuates cytotoxicity via activating the PI3K/Akt/mTOR signaling pathway in H9c2 cells. Mol Med Rep. (2020) 22:310–6. doi: 10.3892/mmr.2020.11099 Ge Y Xu W Zhang L Liu M . Ginkgolide B attenuates myocardial infarction-induced depression-like behaviors via repressing IL-1β in central nervous system. Int Immunopharmacol. (2020) 85:106652. doi: 10.1016/j.intimp.2020.106652 Jiang Q Lu M Li J Zhu Z . Ginkgolide B protects cardiomyocytes from angiotensin II-induced hypertrophy via regulation of autophagy through SIRT1-FoxO1. Cardiovasc Ther. (2021) 2021:5554569. doi: 10.1155/2021/5554569 Jiang YX Li W Wang J Wang GG . Cardiac dysfunction is attenuated by ginkgolide B via reducing oxidative stress and fibrosis in diabetic rats. Iran J Basic Med Sci. (2020) 23:1078–84. doi: 10.22038/ijbms.2020.44210.10358 Mannino F Pallio G Altavilla D Squadrito F Vermiglio G Bitto A . Atherosclerosis plaque reduction by lycopene is mediated by increased energy expenditure through AMPK and PPARα in ApoE KO mice fed with a high fat diet. Biomolecules. (2022) 12:973. doi: 10.3390/biom12070973 Li X Jia P Huang Z Liu S Miao J Guo Y . Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Drug Des Devel Ther. (2019) 13:2331–42. doi: 10.2147/DDDT.S194753 Fan S Sun JB Li R Song X Li J . Lycopene protects myocardial ischemia injury through anti-apoptosis and anti-oxidative stress. Eur Rev Med Pharmacol Sci. (2019) 23:3096–104. doi: 10.26355/eurrev_201904_17593 Zeng J Zhao J Dong B Cai X Jiang J Xue R . Lycopene protects against pressure overload-induced cardiac hypertrophy by attenuating oxidative stress. J Nutr Biochem. (2019) 66:70–8. doi: 10.1016/j.jnutbio.2019.01.002 Jiang Y Du H Liu X Fu X Li X Cao Q . Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-κB/NLRP3 inflammasomes pathway. J Drug Target. (2020) 28:70–9. doi: 10.1080/1061186X.2019.1616296 Wang P Tian X Tang J Duan X Wang J Cao H . Artemisinin protects endothelial function and vasodilation from oxidative damage via activation of PI3K/Akt/eNOS pathway. Exp Gerontol. (2021) 147:111270. doi: 10.1016/j.exger.2021.111270 Liu X Wang X Pan Y Zhao L Sun S Luo A . Artemisinin improves acetylcholine-induced vasodilatation in rats with primary hypertension. Drug Des Devel Ther. (2021) 15:4489–502. doi: 10.2147/DDDT.S330721 Kong L Ji X Liu Y Du Y . Effect of artemisinin combined with allicin on improving cardiac function, fibrosis and NF-κB signaling pathway in rats with diabetic cardiomyopathy. Acta Biochim Pol. (2023) 70:401–5. doi: 10.18388/abp.2020_6692 Wang L Zhao X Ding J Liu Y Liu H Zheng L . Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice. Inflammopharmacology. (2023) 31:1993–2005. doi: 10.1007/s10787-023-01161-9 Lin J Lai X Fan X Ye B Zhong L Zhang Y . Oridonin protects against myocardial ischemia-reperfusion injury by inhibiting GSDMD-mediated pyroptosis. Genes (Basel). (2022) 13:2133. doi: 10.3390/genes13112133 Gao RF Li X Xiang HY Yang H Lv CY Sun XL . The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice. Int Immunopharmacol. (2021) 90:107133. doi: 10.1016/j.intimp.2020.107133 Xu M Wan CX Huang SH Wang HB Fan D Wu HM . Oridonin protects against cardiac hypertrophy by promoting P21-related autophagy. Cell Death Dis. (2019) 10:403. doi: 10.1038/s41419-019-1617-y Ma SR Tong Q Lin Y Pan LB Fu J Peng R . Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota. Signal Transduct Target Ther. (2022) 7:207. doi: 10.1038/s41392-022-01027-6 Jia X Shao W Tian S . Berberine alleviates myocardial ischemia-reperfusion injury by inhibiting inflammatory response and oxidative stress: the key function of miR-26b-5p-mediated PTGS2/MAPK signal transduction. Pharm Biol. (2022) 60:652–63. doi: 10.1080/13880209.2022.2048029 Zhu N Li J Li Y Zhang Y Du Q Hao P . Berberine protects against simulated ischemia/reperfusion injury-induced H9C2 cardiomyocytes apoptosis in vitro and myocardial ischemia/reperfusion-induced apoptosis in vivo by regulating the mitophagy-mediated HIF-1α/BNIP3 pathway. Front Pharmacol. (2020) 11:367. doi: 10.3389/fphar.2020.00367 Abudureyimu M Yu W Cao RY Zhang Y Liu H Zheng H . Berberine promotes cardiac function by upregulating PINK1/Parkin-mediated mitophagy in heart failure. Front Physiol. (2020) 11:565751. doi: 10.3389/fphys.2020.565751 Tian CX Li MY Shuai XX Jiang F Dong YL Gui Y . Berberine plays a cardioprotective role by inhibiting macrophage Wnt5a/β-catenin pathway in the myocardium of mice after myocardial infarction. Phytother Res. (2023) 37:50–61. doi: 10.1002/ptr.v37.1 Yang B Li J Wang B Wang G Li P Guo H . Hydroxycitrate prevents calcium oxalate crystallization and kidney injury in a nephrolithiasis rat model. Urolithiasis. (2022) 50:47–53. doi: 10.1007/s00240-021-01283-1 Chen X Jiang X Cheng C Chen J Huang S Xu M . Berberine attenuates cardiac hypertrophy through inhibition of mTOR signaling pathway. Cardiovasc Drugs Ther. (2020) 34:463–73. doi: 10.1007/s10557-020-06977-z Yang B Wang G Li Y Yang T Guo H Li P . Hydroxycitric acid prevents hyperoxaluric-induced nephrolithiasis and oxidative stress via activation of the Nrf2/Keap1 signaling pathway. Cell Cycle. (2023) 22:1884–99. doi: 10.1080/15384101.2023.2247251 Yang M Lv H Liu Q Zhang L Zhang R Huang X . Colchicine alleviates cholesterol crystal-induced endothelial cell pyroptosis through activating AMPK/SIRT1 pathway. Oxid Med Cell Longev. (2020) 2020:9173530. doi: 10.1155/2020/9173530 Shen S Duan J Hu J Qi Y Kang L Wang K . Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fraction. Eur J Pharmacol. (2022) 929:175126. doi: 10.1016/j.ejphar.2022.175126 Sun X Duan J Gong C Feng Y Hu J Gu R . Colchicine ameliorates dilated cardiomyopathy via SIRT2-mediated suppression of NLRP3 inflammasome activation. J Am Heart Assoc. (2022) 11:e025266. doi: 10.1161/JAHA.122.025266 Li YW Chen SX Yang Y Zhang ZH Zhou WB Huang YN . Colchicine inhibits NETs and alleviates cardiac remodeling after acute myocardial infarction. Cardiovasc Drugs Ther. (2022) 38:31–41. doi: 10.1007/s10557-022-07326-y Geng P Xu X Gao Z . Sinomenine suppress the vitamin D3 and high fat induced atherosclerosis in rats via suppress of oxidative stress and inflammation. J Oleo Sci. (2021) 70:1815–28. doi: 10.5650/jos.ess21255 Xia B Li Q Wu J Yuan X Wang F Lu X . Sinomenine confers protection against myocardial ischemia reperfusion injury by preventing oxidative stress, cellular apoptosis, and inflammation. Front Pharmacol. (2022) 13:922484. doi: 10.3389/fphar.2022.922484 Fu YF Li L Fang P Song J Sun XH Meng TH . Sinomenine's protective role and mechanism in stress load-induced heart failure. J Pharm Pharmacol. (2020) 72:209–17. doi: 10.1111/jphp.13181 Yuan M Zhao B Jia H Zhang C Zuo X . Sinomenine ameliorates cardiac hypertrophy by activating Nrf2/ARE signaling pathway. Bioengineered. (2021) 12:12778–88. doi: 10.1080/21655979.2021.2000195 Xiao M Xian C Wang Y Qi X Zhang R Liu Z . Nuciferine attenuates atherosclerosis by regulating the proliferation and migration of VSMCs through the Calm4/MMP12/AKT pathway in ApoE((-/-)) mice fed with High-Fat-Diet. Phytomedicine. (2023) 108:154536. doi: 10.1016/j.phymed.2022.154536 Li R Qin X Yue L Liu W Gao Y Zhu F . Nuciferine improves cardiac function in mice subjected to myocardial ischemia/reperfusion injury by upregulating PPAR-γ. Heliyon. (2023) 9:e13630. doi: 10.1016/j.heliyon.2023.e13630 HarishKumar R Selvaraj CI . Nuciferine from Nelumbo nucifera Gaertn. attenuates isoproterenol-induced myocardial infarction in Wistar rats. Biotechnol Appl Biochem. (2022) 69:1176–89. doi: 10.1002/bab.v69.3 Fan X Han J Zhu L Chen Z Li J Gu Y . Protective activities of Dendrobium huoshanense C. Z. Tang et S. J. Cheng polysaccharide against high-cholesterol diet-induced atherosclerosis in zebrafish. Oxid Med Cell Longev. (2020) 2020:8365056. doi: 10.1155/2020/8365056 Li QM Zha XQ Zhang WN Liu J Pan LH Luo JP . Laminaria japonica polysaccharide prevents high-fat-diet-induced insulin resistance in mice via regulating gut microbiota. Food Funct. (2021) 12:5260–73. doi: 10.1039/D0FO02100H Yin F Lin P Yu WQ Shen N Li Y Guo SD . The Cordyceps militaris-derived polysaccharide CM1 alleviates atherosclerosis in LDLR-/- mice by improving hyperlipidemia. Front Mol Biosci. (2021) 8:783807. doi: 10.3389/fmolb.2021.783807 Song Z Li H Liang J Xu Y Zhu L Ye X . Sulfated polysaccharide from Undaria pinnatifida stabilizes the atherosclerotic plaque via enhancing the dominance of the stabilizing components. Int J Biol Macromol. (2019) 140:621–30. doi: 10.1016/j.ijbiomac.2019.08.173 Xiong Q Zhu L Zhang F Li H Wu J Liang J . Protective activities of polysaccharides from Cipangopaludina chinensis against high-fat-diet-induced atherosclerosis via regulating gut microbiota in ApoE-deficient mice. Food Funct. (2019) 10:6644–54. doi: 10.1039/C9FO01530B Li W Yu J Zhao J Xiao X Li W Zang L . Poria cocos polysaccharides reduces high-fat diet-induced arteriosclerosis in ApoE-/- mice by inhibiting inflammation. Phytother Res. (2021) 35:2220–9. doi: 10.1002/ptr.v35.4 Zhang Z Liu H Yu B Tao H Li J Wu Z . Lycium barbarum polysaccharide attenuates myocardial injury in high-fat diet-fed mice through manipulating the gut microbiome and fecal metabolome. Food Res Int. (2020) 138:109778. doi: 10.1016/j.foodres.2020.109778 Pan H Niu L Wu Y Chen L Zhou X Zhao Y . Lycium barbarum polysaccharide protects rats and cardiomyocytes against ischemia/reperfusion injury via Nrf2 activation through autophagy inhibition. Mol Med Rep. (2021) 24. doi: 10.3892/mmr.2021.12418 Liu Q Han Q Lu M Wang H Tang F . Lycium barbarum polysaccharide attenuates cardiac hypertrophy, inhibits calpain-1 expression and inhibits NF-κB activation in streptozotocin-induced diabetic rats. Exp Ther Med. (2019) 18:509–16. doi: 10.3892/etm.2019.7612 Shi X Han B Zhang B Chu Z Zhang X Lu Q . Schisandra chinensis polysaccharides prevent cardiac hypertrophy by dissociating thioredoxin-interacting protein/thioredoxin-1 complex and inhibiting oxidative stress. BioMed Pharmacother. (2021) 139:111688. doi: 10.1016/j.biopha.2021.111688 He P Zhang M Zhao M Zhang M Ma B Lv H . A novel polysaccharide from Chuanminshen violaceum and its protective effect against myocardial injury. Front Nutr. (2022) 9:961182. doi: 10.3389/fnut.2022.961182 Zhu X Wu W Chen X Yang F Zhang J Hou J . Protective effects of Polygonatum sibiricum polysaccharide on acute heart failure in rats 1. Acta Cir Bras. (2018) 33:868–78. doi: 10.1590/s0102-865020180100000001 Ma D Wu T Qu Y Yang J Cai L Li X . Astragalus polysaccharide prevents heart failure-induced cachexia by alleviating excessive adipose expenditure in white and brown adipose tissue. Lipids Health Dis. (2023) 22:9. doi: 10.1186/s12944-022-01770-3